Etoposide (Synonyms: VP-16; VP-16-213)

Name: Etoposide
Brand: MedChemExpress
SKU: HY-13629
Rating: 5.0 (174 reviews)

Cat. No.: HY-13629 Purity: 99.93%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy.

For research use only. We do not sell to patients.

CAS No. : 33419-42-0

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 174 publication(s) in Google Scholar

Other Forms of Etoposide:

174 Publications Citing Use of MCE Etoposide

RT-PCR

Cell Proliferation/Viability Assay

: Etoposide purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]; The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.

: Etoposide purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2023 Nov 8;31(11):1820-1836.e10. [Abstract]; Immunoblot and immunoprecipitation of lysates of HEK293T cells transfected with plasmids encoding Flag-UreC and exposed to etoposide (100 μg/ml) for 4 h.

: Etoposide purchased from MedChemExpress. Usage Cited in: Oncogene. 2023 Mar;42(13):967-979. [Abstract]; Etoposide (VP16; 5 mg/kg; s.c.; every two days for 8 days) strongly suppresses tumor growth in mice.

: Etoposide purchased from MedChemExpress. Usage Cited in: J Pharm Pharmacol. 2023 Apr 7;75(4):523-532. [Abstract]; Irinotecan (CPT11; 20 μM; 48 h) or Etoposide (VP16; 20 μM; 48 h) induces MDA-MB-231 cells cycle arrest significantly.

: Etoposide purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255. [Abstract]; Cell sensitivity to Etoposide (ETO). Cancer cells are treated with etoposide at gradient concentrations for 48 hr.

: Etoposide purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255. [Abstract]; BCL6 mRNA expression in Etoposide (ETO)-resistant and -sensitive cells. Cells are treated with Etoposide at their respective 1/2 IC50s for 24 hr.

: Etoposide purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255. [Abstract]; Etoposide induced BCL6 protein expression in a time-dependent manner. ETO-resistant or -sensitive cells are treated with etoposide at their respective 1/4 IC50s for 2, 4, or 6 days.

: Etoposide purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255. [Abstract]; STAT1 protein and its phosphorylation levels by immunoblotting analysis. Etoposide (ETO)-resistant and -sensitive cells are treated with Etoposide at their respective 1/2 IC50s for indicated time points.

: Etoposide purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255. [Abstract]; Etoposide activated mTOR signaling components in Etoposide-resistant Capan-2 and PANC28 cells. Cells were treated with etoposide at their respective 1/2 IC50s for 6 or 12 hr. A long-term treatment with Etoposide activated mTOR signaling components in ETO-resistant cells. Capan-2 and PANC28 cells are treated with 10 μM Etoposide for 2 or 4 days.

: Etoposide purchased from MedChemExpress. Usage Cited in: Protein Cell. 2022 Jan;13(1):47-64. [Abstract]; FISH of telomeres on metaphase spreads to detect chromosome end-to-end fusions in 6 kb-HeLa treated with VP-16. Control (Scr) or cGAS-depleted cells (gcGAS-1, gcGAS-2) are either harvested immediately following treatment (VP-16, 2 μM, 1 h) or released for 4 h (Release 4 h) during mitosis.

: Etoposide purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2021 Mar 12;12(3):265. [Abstract]; Inhibition of PRDX1 increased the sensitivity of HCT116 cells to Etoposide-induced apoptosis: HCT116 cells infected with lentivirus expressing the indicated shRNAs were treated with 50 μM Etoposide for 0-6 h.

: Etoposide purchased from MedChemExpress. Usage Cited in: Hepatology. 2020 May;71(5):1660-1677. [Abstract]; Exposure to Etoposide (Eto), another DNA-damaging agent, induces PDIA3P1 expression, suggesting that PDIA3P1 may be up-regulated by DNA-damaging agents.

: Etoposide purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Sep 28;7(21):2001364. [Abstract]; Lnc‐Ip53 attenuated the DNA damage- and oxidation stress-induced p53 acetylation at K382. Cells are incubated with 50 µM Etoposide (Eto) for 5 h.

: Etoposide purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Sep 28;7(21):2001364. [Abstract]; Lnc‐Ip53 attenuated the DNA damage‐ and oxidation stress‐triggered increase of CDKN1A and PUMA. Cells are incubated with 50 µM Etoposide (Eto) for 6 h.

: Etoposide purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 25;10(21):9477-9494. [Abstract]; Fibroblasts and HT-1080 cells are treated with 20 µM Etoposide or DMSO (vehicle group) for 2, 4, 8, 16, 24 and 36 h.

: Etoposide purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 25;10(21):9477-9494. [Abstract]; When cells are treated with 20 µM Etoposide or DMSO (vehicle group) for 4 h, western blots (WB) shows elevated expression of γH2AX, a marker of double-strand breaks (DSBs), in the Etoposide group.

: Etoposide purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 25;10(21):9477-9494. [Abstract]; When cells are treated with 20 µM Etoposide, an obvious increased green focus of RAD51 is observed in the treated fibroblasts using immunofluorescence (IF) staining.

: Etoposide purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2020 Nov 6;12(11):e12525. [Abstract]; Immunoblot of PARP1 cleavage of PeTa cells after 6 days of indicated treatment. Etoposide (10 μM; for 24 h) serves as positive control for apoptosis, and H3 serves as loading control.

: Etoposide purchased from MedChemExpress. Usage Cited in: Aging Cell. 2020 Jul;19(7):e13171. [Abstract]; RPE p16‐mCherry cells were treated with DMSO, Etoposide (20 μM), H2O2 (200 μM), or serum starved for 24 hr.

: Etoposide purchased from MedChemExpress. Usage Cited in: Leuk Lymphoma. 2018 Jan;59(1):162-170. [Abstract]; WT1 and caspase-3 protein levels are detected in two primary AML blasts treated with 100 μM Eto for 24 h.

: Etoposide purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2017 Nov 1:408:43-54. [Abstract]; Western blot analysis of p-p70S6k, p70S6k, p-AKT and AKT after 6 h of treatment with 20 μM RAD001. Levels of p-p70S6k and p-AKT are quantified by densitometric analysis and a corresponding histogram is constructed as relative to p70S6k or AKT and α-tubulin. The lower panel shows a representative Western blot.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Isoforms

Topoisomerase Topo I Topo II DNA gyrase

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

Topoisomerase II

Cellular Effect

Cell Line	Type	Value	Description	References
1A9	ED₅₀	0.15 μM Compound: 1	Dose required to cause reduction in human ovarian 1A9 cancer cells after 3 days incubation Dose required to cause reduction in human ovarian 1A9 cancer cells after 3 days incubation	[PMID: 15456257]
1A9/ptx-10	ED₅₀	> 5 μM Compound: 1	Dose required for reduction in paclitaxel resistant human ovarian 1A9-PTX10 cancer cells after 3 days incubation Dose required for reduction in paclitaxel resistant human ovarian 1A9-PTX10 cancer cells after 3 days incubation	[PMID: 15456257]
4T1	IC₅₀	> 10 μM Compound: ETP	Growth inhibition of mouse 4T1 cells after 72 hrs by MTT assay Growth inhibition of mouse 4T1 cells after 72 hrs by MTT assay	[PMID: 30471828]
5637	IC₅₀	0.53 μM Compound: Etoposide	Growth inhibition against human 5637 cell lines Growth inhibition against human 5637 cell lines	[PMID: 15189040]
5637	IC₅₀	0.54 μM Compound: Etoposide	Antiproliferative activity against human 5637 cells after 96 hrs by crystal violet assay Antiproliferative activity against human 5637 cells after 96 hrs by crystal violet assay	[PMID: 18434163]
A-375	IC₅₀	0.24 μM Compound: Etoposide	Cytotoxicity against human A375 cells assessed as growth inhibition after 72 hrs by ATPlite assay Cytotoxicity against human A375 cells assessed as growth inhibition after 72 hrs by ATPlite assay	[PMID: 26793989]
A-375	IC₅₀	0.24 μM Compound: Etoposide	Antiproliferative activity against human A375 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay Antiproliferative activity against human A375 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay	[PMID: 27096049]
A-375	IC₅₀	0.28 μM Compound: VP-16	Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
A-375	IC₅₀	0.5 μM Compound: Etoposide	Antiproliferation activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferation activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33079544]
A-375	IC₅₀	1.39 μM Compound: 2, Etop	Anticancer activity against human A375 cells after 48 hrs by MTT assay Anticancer activity against human A375 cells after 48 hrs by MTT assay	[PMID: 22136907]
A-375	IC₅₀	12 μM Compound: Etoposide	Cytotoxicity activity against human A375 cells after 48 hrs by NRU assay Cytotoxicity activity against human A375 cells after 48 hrs by NRU assay	[PMID: 20570625]
A-375	IC₅₀	19 μM Compound: Etoposide	Cytotoxicity activity against human A375 cells after 24 hrs by NRU assay Cytotoxicity activity against human A375 cells after 24 hrs by NRU assay	[PMID: 20570625]
A-375	IC₅₀	2.31 μg/mL Compound: Etoposide	Antiproliferative activity against human A375 cells after 48 hrs by MTT assay Antiproliferative activity against human A375 cells after 48 hrs by MTT assay	[PMID: 19410455]
A-375	IC₅₀	24.46 μM Compound: Etoposide	Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32199733]
A-375	IC₅₀	3.92 μM Compound: Etoposide	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 19036584]
A-375	IC₅₀	3.92 μM Compound: Etoposide	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 19782567]
A-427	IC₅₀	0.095 μg/mL Compound: Etoposide	Cytotoxic activity of compound against A-427 lung human tumor cell line Cytotoxic activity of compound against A-427 lung human tumor cell line	[PMID: 12459024]
A-427	IC₅₀	0.095 μg/mL Compound: Etoposide	Cytotoxic activity against human A-427 lung tumor cell line Cytotoxic activity against human A-427 lung tumor cell line	[PMID: 15149673]
A-427	IC₅₀	0.13 μM Compound: Etoposide	Antiproliferative activity against human A427 cells after 96 hrs by crystal violet assay Antiproliferative activity against human A427 cells after 96 hrs by crystal violet assay	[PMID: 18434163]
A-431	IC₅₀	591 nM Compound: 1 (VP16)	In vivo antiproliferative activity against A431 cell line In vivo antiproliferative activity against A431 cell line	[PMID: 15084135]
A2058	IC₅₀	8.9 μM Compound: Etoposide	Cytotoxicity against human A2058 cells incubated for 24 hrs by AlamarBlue staining based analysis Cytotoxicity against human A2058 cells incubated for 24 hrs by AlamarBlue staining based analysis	[PMID: 36857518]
A2780	GI₅₀	1.3 μM Compound: 2	Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B based ELISA Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B based ELISA	[PMID: 21402478]
A2780	GI₅₀	1.3 μM Compound: 2, VP-16	Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 21489802]
A2780	GI₅₀	1.3 μM Compound: Etoposide	Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
A2780	GI₅₀	1.31 μM Compound: 2, Eto	Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
A2780	GI₅₀	1.31 μM Compound: 2, Eto	Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
A2780	IC₅₀	0.07 μM Compound: EP	Growth inhibition human A2780 cells after 72 hrs by MTS assay Growth inhibition human A2780 cells after 72 hrs by MTS assay	[PMID: 30633861]
A2780	IC₅₀	65 μM Compound: 1	Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene	[PMID: 11844671]
A498	GI₅₀	8 μM Compound: 2	In vitro cytotoxic activity against renal (A 498) cancer cell line. In vitro cytotoxic activity against renal (A 498) cancer cell line.	[PMID: 10465531]
A498	IC₅₀	0.23 μM Compound: Etoposide	Antiproliferative activity against human A498 cells assessed as reduction in cell viability incubated for 72 hr by SRB assay Antiproliferative activity against human A498 cells assessed as reduction in cell viability incubated for 72 hr by SRB assay	[PMID: 34931849]
A549	EC₅₀	0.4 μg/mL Compound: Etoposide	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 23043462]
A549	EC₅₀	0.4 μg/mL Compound: etoposide	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 20073490]
A549	EC₅₀	0.8 μg/mL Compound: Etoposide	Cytotoxicity against human A549 cells after 2 days Cytotoxicity against human A549 cells after 2 days	[PMID: 17629328]
A549	EC₅₀	0.8 μg/mL Compound: etoposide	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 17672504]
A549	ED₅₀	1.5 μg/mL Compound: etoposide	Cytotoxicity against human A549 cells by SRB method Cytotoxicity against human A549 cells by SRB method	[PMID: 16252909]
A549	ED₅₀	1.95 mM Compound: VP-16	The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line. The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.	[PMID: 10395485]
A549	ED₅₀	10.6 μM Compound: 1	Dose required for reduction in human lung A549 cancer cells after 3 days incubation Dose required for reduction in human lung A549 cancer cells after 3 days incubation	[PMID: 15456257]
A549	ED₅₀	1900 nM Compound: Etoposide	In vitro cytotoxicity against A549 (human lung carcinoma) cell line. In vitro cytotoxicity against A549 (human lung carcinoma) cell line.	[PMID: 12419378]
A549	ED₅₀	2.9 μg/mL Compound: VP-16	Inhibition of growth of lung non-small cell carcinoma A-549 cell line Inhibition of growth of lung non-small cell carcinoma A-549 cell line	[PMID: 8389875]
A549	ED₅₀	3.39 μM Compound: Etoposide	Effective dose on human lung carcinoma (A549) cells Effective dose on human lung carcinoma (A549) cells	[PMID: 15914002]
A549	ED₅₀	3.76 μM Compound: etoposide	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 16441087]
A549	GI₅₀	0.7 μM Compound: Etoposide	Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 27023255]
A549	GI₅₀	1.5 μM Compound: Etoposide	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 30840453]
A549	GI₅₀	1.5 μM Compound: Etoposide	Antiproliferative activity against human A549 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
A549	GI₅₀	1.5 μM Compound: VP-16	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 29129514]
A549	GI₅₀	1.7 μM Compound: Etoposide	Growth inhibition of human A549 cells after 72 hrs by MTT assay Growth inhibition of human A549 cells after 72 hrs by MTT assay	[PMID: 28406636]
A549	GI₅₀	10 μM Compound: ETP	Cytotoxicity against human A549 cells assessed as cell growth inhibition for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition for 72 hrs by MTT assay	[PMID: 35580424]
A549	GI₅₀	2.2 μM Compound: Etoposide	Growth inhibition of human A549 cells after 72 hrs by SRB assay Growth inhibition of human A549 cells after 72 hrs by SRB assay	[PMID: 23153810]
A549	GI₅₀	3.08 μM Compound: 2	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B based ELISA Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B based ELISA	[PMID: 21402478]
A549	GI₅₀	3.08 μM Compound: 2, Eto	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
A549	GI₅₀	3.08 μM Compound: 2, Eto	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
A549	GI₅₀	3.08 μM Compound: 2, VP-16	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 21489802]
A549	GI₅₀	3.08 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
A549	GI₅₀	4.46 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 72 hrs by MTT assay relative to untreated control Cytotoxicity against human A549 cells after 72 hrs by MTT assay relative to untreated control	[PMID: 24389510]
A549	IC₅₀	0.1 μM Compound: Etoposide	Growth inhibition of human A549 cells after 72 hrs by MTT assay Growth inhibition of human A549 cells after 72 hrs by MTT assay	[PMID: 24950030]
A549	IC₅₀	0.16 μM Compound: Etoposide	Inhibitory activity against A549 cell line using MTT assay(Wild type p53) Inhibitory activity against A549 cell line using MTT assay(Wild type p53)	[PMID: 10780913]
A549	IC₅₀	0.24 μM Compound: Etoposide	Cytotoxicity in human A549 cells by sulforhodamine B colorimetric assay Cytotoxicity in human A549 cells by sulforhodamine B colorimetric assay	[PMID: 27933890]
A549	IC₅₀	0.29 μM Compound: 2, VP-16	Cytotoxicity against human A549 cells after 48 hrs Cytotoxicity against human A549 cells after 48 hrs	[PMID: 20053564]
A549	IC₅₀	0.3 μM Compound: Etoposide	Growth inhibition of human A549 cells incubated for 72 hrs by sulforhodamine B assay Growth inhibition of human A549 cells incubated for 72 hrs by sulforhodamine B assay	[PMID: 28625715]
A549	IC₅₀	0.3 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30041947]
A549	IC₅₀	0.3 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by SRB assay	[PMID: 33636429]
A549	IC₅₀	0.31 μM Compound: Etoposide	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
A549	IC₅₀	0.32 μM Compound: etoposide	Cytotoxicity against human A549 cells after 48 hrs by SRB method Cytotoxicity against human A549 cells after 48 hrs by SRB method	[PMID: 17493824]
A549	IC₅₀	0.4 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 37672645]
A549	IC₅₀	0.4 μM Compound: etoposide	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
A549	IC₅₀	0.44 μM Compound: Etoposide	Cytotoxicity against human A549 cells by sulforhodamine B assay Cytotoxicity against human A549 cells by sulforhodamine B assay	[PMID: 21936523]
A549	IC₅₀	0.47 μM Compound: Etoposide	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 30755350]
A549	IC₅₀	0.48 μM Compound: Etoposide	Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 31894983]
A549	IC₅₀	0.48 μM Compound: etoposide	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by Hoechst assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by Hoechst assay	[PMID: 26225905]
A549	IC₅₀	0.5 μM Compound: VP-16	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 11473438]
A549	IC₅₀	0.59 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by ATPlite assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by ATPlite assay	[PMID: 26793989]
A549	IC₅₀	0.59 μM Compound: Etoposide	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay	[PMID: 27096049]
A549	IC₅₀	0.6 μM Compound: Etoposide	Antiproliferative activity against human A549 cells assessed as reduction in cell viability by sulforhodamine B assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability by sulforhodamine B assay	[PMID: 32073848]
A549	IC₅₀	0.6 μM Compound: VP-16	Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
A549	IC₅₀	0.63 μM Compound: VP-16	Cytotoxicity against human A549 cells after 24 hrs by SRB assay Cytotoxicity against human A549 cells after 24 hrs by SRB assay	[PMID: 19769341]
A549	IC₅₀	0.63 μM Compound: VP-16	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 20415462]
A549	IC₅₀	0.63 μM Compound: etoposide	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19685913]
A549	IC₅₀	0.6 μg/mL Compound: Etoposide	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 21216051]
A549	IC₅₀	0.7 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 31082231]
A549	IC₅₀	0.71 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 30776236]
A549	IC₅₀	0.72 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 29893558]
A549	IC₅₀	0.8 μM Compound: Etoposide	Antiproliferative activity against human A549 cells after 24 to 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 24 to 72 hrs by SRB assay	[PMID: 26595875]
A549	IC₅₀	0.8 μM Compound: Etoposide	Antiproliferative activity against human A549 cells measured after 72 hrs by SRB assay Antiproliferative activity against human A549 cells measured after 72 hrs by SRB assay	[PMID: 35362983]
A549	IC₅₀	0.8 μM Compound: etoposide	Antiproliferative activity at human A549 cells after 72 hrs by MTT assay Antiproliferative activity at human A549 cells after 72 hrs by MTT assay	[PMID: 22861499]
A549	IC₅₀	0.8 μM Compound: etoposide	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 25495422]
A549	IC₅₀	0.8 μM Compound: etoposide	Antiproliferative activity against human A549 cells after 3 days by sulforhodamine B assay Antiproliferative activity against human A549 cells after 3 days by sulforhodamine B assay	[PMID: 25700232]
A549	IC₅₀	0.83 μM Compound: VP-16	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 20071056]
A549	IC₅₀	0.92 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 28165740]
A549	IC₅₀	1.03 μg/mL Compound: 1	Growth inhibition of A549 (human lung carcinoma) cell line. Growth inhibition of A549 (human lung carcinoma) cell line.	[PMID: 2002477]
A549	IC₅₀	1.06 μM Compound: Etoposide	Concentration required for inhibiting proliferation of human lung tumor cell line A549 after 72 hr of incubation was determined Concentration required for inhibiting proliferation of human lung tumor cell line A549 after 72 hr of incubation was determined	[PMID: 15482917]
A549	IC₅₀	1.06 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 32992133]
A549	IC₅₀	1.1 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 28841320]
A549	IC₅₀	1.16 μM Compound: etoposide	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 17194596]
A549	IC₅₀	1.16 μM Compound: etoposide	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 18321715]
A549	IC₅₀	1.2 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs Cytotoxicity against human A549 cells after 48 hrs	[PMID: 19115839]
A549	IC₅₀	1.3 μM Compound: Etoposide	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29077404]
A549	IC₅₀	1.3 μM Compound: Etoposide	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 32196342]
A549	IC₅₀	1.4 μM Compound: Etoposide	Cytotoxicity in human A549 cells by SRB assay Cytotoxicity in human A549 cells by SRB assay	[PMID: 26812172]
A549	IC₅₀	1.4 μM Compound: etoposide	Cytotoxicity against human A549 cells by SRB microtiter plate assay Cytotoxicity against human A549 cells by SRB microtiter plate assay	[PMID: 17585747]
A549	IC₅₀	1.7 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by WST-8 assay Cytotoxicity against human A549 cells after 48 hrs by WST-8 assay	[PMID: 19072209]
A549	IC₅₀	1.7 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by SRB method Cytotoxicity against human A549 cells after 48 hrs by SRB method	[PMID: 19425589]
A549	IC₅₀	1.7 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by resazurin assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by resazurin assay	[PMID: 26592897]
A549	IC₅₀	1.71 μM Compound: VP-16	Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24095018]
A549	IC₅₀	1.74 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 26706168]
A549	IC₅₀	1.85 μM Compound: Etoposide	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 21182258]
A549	IC₅₀	1.85 μM Compound: Etoposide	Anticancer activity against human A549 cells by SRB assay Anticancer activity against human A549 cells by SRB assay	[PMID: 21420296]
A549	IC₅₀	1.85 μM Compound: Etoposide	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 26988298]
A549	IC₅₀	1.9 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay	[PMID: 38718553]
A549	IC₅₀	1.97 μM Compound: Etoposide	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 29289884]
A549	IC₅₀	1.97 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 34838335]
A549	IC₅₀	10 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as cell growth inhibition by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition by MTT assay	[PMID: 37676247]
A549	IC₅₀	10.12 μM Compound: 2	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 22687745]
A549	IC₅₀	10.12 μM Compound: Etoposideg	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25462233]
A549	IC₅₀	10.44 μM Compound: VP-16	Cytotoxicity against human A549 cells assessed as reduction in cell growth measured after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells assessed as reduction in cell growth measured after 48 hrs by sulforhodamine B assay	[PMID: 31239178]
A549	IC₅₀	10.71 μg/mL Compound: Etoposide	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25016373]
A549	IC₅₀	100 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 30447888]
A549	IC₅₀	11 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21397370]
A549	IC₅₀	11.92 μM Compound: 2	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 25744190]
A549	IC₅₀	13.71 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 29545100]
A549	IC₅₀	13.78 μM Compound: VP-16	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 25240702]
A549	IC₅₀	14.3 μM Compound: VP-16	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19394829]
A549	IC₅₀	14.3 μM Compound: VP-16	Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
A549	IC₅₀	14.7 μM Compound: 2; VP-16	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 28512026]
A549	IC₅₀	14.8 μM Compound: VP-16	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21733601]
A549	IC₅₀	14.9 μM Compound: VP-16	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24095019]
A549	IC₅₀	15.1 μM Compound: VP-16	Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 assay	[PMID: 36063665]
A549	IC₅₀	15.8 nM Compound: Ref 34, Cpd 2	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
A549	IC₅₀	16 μM Compound: etoposide	Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction assay Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction assay	[PMID: 20413315]
A549	IC₅₀	16.6 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 28571311]
A549	IC₅₀	167.97 μM Compound: VP-16	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 24775914]
A549	IC₅₀	170 nM Compound: 1a	In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line	[PMID: 14980682]
A549	IC₅₀	18.2 μM Compound: Etop	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 26216018]
A549	IC₅₀	19.83 μM Compound: Etoposide	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28462840]
A549	IC₅₀	2 μM Compound: Etoposide	Growth inhibition of human A549 cells after 72 hrs by MTT assay Growth inhibition of human A549 cells after 72 hrs by MTT assay	[PMID: 24180210]
A549	IC₅₀	2.03 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 29269253]
A549	IC₅₀	2.1 μM Compound: Etoposide	Cytotoxicity against human lung adenocarcinoma cell line A549 assessed as inhibition of cell viability measured after 24 hrs by MTT assay Cytotoxicity against human lung adenocarcinoma cell line A549 assessed as inhibition of cell viability measured after 24 hrs by MTT assay	[PMID: 23305918]
A549	IC₅₀	2.17 μM Compound: Etoposide	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31227365]
A549	IC₅₀	2.2 μM Compound: Etoposide	Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 33421712]
A549	IC₅₀	2.27 μM Compound: V	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 29289881]
A549	IC₅₀	2.27 μM Compound: VP-16	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38107170]
A549	IC₅₀	2.34 μM Compound: 2, Etop	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 22136907]
A549	IC₅₀	2.4 μM Compound: Etoposide	Antiproliferation activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferation activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33079544]
A549	IC₅₀	2.45 μM Compound: 2	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 24721832]
A549	IC₅₀	2.46 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 30109008]
A549	IC₅₀	2.56 nM Compound: 1, VP-16	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21145139]
A549	IC₅₀	2.58 μM Compound: 2	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 24553146]
A549	IC₅₀	2.58 μM Compound: 3	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 23490151]
A549	IC₅₀	2.58 μM Compound: 3	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 24332656]
A549	IC₅₀	2.675 μM Compound: Etoposide	Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 26615886]
A549	IC₅₀	2.8 μM Compound: 2a, VP-16	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23182091]
A549	IC₅₀	2.87 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by Alamar Blue assay Cytotoxicity against human A549 cells after 48 hrs by Alamar Blue assay	[PMID: 25466187]
A549	IC₅₀	20.9 μM Compound: etoposide	Cytotoxicity against human A549 cell line by MTT assay Cytotoxicity against human A549 cell line by MTT assay	[PMID: 17243725]
A549	IC₅₀	21.4 μM Compound: etoposide	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 3 days by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 3 days by MTT assay	[PMID: 21277655]
A549	IC₅₀	22.5 μM Compound: VP-16	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 30265994]
A549	IC₅₀	23.8 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 22342101]
A549	IC₅₀	23.94 μM Compound: VP16; 2	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26873416]
A549	IC₅₀	24.31 μM Compound: vp16	Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
A549	IC₅₀	24.9 μM Compound: 2, VP-16	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 22244588]
A549	IC₅₀	24.9 μM Compound: 5, VP-16	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 22041063]
A549	IC₅₀	241.9 μM Compound: Etoposide	Antiproliferative against human A549 cells after 48 hrs by MTT assay Antiproliferative against human A549 cells after 48 hrs by MTT assay	[PMID: 24996136]
A549	IC₅₀	25.6 μM Compound: 2; VP-16	Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 31278032]
A549	IC₅₀	29.7 μM Compound: VP16	Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 27517805]
A549	IC₅₀	3.01 μM Compound: Etoposide	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 25615796]
A549	IC₅₀	3.08 μM Compound: Etoposide	Anticancer activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay Anticancer activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21074444]
A549	IC₅₀	3.08 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 31281022]
A549	IC₅₀	3.08 μM Compound: Etoposide	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 38784476]
A549	IC₅₀	3.2 μM Compound: 2, VP-16	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23711769]
A549	IC₅₀	3.2 μM Compound: 2, VP-16	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24140948]
A549	IC₅₀	3.25 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 29525336]
A549	IC₅₀	3.82 μM Compound: Etoposide	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 27060757]
A549	IC₅₀	3.9 μM Compound: Etoposide	Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay	10.1007/s00044-011-9937-1
A549	IC₅₀	3.9 μM Compound: Etoposide	Anticancer activity against Homo sapiens (human) A549 cells assessed as decrease in cell growth after 3 days by MTT assay Anticancer activity against Homo sapiens (human) A549 cells assessed as decrease in cell growth after 3 days by MTT assay	10.1007/s00044-012-0245-1
A549	IC₅₀	3.9 μM Compound: Etoposide	Growth inhibition of human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Growth inhibition of human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	10.1039/C5MD00314H
A549	IC₅₀	32.05 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 23968711]
A549	IC₅₀	32.61 μM Compound: VP-16	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29335211]
A549	IC₅₀	38.5 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26292628]
A549	IC₅₀	4.7 μM Compound: Etoposide	Anticancer activity against human A549 cells by MTT assay Anticancer activity against human A549 cells by MTT assay	10.1039/C4MD00279B
A549	IC₅₀	4.8 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst staining based assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst staining based assay	[PMID: 34786945]
A549	IC₅₀	4.9 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human A549 cells incubated for 3 days by MTT assay Antiproliferative activity against human A549 cells incubated for 3 days by MTT assay	[PMID: 32992133]
A549	IC₅₀	5.62 μM Compound: 2	Cytotoxicity against human A549 cells by sulforhodamine B assay Cytotoxicity against human A549 cells by sulforhodamine B assay	[PMID: 17988764]
A549	IC₅₀	5.62 μM Compound: 2	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 21477899]
A549	IC₅₀	5.87 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28068602]
A549	IC₅₀	5.9 μM Compound: etoposide	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19053514]
A549	IC₅₀	50 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 25453799]
A549	IC₅₀	6 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31669850]
A549	IC₅₀	6.21 μM Compound: 2	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 28757065]
A549	IC₅₀	6.74 μM Compound: Etoposide	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 26649766]
A549	IC₅₀	664 nM Compound: 1 (VP16)	In vivo antiproliferative activity against A549 cell line In vivo antiproliferative activity against A549 cell line	[PMID: 15084135]
A549	IC₅₀	67.25 μM Compound: VP-16	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24775914]
A549	IC₅₀	68 μM Compound: Eto	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30109001]
A549	IC₅₀	8.01 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 36 hrs by MTT assay Cytotoxicity against human A549 cells after 36 hrs by MTT assay	[PMID: 27262599]
A549	IC₅₀	8.37 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 18844422]
A549	IC₅₀	8.91 μM Compound: VP-16	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25599951]
A549	IC₅₀	8.9 μg/mL Compound: Etoposide	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	10.1039/C4MD00525B
A549	IC₅₀	9.1 μM Compound: 2; VP-16	Cytotoxicity against human A549 cells assessed as reduction in inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 29248296]
A549	IC₅₀	9.3 μM Compound: etoposide	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 25402632]
A549	IC₅₀	9.51 μM Compound: Etoposide	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 19036584]
A549	IC₅₀	9.51 μM Compound: Etoposide	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 19782567]
A549	IC₅₀	9.51 μM Compound: Etoposide	Cytotoxicity against human A549 cells after 2 days by MTT assay Cytotoxicity against human A549 cells after 2 days by MTT assay	[PMID: 22325897]
A549	IC₅₀	9.9 μM Compound: VP-16	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 38107170]
A549	IC₅₀	9.98 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as reduction of cell growth by SRB method Cytotoxicity against human A549 cells assessed as reduction of cell growth by SRB method	[PMID: 18782668]
A549	IC₅₀	9469.5 nM Compound: VP-16	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29886322]
A549	IC₅₀	> 10 μM Compound: 3; Etop	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
A549	IC₅₀	> 10 μM Compound: Etoposide	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 29072457]
A549	IC₅₀	> 10 μM Compound: VP-16	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 30543429]
A549	IC₅₀	> 100 μM Compound: Etoposide	Cytotoxicity against human A549 cells incubated for 24 hrs by AlamarBlue staining based analysis Cytotoxicity against human A549 cells incubated for 24 hrs by AlamarBlue staining based analysis	[PMID: 36857518]
A549	IC₅₀	> 30 μM Compound: ETP	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 28094224]
A549	IC₅₀	> 50 μM Compound: Etoposide	Cytotoxicity against human A549 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by SRB assay	[PMID: 31404864]
A549	IC₅₀	>= 2.91 μM Compound: Etoposide	Anticancer activity against human A549 cells after 48 hrs by SRB assay Anticancer activity against human A549 cells after 48 hrs by SRB assay	[PMID: 30660827]
A549	IC₅₀	>= 6.94 μM Compound: Etoposide	Antiproliferative activity against human A549 cells by SRB assay Antiproliferative activity against human A549 cells by SRB assay	[PMID: 31546197]
ACHN	ED₅₀	13 μg/mL Compound: VP-16	Inhibition of growth of renal cancer ACHN cell line Inhibition of growth of renal cancer ACHN cell line	[PMID: 8389875]
ACHN	IC₅₀	2.04 μM Compound: 2	Anticancer activity against human ACHN cells after 48 hrs by MTT assay Anticancer activity against human ACHN cells after 48 hrs by MTT assay	[PMID: 24721832]
ACHN	IC₅₀	2.15 μM Compound: VP-16	Antiproliferative activity against human ACHN cells after 96 hrs by MTT assay Antiproliferative activity against human ACHN cells after 96 hrs by MTT assay	[PMID: 19053767]
ACHN	IC₅₀	2.15 μM Compound: VP-16	Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
ACHN	IC₅₀	7.61 μM Compound: 2, Etop	Anticancer activity against human ACHN cells after 48 hrs by MTT assay Anticancer activity against human ACHN cells after 48 hrs by MTT assay	[PMID: 22136907]
ACHN	IC₅₀	7.61 μM Compound: 2a, VP-16	Cytotoxicity against human ACHN cells after 72 hrs by MTT assay Cytotoxicity against human ACHN cells after 72 hrs by MTT assay	[PMID: 23182091]
AGS	IC₅₀	0.36 μM Compound: Etoposide	Cytotoxicity against human AGS cells after 3 days by MTT assay Cytotoxicity against human AGS cells after 3 days by MTT assay	[PMID: 19013074]
AGS	IC₅₀	0.36 μM Compound: Etoposide	Cytotoxicity against human AGS cells after 72 hrs by MTT assay Cytotoxicity against human AGS cells after 72 hrs by MTT assay	[PMID: 19269832]
AGS	IC₅₀	0.36 μM Compound: Etoposide	Cytotoxicity against human AGS cells after 3 days by MTT assay Cytotoxicity against human AGS cells after 3 days by MTT assay	[PMID: 19419803]
AGS	IC₅₀	0.36 μM Compound: Etoposide	Cytotoxicity against human AGS cells after 72 hrs by MTT assay Cytotoxicity against human AGS cells after 72 hrs by MTT assay	[PMID: 20828890]
AGS	IC₅₀	0.36 μM Compound: Etoposide	Anticancer activity against human AGS cells after 3 days by MTT assay Anticancer activity against human AGS cells after 3 days by MTT assay	[PMID: 21621882]
AGS	IC₅₀	0.36 μM Compound: Etoposide	Cytotoxicity against human AGS cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human AGS cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23454511]
AGS	IC₅₀	0.36 μM Compound: etoposide	Antitumor against human AGS cells after 72 hrs by MTT assay Antitumor against human AGS cells after 72 hrs by MTT assay	[PMID: 18299197]
Astrocyte	EC₅₀	0.433 μM Compound: 2	Antiproliferative activity against mouse astrocyte cells by MTT assay Antiproliferative activity against mouse astrocyte cells by MTT assay	[PMID: 17417631]
Astrocyte	IC₅₀	> 10 μM Compound: Etoposide	Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method	[PMID: 26355532]
B16	IC₅₀	0.13 μM Compound: Etoposide	Cytotoxicity activity against mouse B16 cells after 48 hrs by NRU assay Cytotoxicity activity against mouse B16 cells after 48 hrs by NRU assay	[PMID: 20570625]
B16	IC₅₀	0.28 μM Compound: etoposide	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 19919064]
B16	IC₅₀	0.32 μM Compound: ETP	Cytotoxic activity against solid tumor, B16 (murine melanoma) concentration of agent required to reduce cell viability by 50% Cytotoxic activity against solid tumor, B16 (murine melanoma) concentration of agent required to reduce cell viability by 50%	[PMID: 10377219]
B16	IC₅₀	1.39 μM Compound: 2a, VP-16	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 23182091]
B16	IC₅₀	1.85 μM Compound: 2	Cytotoxicity against human B16 cells after 48 hrs by MTT assay Cytotoxicity against human B16 cells after 48 hrs by MTT assay	[PMID: 30108892]
B16	IC₅₀	9 μM Compound: Etoposide	Cytotoxicity activity against mouse B16 cells after 24 hrs by NRU assay Cytotoxicity activity against mouse B16 cells after 24 hrs by NRU assay	[PMID: 20570625]
B16	IC₅₀	> 0.91 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human B16 cells incubated for 48 to 72 hrs by MTT assay Antiproliferative activity against human B16 cells incubated for 48 to 72 hrs by MTT assay	[PMID: 32992133]
B16-F10	IC₅₀	18.69 μM Compound: Etoposide	Cytotoxicity against mouse B16F10 cells after 48 hrs by MTT assay Cytotoxicity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 22115593]
B16-F10	IC₅₀	18.71 μM Compound: Etoposide	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 22578452]
B16-F10	IC₅₀	3.8 μg/mL Compound: Etoposide	Cytotoxicity against mouse B16F10 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse B16F10 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 24424132]
B16-F10	IC₅₀	4.12 μg/mL Compound: Etoposide	Cytotoxicity against mouse B16F10 cells assessed as decrease in cell number after 24 hrs by MTT assay Cytotoxicity against mouse B16F10 cells assessed as decrease in cell number after 24 hrs by MTT assay	[PMID: 25978960]
B16-F10	IC₅₀	> 50 μM Compound: Etoposide	Activation of procaspase-3-mediated human B16-F10 cell death after 72 hrs by MTS/PMS assay Activation of procaspase-3-mediated human B16-F10 cell death after 72 hrs by MTS/PMS assay	[PMID: 16936720]
BEAS-2B	IC₅₀	21 μM Compound: VP-16	Antiproliferative activity against human BEAS-2B cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human BEAS-2B cells incubated for 72 hrs by CCK8 assay	[PMID: 36063665]
BEAS-2B	IC₅₀	> 10 μM Compound: 3; Etop	Antiproliferative activity against human BEAS-2B cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human BEAS-2B cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
BGC-823	IC₅₀	1.06 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human BGC-823 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human BGC-823 cells incubated for 48 hrs by MTT assay	[PMID: 32992133]
BGC-823	IC₅₀	2.88 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human BGC-823 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human BGC-823 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
BGC-823	IC₅₀	25.72 μM Compound: VP-16	Cytotoxicity against human BGC823 cells Cytotoxicity against human BGC823 cells	[PMID: 24775914]
BGC-823	IC₅₀	30.74 μM Compound: VP-16	Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay	[PMID: 24775914]
BT-474	IC₅₀	6.6 μM Compound: Etoposide	Antiproliferative activity against human BT474 cells after 72 hrs by CCK8 assay Antiproliferative activity against human BT474 cells after 72 hrs by CCK8 assay	[PMID: 26988802]
BT-549	IC₅₀	1 μM Compound: Etoposide	Cytotoxicity against human BT549 cells after 48 hrs by SRB assay Cytotoxicity against human BT549 cells after 48 hrs by SRB assay	[PMID: 28841320]
BT-549	IC₅₀	1.24 μM Compound: Etoposide	Cytotoxicity against human BT549 cells after 48 hrs by SRB assay Cytotoxicity against human BT549 cells after 48 hrs by SRB assay	[PMID: 28165740]
BT-549	IC₅₀	1.8 μM Compound: Etoposide	Cytotoxicity against human BT549 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human BT549 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30457333]
BV-173	IC₅₀	0.9 μM Compound: Etoposide	Cytotoxicity against human BV173 cells after 72 hrs by MTT assay Cytotoxicity against human BV173 cells after 72 hrs by MTT assay	[PMID: 17459529]
Bel-7402	IC₅₀	0.08 μM Compound: etoposide	Cytotoxicity against human Bel7402 cells Cytotoxicity against human Bel7402 cells	[PMID: 23092389]
Bel-7402	IC₅₀	1.03 μM Compound: etoposide	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 19685913]
Bel-7402	IC₅₀	1.9 μM Compound: etoposide	Cytotoxicity against human Bel7402 cells after 5 days by MTT assay Cytotoxicity against human Bel7402 cells after 5 days by MTT assay	[PMID: 8778240]
C-33-A	IC₅₀	0.084 μg/mL Compound: Etoposide	Cytotoxic activity against human C-33A cervix tumor cell line Cytotoxic activity against human C-33A cervix tumor cell line	[PMID: 15149673]
C6	EC₅₀	6.8 x 10^-4 M Compound: etoposide	Inhibition of tubulin polymerization in rat C6 cells after 4 hrs Inhibition of tubulin polymerization in rat C6 cells after 4 hrs	[PMID: 8988604]
C6	IC₅₀	4.32 μM Compound: Etoposide	Cytotoxicity against rat C6 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against rat C6 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33243532]
C6	IC₅₀	< 1.85 μM Compound: vp16	Antiproliferative activity against human C6 cells measured after 72 hrs by MTT assay Antiproliferative activity against human C6 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
CAKI-1	ED₅₀	2.2 mM Compound: VP-16	The compound was tested for tumor cell growth inhibitory activity against human renal cancer(CAKI-1) cell line The compound was tested for tumor cell growth inhibitory activity against human renal cancer(CAKI-1) cell line	[PMID: 10395485]
CAKI-1	ED₅₀	> 100 μM Compound: 1	Dose required for reduction in human renal CAKI-1 cancer cells after 3 days incubation Dose required for reduction in human renal CAKI-1 cancer cells after 3 days incubation	[PMID: 15456257]
CAKI-1	IC₅₀	1.1 μM Compound: Etoposide	Antiproliferative activity against human CAKI-1 cells after 24 to 72 hrs by SRB assay Antiproliferative activity against human CAKI-1 cells after 24 to 72 hrs by SRB assay	[PMID: 26595875]
CAPAN-1	IC₅₀	0.15 μM Compound: Etoposide	Cytostatic activity against human Capan1 cells Cytostatic activity against human Capan1 cells	[PMID: 30738653]
CAPAN-1	IC₅₀	1.45 μM Compound: Etoposide	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
CCD-18Co	IC₅₀	18.42 μM Compound: Etoposide	Antiproliferative activity against human CCD-18Co cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human CCD-18Co cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33398999]
CCD-18Co	IC₅₀	20.3 μM Compound: Etoposide	Antiproliferative activity against human CCD-18Co cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human CCD-18Co cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
CCD-18Co	IC₅₀	43.6 μg/mL Compound: Etoposide	Cytotoxicity against human CCD-18Co cells after 72 hrs by MTS assay Cytotoxicity against human CCD-18Co cells after 72 hrs by MTS assay	[PMID: 22032697]
CCD-18Co	IC₅₀	44.4 μM Compound: Etoposide	Cytotoxicity against human CCD-18Co cells after 72 hrs by MTS assay Cytotoxicity against human CCD-18Co cells after 72 hrs by MTS assay	[PMID: 21724394]
CCD-841CoN	IC₅₀	7.6 μM Compound: Etoposide	Antiproliferative activity against human CCD-841CoN cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human CCD-841CoN cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
CCD-841CoN	IC₅₀	8.71 μM Compound: Etoposide	Antiproliferative activity against human CCD-841CoN cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human CCD-841CoN cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33398999]
CCRF-CEM	CC₅₀	0.09 μM Compound: Etoposide	Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay	[PMID: 21741130]
CCRF-CEM	GI₅₀	1.26 μM Compound: Etoposide	Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
CCRF-CEM	GI₅₀	1.6 μM Compound: Etoposide	Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 25792142]
CCRF-CEM	GI₅₀	1.6 μM Compound: Etoposide	Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 30071406]
CCRF-CEM	GI₅₀	12.59 μM Compound: Etoposide	Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 22104973]
CCRF-CEM	IC₅₀	0.002 μM Compound: VP-16	Tested for the inhibitory activity against CCRF CEM T- cell leukemia cells Tested for the inhibitory activity against CCRF CEM T- cell leukemia cells	[PMID: 7932571]
CCRF-CEM	IC₅₀	0.12 μM Compound: Etoposide	Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay	[PMID: 27060757]
CCRF-CEM	IC₅₀	0.24 μM Compound: etoposide	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
CCRF-CEM	IC₅₀	1.1 μM Compound: VP-16	Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 19394829]
CCRF-CEM	IC₅₀	1.1 μM Compound: VP-16	Antiproliferative activity against human CCRF-CEM cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
CCRF-CEM	IC₅₀	1.1 μM Compound: VP-16	Cytotoxicity against human CCRF-CEM cells by MTT assay Cytotoxicity against human CCRF-CEM cells by MTT assay	[PMID: 30543429]
CCRF-CEM	IC₅₀	1.2 μM Compound: VP-16	Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay	[PMID: 19053767]
CCRF-CEM	IC₅₀	1.2 μM Compound: VP-16	Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
CCRF-CEM	IC₅₀	1146 ng/mL Compound: Etoposide	Cytotoxicity was assessed using human leukemic cell line CCRF-CEM Cytotoxicity was assessed using human leukemic cell line CCRF-CEM	[PMID: 11170627]
CCRF-SB	CC₅₀	0.1 μM Compound: Etoposide	Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay	[PMID: 21741130]
CCRF-SB	IC₅₀	0.1 μM Compound: VP-16	Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay	[PMID: 19053767]
CCRF-SB	IC₅₀	0.1 μM Compound: VP-16	Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
CHO	IC₅₀	0.35 μM Compound: ETP	Cytotoxic activity against solid tumor, CHO (Chinese hamster ovaric carcinoma) concentration of agent required to reduce cell viability by 50% Cytotoxic activity against solid tumor, CHO (Chinese hamster ovaric carcinoma) concentration of agent required to reduce cell viability by 50%	[PMID: 10377219]
COLO	ED₅₀	59 μg/mL Compound: VP-16	Inhibition of growth of colon carcinoma COLO 2-1 cell line Inhibition of growth of colon carcinoma COLO 2-1 cell line	[PMID: 8389875]
COLO 205	GI₅₀	0.13 μM Compound: 2	Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B based ELISA Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B based ELISA	[PMID: 21402478]
COLO 205	GI₅₀	0.13 μM Compound: 2, Eto	Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
COLO 205	GI₅₀	0.13 μM Compound: 2, Eto	Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
COLO 205	GI₅₀	0.13 μM Compound: 2, VP-16	Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay	[PMID: 21489802]
COLO 205	GI₅₀	0.13 μM Compound: Etoposide	Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
COLO 205	GI₅₀	18.1 μM Compound: Etoposide	In vitro cytotoxicity against human colon cancer COLO 205 cell line In vitro cytotoxicity against human colon cancer COLO 205 cell line	[PMID: 9871772]
COLO 205	IC₅₀	0.43 μM Compound: Etoposide	Antiproliferative activity against human COLO205 cells after 48 hrs by MTT assay Antiproliferative activity against human COLO205 cells after 48 hrs by MTT assay	[PMID: 22578452]
COLO 205	IC₅₀	0.47 μM Compound: Etoposide	Anticancer activity against human COLO205 cells by MTT assay Anticancer activity against human COLO205 cells by MTT assay	10.1039/C4MD00279B
COLO 205	IC₅₀	1.07 μg/mL Compound: Etoposide	Cytotoxicity against human COLO205 cells assessed as decrease in cell number after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as decrease in cell number after 24 hrs by MTT assay	[PMID: 25978960]
COLO 205	IC₅₀	12.3 μM Compound: Etoposide	Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay	10.1007/s00044-013-0757-3
COLO 205	IC₅₀	14.23 μM Compound: Etoposide	Cytotoxicity against human COLO205 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human COLO205 cells assessed as growth inhibition after 48 hrs by SRB assay	10.1039/C4MD00325J
COLO 205	IC₅₀	5.12 μg/mL Compound: Etoposide	Cytotoxicity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28351589]
COLO 205	IC₅₀	5.3 μM Compound: Etoposide	Cytotoxicity against human colon cancer line COLO205 assessed as inhibition of cell viability measured after 24 hrs by MTT assay Cytotoxicity against human colon cancer line COLO205 assessed as inhibition of cell viability measured after 24 hrs by MTT assay	[PMID: 23305918]
COLO 205	IC₅₀	7.24 μg/mL Compound: Etoposide	Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay	[PMID: 21632155]
COLO 320DM	ED₅₀	14 μg/mL Compound: VP-16	Inhibition of growth of colon carcinoma COLO 320DM Inhibition of growth of colon carcinoma COLO 320DM	[PMID: 8389875]
CT26	IC₅₀	0.2 μM Compound: etoposide	Antiproliferative activity against mouse CT26 cell line Antiproliferative activity against mouse CT26 cell line	[PMID: 16686539]
CWR22R	IC₅₀	0.364 μM Compound: 2	Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide-based monolayer assay Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide-based monolayer assay	[PMID: 26854430]
CWR22R	IC₅₀	2.3 μM Compound: Etoposide	Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 38237151]
Caco-2	IC₅₀	18.6 μM Compound: Etoposide	Cytotoxicity against human Caco2 cells after 72 hrs by MTS assay Cytotoxicity against human Caco2 cells after 72 hrs by MTS assay	[PMID: 21724394]
Caco-2	IC₅₀	9.4 μg/mL Compound: Etoposide	Cytotoxicity against human Caco2 cells after 72 hrs by MTS assay Cytotoxicity against human Caco2 cells after 72 hrs by MTS assay	[PMID: 22032697]
Calu-1	IC₅₀	> 100 μM Compound: Etoposide	Cytotoxicity against human Calu-1 cells incubated for 24 hrs by AlamarBlue staining based analysis Cytotoxicity against human Calu-1 cells incubated for 24 hrs by AlamarBlue staining based analysis	[PMID: 36857518]
Cancer cell lines	GI₅₀	1.3 μM Compound: Etoposide	Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
Cancer cell lines	GI₅₀	1.3 μM Compound: Etoposide	Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
Cancer cell lines	GI₅₀	1.3 μM Compound: Etoposide	Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
DAN-G	IC₅₀	0.38 μM Compound: Etoposide	Growth inhibition against human DAN-G cell lines Growth inhibition against human DAN-G cell lines	[PMID: 15189040]
DLD-1	IC₅₀	0.57 μM Compound: Etoposide	Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst staining based assay Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst staining based assay	[PMID: 34786945]
DLD-1	IC₅₀	10 μM Compound: etoposide	Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction assay Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction assay	[PMID: 20413315]
DLD-1	IC₅₀	2 μM Compound: Etoposide	Cytotoxicity against human DLD1 cells assessed as growth inhibition after 48 hrs by resazurin assay Cytotoxicity against human DLD1 cells assessed as growth inhibition after 48 hrs by resazurin assay	[PMID: 26592897]
DLD-1	IC₅₀	20 μM Compound: Etoposide	Growth inhibition of human DLD1 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Growth inhibition of human DLD1 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 24527835]
DLD-1	IC₅₀	27 μM Compound: Etoposide	Cytotoxicity against human DLD1 cells after 48 hrs Cytotoxicity against human DLD1 cells after 48 hrs	[PMID: 19115839]
DLD-1	IC₅₀	3.3 μM Compound: etoposide	Cytotoxicity against human DLD1 cells assessed as inhibition of cell growth incubated for 48 hrs by Hoechst assay Cytotoxicity against human DLD1 cells assessed as inhibition of cell growth incubated for 48 hrs by Hoechst assay	[PMID: 26225905]
DLD-1	IC₅₀	5.1 μM Compound: Etoposide	Cytotoxicity against human DLD-1 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay Cytotoxicity against human DLD-1 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay	[PMID: 38718553]
DLD-1	IC₅₀	8.11 μM Compound: ETP	Antiproliferative activity against human DLD1 cells after 48 hrs by SRB assay Antiproliferative activity against human DLD1 cells after 48 hrs by SRB assay	[PMID: 28094224]
DMS-53	IC₅₀	1.5 μM Compound: etoposide	Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay	[PMID: 22861499]
DU-145	CC₅₀	0.4 μM Compound: Etoposide	Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay	[PMID: 21741130]
DU-145	GI₅₀	13 μM Compound: ETP	Cytotoxicity against human DU-145 cells assessed as cell growth inhibition for 72 hrs by MTT assay Cytotoxicity against human DU-145 cells assessed as cell growth inhibition for 72 hrs by MTT assay	[PMID: 35580424]
DU-145	GI₅₀	2 μM Compound: 2	In vitro cytotoxic activity against prostate (DU-145) cancer cell line. In vitro cytotoxic activity against prostate (DU-145) cancer cell line.	[PMID: 10465531]
DU-145	IC₅₀	0.001 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 4 days by CCK-8 assay Cytotoxicity against human DU145 cells after 4 days by CCK-8 assay	[PMID: 25062006]
DU-145	IC₅₀	0.02 μM Compound: Etoposide	Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay	[PMID: 27643560]
DU-145	IC₅₀	0.4 μM Compound: VP-16	Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay	[PMID: 25799376]
DU-145	IC₅₀	0.5 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 2 days by automatic ELISA reader system Cytotoxicity against human DU145 cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
DU-145	IC₅₀	0.5 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 21601964]
DU-145	IC₅₀	0.5 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay	[PMID: 25481396]
DU-145	IC₅₀	0.5 μM Compound: Etoposide	Cytotoxicity against human DU145 cells incubated from day 2 to day 4 by CCK8 assay Cytotoxicity against human DU145 cells incubated from day 2 to day 4 by CCK8 assay	[PMID: 26022080]
DU-145	IC₅₀	0.5 μM Compound: Etoposide	Antiproliferation activity against human DU145 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferation activity against human DU145 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33079544]
DU-145	IC₅₀	1 μM Compound: Etoposide	Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay	[PMID: 29077404]
DU-145	IC₅₀	1 μM Compound: Etoposide	Antiproliferative activity against human DU145 cells by MTT assay Antiproliferative activity against human DU145 cells by MTT assay	[PMID: 32196342]
DU-145	IC₅₀	1.15 μM Compound: Etoposide	Antiproliferative activity against human DU145 cells measured after 72 hrs by EZ-Cytox assay Antiproliferative activity against human DU145 cells measured after 72 hrs by EZ-Cytox assay	[PMID: 31398033]
DU-145	IC₅₀	1.21 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
DU-145	IC₅₀	1.3 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 4 days by ELISA reader assay Cytotoxicity against human DU145 cells after 4 days by ELISA reader assay	[PMID: 19939682]
DU-145	IC₅₀	1.3 μM Compound: VP-16	Antiproliferative activity against human DU145 prostate cell line Antiproliferative activity against human DU145 prostate cell line	[PMID: 10498216]
DU-145	IC₅₀	1.42 μM Compound: ETO	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 22819942]
DU-145	IC₅₀	1.44 μM Compound: Etoposide	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 21115246]
DU-145	IC₅₀	1.5 μM Compound: Etoposide	Cytotoxicity against human DU145 ATCC HTB 81 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 ATCC HTB 81 cells after 72 hrs by MTT assay	[PMID: 18558490]
DU-145	IC₅₀	1.63 μM Compound: etoposide	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 20093033]
DU-145	IC₅₀	1.65 μM Compound: 3; Etop	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
DU-145	IC₅₀	1.97 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 24 hrs by MTT assay Cytotoxicity against human DU145 cells after 24 hrs by MTT assay	[PMID: 31281022]
DU-145	IC₅₀	1.97 μM Compound: Etoposide	Cytotoxicity against human DU-145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human DU-145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 34838335]
DU-145	IC₅₀	1.97 μM Compound: Etoposide	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 38784476]
DU-145	IC₅₀	1.97 μM Compound: V	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 29289881]
DU-145	IC₅₀	1.98 μM Compound: Etoposide	Anticancer activity against human DU145 cells after 48 hrs by MTT assay Anticancer activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 25615796]
DU-145	IC₅₀	10.64 μM Compound: ETP	Antiproliferative activity against human DU145 cells after 48 hrs by SRB assay Antiproliferative activity against human DU145 cells after 48 hrs by SRB assay	[PMID: 28094224]
DU-145	IC₅₀	13.1 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 2 days by CCK8 assay Cytotoxicity against human DU145 cells after 2 days by CCK8 assay	[PMID: 26361737]
DU-145	IC₅₀	13.8 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 4 days by MTT assay Cytotoxicity against human DU145 cells after 4 days by MTT assay	[PMID: 20619511]
DU-145	IC₅₀	13.85 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 24904965]
DU-145	IC₅₀	16.43 μM Compound: Etoposide	Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by SRB assay	10.1039/C4MD00325J
DU-145	IC₅₀	2.03 μM Compound: 2	Cytotoxicity against human DU145 cells after 72 hrs by SRB assay Cytotoxicity against human DU145 cells after 72 hrs by SRB assay	[PMID: 24553146]
DU-145	IC₅₀	2.03 μM Compound: 3	Cytotoxicity against human DU145 cells after 72 hrs by SRB assay Cytotoxicity against human DU145 cells after 72 hrs by SRB assay	[PMID: 23490151]
DU-145	IC₅₀	2.03 μM Compound: 3	Cytotoxicity against human DU145 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human DU145 cells after 72 hrs by sulforhodamine B assay	[PMID: 24332656]
DU-145	IC₅₀	2.03 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 29269253]
DU-145	IC₅₀	2.09 μM Compound: Etoposide	Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay	[PMID: 25936262]
DU-145	IC₅₀	2.09 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 48 hrs by CCK8 assay Cytotoxicity against human DU145 cells after 48 hrs by CCK8 assay	[PMID: 26945111]
DU-145	IC₅₀	2.1 μM Compound: Etoposide	Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay	[PMID: 33421712]
DU-145	IC₅₀	2.13 μM Compound: Etoposide	Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 29525336]
DU-145	IC₅₀	2.19 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 21419530]
DU-145	IC₅₀	2.19 μM Compound: Etoposide	Antiproliferative activity against human DU145 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells measured after 72 hrs by CCK8 assay	[PMID: 27654394]
DU-145	IC₅₀	2.35 μM Compound: Etoposide	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 29289884]
DU-145	IC₅₀	2.4 μM Compound: etoposide	Cytotoxicity against human DU145 cells by SRB microtiter plate assay Cytotoxicity against human DU145 cells by SRB microtiter plate assay	[PMID: 17585747]
DU-145	IC₅₀	2.45 μM Compound: Etoposide	Cytotoxicity against human DU145 cells in presence of 10% fetal bovine serum Cytotoxicity against human DU145 cells in presence of 10% fetal bovine serum	[PMID: 20188578]
DU-145	IC₅₀	2.47 μM Compound: Etoposide	Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31227365]
DU-145	IC₅₀	2.94 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 22318164]
DU-145	IC₅₀	21.07 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 3 days Cytotoxicity against human DU145 cells after 3 days	[PMID: 19954977]
DU-145	IC₅₀	2373.3 nM Compound: 1 (VP16)	In vivo antiproliferative activity against DU-145 cell line In vivo antiproliferative activity against DU-145 cell line	[PMID: 15084135]
DU-145	IC₅₀	29.79 μM Compound: etoposide	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 18178085]
DU-145	IC₅₀	3 μM Compound: VP16	Cytotoxicity against human DU145 cells after 96 hrs Cytotoxicity against human DU145 cells after 96 hrs	[PMID: 22276775]
DU-145	IC₅₀	3.02 μM Compound: Etoposide	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by WST assay Antiproliferative activity against human DU-145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by WST assay	[PMID: 36493620]
DU-145	IC₅₀	3.1 μM Compound: Etoposide	Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28068602]
DU-145	IC₅₀	3.17 μM Compound: 2	Anticancer activity against human DU145 cells after 48 hrs by MTT assay Anticancer activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 24721832]
DU-145	IC₅₀	3.7 μM Compound: Etoposide	Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by SRB assay Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21074444]
DU-145	IC₅₀	3.85 μM Compound: 2	Cytotoxicity against human DU145 cells by sulforhodamine B assay Cytotoxicity against human DU145 cells by sulforhodamine B assay	[PMID: 17988764]
DU-145	IC₅₀	4.13 μM Compound: Etopo	Antiproliferative activity against human DU-145 cells after 72 hrs by EZ-Cytox colorimetric assay Antiproliferative activity against human DU-145 cells after 72 hrs by EZ-Cytox colorimetric assay	[PMID: 34678573]
DU-145	IC₅₀	5.16 μM Compound: Etoposide	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 19836231]
DU-145	IC₅₀	5.21 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 26292628]
DU-145	IC₅₀	6.17 μg/mL Compound: Etoposide	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28351589]
DU-145	IC₅₀	64.26 μM Compound: 2	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 22687745]
DU-145	IC₅₀	64.26 μM Compound: Etoposideg	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 25462233]
DU-145	IC₅₀	7.47 μM Compound: Etoposide	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell proliferation Antiproliferative activity against human DU-145 cells assessed as inhibition of cell proliferation	[PMID: 35123005]
DU-145	IC₅₀	9.29 μM Compound: Etoposide	Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay	[PMID: 24013413]
DU-145	IC₅₀	9.8 μM Compound: Etoposide	Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
DU-145	IC₅₀	9.8 μM Compound: Etoposide	Antiproliferative activity against human DU-145 cells Antiproliferative activity against human DU-145 cells	[PMID: 32688198]
DU-145	IC₅₀	9.8 μM Compound: Etoposide	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34479036]
DU-145	IC₅₀	9.8 μM Compound: VP-16	Cytotoxicity against human DU145 cells assessed as reduction in cell growth measured after 48 hrs by sulforhodamine B assay Cytotoxicity against human DU145 cells assessed as reduction in cell growth measured after 48 hrs by sulforhodamine B assay	[PMID: 31239178]
DU-145	IC₅₀	9.87 μM Compound: Etoposide	Antiproliferative activity against human DU-145 cells incubated for 72 hrs by microplate reader analysis Antiproliferative activity against human DU-145 cells incubated for 72 hrs by microplate reader analysis	[PMID: 37418826]
DU-145	IC₅₀	> 10 μM Compound: VP-16	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 30543429]
DU-145	IC₅₀	>= 2.91 μM Compound: Etoposide	Anticancer activity against human DU145 cells after 48 hrs by SRB assay Anticancer activity against human DU145 cells after 48 hrs by SRB assay	[PMID: 30660827]
DU-145	IC₅₀	>= 6.94 μM Compound: Etoposide	Antiproliferative activity against human DU145 cells by SRB assay Antiproliferative activity against human DU145 cells by SRB assay	[PMID: 31546197]
EBC-1	IC₅₀	15.7 μM Compound: Etoposide	Cytotoxicity against human EBC-1 cells incubated for 24 hrs by AlamarBlue staining based analysis Cytotoxicity against human EBC-1 cells incubated for 24 hrs by AlamarBlue staining based analysis	[PMID: 36857518]
EL4	IC₅₀	4.9 μM Compound: Etoposide	Cytotoxicity against mouse EL4 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay Cytotoxicity against mouse EL4 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay	[PMID: 25644672]
EL4	IC₅₀	4.9 μM Compound: Etoposide	Cytotoxicity against mouse EL4 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mouse EL4 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28062194]
F460pv8/eto	IC₅₀	0.74 μM Compound: Etoposide	Inhibitory activity against F460pv8/eto cell line using MTT assay Inhibitory activity against F460pv8/eto cell line using MTT assay	[PMID: 10780913]
FHC	IC₅₀	49.31 μg/mL Compound: Etoposide	Cytotoxicity against human FHC cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human FHC cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28351589]
FaDu	IC₅₀	16.01 μM Compound: ETP	Antiproliferative activity against human FADU cells after 48 hrs by SRB assay Antiproliferative activity against human FADU cells after 48 hrs by SRB assay	[PMID: 28094224]
G-361	IC₅₀	0.28 μg/mL Compound: Etoposide	Cytotoxic activity of compound against G-361 melanoma human tumor cell line Cytotoxic activity of compound against G-361 melanoma human tumor cell line	[PMID: 12459024]
G-361	IC₅₀	2.3 μM Compound: VP-16	Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
G-361	IC₅₀	3.8 μM Compound: Etoposide	Antiproliferation activity against human G361 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferation activity against human G361 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33079544]
G-402	ED₅₀	4.8 μg/mL Compound: VP-16	Inhibition of growth of renal cancer G-402 cell line Inhibition of growth of renal cancer G-402 cell line	[PMID: 8389875]
GLIOMA#108	IC₅₀	76 μM Compound: Etoposide	Inhibitory activity against GLIOMA#108 cell line Inhibitory activity against GLIOMA#108 cell line	[PMID: 9554873]
GLIOMA#112	IC₅₀	62 μM Compound: Etoposide	Inhibitory activity against GLIOMA#112 cell line Inhibitory activity against GLIOMA#112 cell line	[PMID: 9554873]
H69AR	IC₅₀	30 μg/mL Compound: Etoposide	Cytotoxicity against human H69AR cells after 3 days by MTT assay Cytotoxicity against human H69AR cells after 3 days by MTT assay	[PMID: 21216051]
H69AR	IC₅₀	45.9 μM Compound: Etoposide	Cytotoxicity against human NCI-H69AR cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human NCI-H69AR cells assessed as reduction in cell viability by SRB assay	[PMID: 33276991]
HBL-100	GI₅₀	1.4 μM Compound: Etoposide	Growth inhibition of human HBL100 cells after 48 hrs by SRB assay Growth inhibition of human HBL100 cells after 48 hrs by SRB assay	[PMID: 24211632]
HBL-100	GI₅₀	1.4 μM Compound: Etoposide	Antiproliferative activity against human HBL100 cells after 48 hrs by SRB assay Antiproliferative activity against human HBL100 cells after 48 hrs by SRB assay	[PMID: 30840453]
HBL-100	GI₅₀	1.4 μM Compound: Etoposide	Antiproliferative activity against human HBL-100 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human HBL-100 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
HBL-100	GI₅₀	1.4 μM Compound: VP-16	Cytotoxicity against human HBL100 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human HBL100 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27765506]
HBL-100	GI₅₀	1.9 μM Compound: VP-16	Antiproliferative activity against human HBL100 cells after 48 hrs incubation by SRB assay Antiproliferative activity against human HBL100 cells after 48 hrs incubation by SRB assay	[PMID: 25899335]
HBL-100	GI₅₀	2.3 μM Compound: Etoposide	Growth inhibition of human HBL100 cells Growth inhibition of human HBL100 cells	[PMID: 21986585]
HBL-100	GI₅₀	2.3 μM Compound: Etoposide	Antiproliferative activity against human HBL100 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HBL100 cells after 48 hrs by sulforhodamine B assay	[PMID: 27023255]
HBL-100	GI₅₀	2.3 μM Compound: VP-16	Antiproliferative activity against human HBL100 cells after 48 hrs by SRB assay Antiproliferative activity against human HBL100 cells after 48 hrs by SRB assay	[PMID: 29129514]
HCC 2998	GI₅₀	3.46 μM Compound: Etoposide	In vitro cytotoxicity against human colon cancer HCC 2998 cell line In vitro cytotoxicity against human colon cancer HCC 2998 cell line	[PMID: 9871772]
HCC70	IC₅₀	1.8 μM Compound: Etoposide	Cytotoxicity against human HCC70 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human HCC70 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30457333]
HCC70	IC₅₀	> 50 μM Compound: Etoposide	Antiproliferative activity against human HCC70 cells measured after 72 hrs by Ez-cytox assay Antiproliferative activity against human HCC70 cells measured after 72 hrs by Ez-cytox assay	[PMID: 31398033]
HCCLM9	IC₅₀	> 150 μM Compound: vp16	Antiproliferative activity against human HCCLM9 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCCLM9 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HCT cell line	IC₅₀	5.2 μg/mL Compound: 1	Compound was evaluated for in vitro cytotoxicity against HCT/VP35 cells Compound was evaluated for in vitro cytotoxicity against HCT/VP35 cells	10.1016/S0960-894X(00)80029-3
HCT-116	GI₅₀	5 μM Compound: Etoposide	Growth inhibition of human HCT116 cells incubated for 72 hrs by MTT assay Growth inhibition of human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 31718941]
HCT-116	GI₅₀	6.16 μM Compound: Etoposide	In vitro cytotoxicity against human colon cancer HCT 116 cell line In vitro cytotoxicity against human colon cancer HCT 116 cell line	[PMID: 9871772]
HCT-116	IC₅₀	0.25 μM Compound: Etoposide	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hr by SRB assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hr by SRB assay	[PMID: 34931849]
HCT-116	IC₅₀	0.3 μM Compound: Etoposide	Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by SRB assay	[PMID: 26595875]
HCT-116	IC₅₀	0.34 μg/mL Compound: 1	Compound was tested for its in vitro cytotoxicity in HCT116 cell line after 72 hours Compound was tested for its in vitro cytotoxicity in HCT116 cell line after 72 hours	10.1016/S0960-894X(00)80646-0
HCT-116	IC₅₀	0.35 μg/mL Compound: 1	Tested for in vitro cytotoxicity against HCT116 cells Tested for in vitro cytotoxicity against HCT116 cells	10.1016/S0960-894X(00)80029-3
HCT-116	IC₅₀	0.37 μM Compound: VP-16	Antiproliferative activity against doxorubicin sensitive human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against doxorubicin sensitive human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 35612499]
HCT-116	IC₅₀	0.38 μM Compound: VP-16	Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
HCT-116	IC₅₀	0.4 μM Compound: Etoposide	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 37672645]
HCT-116	IC₅₀	0.41 μM Compound: EP	Growth inhibition human HCT116 cells after 72 hrs by MTS assay Growth inhibition human HCT116 cells after 72 hrs by MTS assay	[PMID: 30633861]
HCT-116	IC₅₀	0.49 μM Compound: Etoposide	Cytotoxicity against human HCT116 cells assessed as growth inhibition by MTS assay Cytotoxicity against human HCT116 cells assessed as growth inhibition by MTS assay	[PMID: 28055208]
HCT-116	IC₅₀	0.5 μM Compound: Etoposide	Antiproliferative activity against human HCT-116 cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
HCT-116	IC₅₀	0.52 μM Compound: Etoposide	Antiproliferative activity against human HCT116 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human HCT116 cells after 72 hrs by sulforhodamine B assay	[PMID: 31894983]
HCT-116	IC₅₀	0.66 μM Compound: Etoposide	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33398999]
HCT-116	IC₅₀	0.68 μM Compound: Etoposide	Cytotoxicity against human HCT116 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 72 hrs by sulforhodamine B assay	[PMID: 29893558]
HCT-116	IC₅₀	0.87 μM Compound: VP-16	Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24095018]
HCT-116	IC₅₀	0.91 μM Compound: VP-16	Cytotoxicity against human HCT116 cells after 72 hrs by sulforhodamine B and MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by sulforhodamine B and MTT assay	[PMID: 22119124]
HCT-116	IC₅₀	1 μM Compound: Etoposide	Cytotoxicity in human HCT116 cells by SRB assay Cytotoxicity in human HCT116 cells by SRB assay	[PMID: 26812172]
HCT-116	IC₅₀	1 μM Compound: etoposide	Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTS assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 24328269]
HCT-116	IC₅₀	1.06 μM Compound: Etoposide	Growth inhibition of human HCT116 cells incubated for 72 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells incubated for 72 hrs by sulforhodamine B assay	[PMID: 28625715]
HCT-116	IC₅₀	1.06 μM Compound: Etoposide	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30041947]
HCT-116	IC₅₀	1.1 μM Compound: Eto	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30109001]
HCT-116	IC₅₀	1.1 μM Compound: Etoposide	Antiproliferative activity against p53-expressing human HCT116 cells assessed as cell viability after 72 hrs by SRB assay Antiproliferative activity against p53-expressing human HCT116 cells assessed as cell viability after 72 hrs by SRB assay	[PMID: 26595875]
HCT-116	IC₅₀	1.2 μM Compound: Etoposide	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay	[PMID: 33636429]
HCT-116	IC₅₀	1.22 μM Compound: Etoposide	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 30755350]
HCT-116	IC₅₀	1.25 μM Compound: Etoposide	Cytotoxicity in human HCT-116 cells by sulforhodamine B colorimetric assay Cytotoxicity in human HCT-116 cells by sulforhodamine B colorimetric assay	[PMID: 27933890]
HCT-116	IC₅₀	1.36 μM Compound: Etoposide	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability by sulforhodamine B assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability by sulforhodamine B assay	[PMID: 32073848]
HCT-116	IC₅₀	1.4 μM Compound: Etoposide	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay	[PMID: 35362983]
HCT-116	IC₅₀	1.45 μM Compound: Etoposide	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
HCT-116	IC₅₀	1.7 μM Compound: Etoposide	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 26804229]
HCT-116	IC₅₀	1.7 μM Compound: VP16	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 33191085]
HCT-116	IC₅₀	1.7 μM Compound: etoposide	Cytotoxicity against human HCT116 cells by XTT assay Cytotoxicity against human HCT116 cells by XTT assay	[PMID: 17368022]
HCT-116	IC₅₀	1.7 μM Compound: etoposide	Antiproliferative activity against human HCT116 cells after 3 days by XTT assay Antiproliferative activity against human HCT116 cells after 3 days by XTT assay	[PMID: 19691293]
HCT-116	IC₅₀	1.78 μg/mL Compound: 1	Compound was tested for its in vitro cytotoxicity in HCT-VP35 cell line after 72 hours Compound was tested for its in vitro cytotoxicity in HCT-VP35 cell line after 72 hours	10.1016/S0960-894X(00)80646-0
HCT-116	IC₅₀	1.8 μM Compound: Etoposide	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 38237151]
HCT-116	IC₅₀	1.87 μM Compound: etoposide	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 17194596]
HCT-116	IC₅₀	1.9 μM Compound: etoposide	Cytotoxicity against human HCT116 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 72 hrs by sulforhodamine B assay	[PMID: 25495422]
HCT-116	IC₅₀	1.9 μM Compound: etoposide	Antiproliferative activity against human HCT116 cells after 3 days by sulforhodamine B assay Antiproliferative activity against human HCT116 cells after 3 days by sulforhodamine B assay	[PMID: 25700232]
HCT-116	IC₅₀	1.9 μM Compound: etoposide	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
HCT-116	IC₅₀	11.9 μM Compound: Etoposide	Cytotoxicity against human HCT116 cells after 4 days by MTT assay Cytotoxicity against human HCT116 cells after 4 days by MTT assay	[PMID: 20619511]
HCT-116	IC₅₀	1200 μg/mL Compound: etoposide	Cytotoxicity against human HCT116 cells after 72 hrs by MTS reduction assay Cytotoxicity against human HCT116 cells after 72 hrs by MTS reduction assay	[PMID: 16441091]
HCT-116	IC₅₀	13.5 μM Compound: Etoposide	Anticancer activity against Homo sapiens (human) HCT116 cells assessed as decrease in cell growth after 3 days by MTT assay Anticancer activity against Homo sapiens (human) HCT116 cells assessed as decrease in cell growth after 3 days by MTT assay	10.1007/s00044-012-0245-1
HCT-116	IC₅₀	13.5 μM Compound: etoposide	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 3 days by MTT assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 3 days by MTT assay	[PMID: 21277655]
HCT-116	IC₅₀	14.39 μM Compound: Etoposide	Cytotoxicity against human HCT116 cells after 4 days Cytotoxicity against human HCT116 cells after 4 days	[PMID: 19800803]
HCT-116	IC₅₀	15.11 μM Compound: etoposide	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 18178085]
HCT-116	IC₅₀	15.6 μM Compound: Vp-16	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 33979690]
HCT-116	IC₅₀	17.92 μM Compound: Etoposide	Cytotoxicity against human HCT116 cells after 3 days Cytotoxicity against human HCT116 cells after 3 days	[PMID: 19954977]
HCT-116	IC₅₀	2 μM Compound: 3; Etop	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
HCT-116	IC₅₀	2.13 μM Compound: Vp-16	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	10.1039/C4MD00209A
HCT-116	IC₅₀	2.3 μM Compound: Etoposide	Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 26595875]
HCT-116	IC₅₀	2.4 μM Compound: VP-16	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CCK8 assay	[PMID: 36063665]
HCT-116	IC₅₀	2.5 μM Compound: etoposide	Tested for the cytotoxicity to inhibit replication assay against the human colon tumor cell line HCT116 Tested for the cytotoxicity to inhibit replication assay against the human colon tumor cell line HCT116	[PMID: 7525959]
HCT-116	IC₅₀	2.5 μM Compound: etopside	Cytotoxicity against HCT116 cells. Cytotoxicity against HCT116 cells.	[PMID: 7473578]
HCT-116	IC₅₀	2.6 μM Compound: Etoposide	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 29525336]
HCT-116	IC₅₀	2.8 μM Compound: Etoposide	Cytotoxicity against resistant human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against resistant human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 27560280]
HCT-116	IC₅₀	22 μM Compound: Etoposide	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30447888]
HCT-116	IC₅₀	23 μM Compound: Etoposide	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth	[PMID: 36690039]
HCT-116	IC₅₀	25.5 μM Compound: Etoposide	Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 21724394]
HCT-116	IC₅₀	26.1 μM Compound: VP16	Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by SRB assay	[PMID: 26618211]
HCT-116	IC₅₀	26.14 μM Compound: Etoposide	Cytotoxicity against human HCT-116 cells assessed as cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell viability incubated for 24 hrs by MTT assay	[PMID: 35567964]
HCT-116	IC₅₀	3 μM Compound: ET	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385594]
HCT-116	IC₅₀	3.1 μM Compound: Etoposide	Antiproliferative activity against p53-null human HCT116 cells assessed as cell viability after 72 hrs by SRB assay Antiproliferative activity against p53-null human HCT116 cells assessed as cell viability after 72 hrs by SRB assay	[PMID: 26595875]
HCT-116	IC₅₀	3.3 μM Compound: Etoposide	Antiproliferative activity against human HCT116 cells after 24 to 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 24 to 72 hrs by SRB assay	[PMID: 26595875]
HCT-116	IC₅₀	3.52 μM Compound: VP-16	Antiproliferative activity against doxorubicin resistant human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against doxorubicin resistant human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 35612499]
HCT-116	IC₅₀	4.9 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human HCT116 cells incubated for 3 days by MTT assay Antiproliferative activity against human HCT116 cells incubated for 3 days by MTT assay	[PMID: 32992133]
HCT-116	IC₅₀	5 μM Compound: Etoposide	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 24780599]
HCT-116	IC₅₀	5 μM Compound: Etoposide	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 27448912]
HCT-116	IC₅₀	5 μM Compound: Etoposide	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33751978]
HCT-116	IC₅₀	6.03 μM Compound: Etoposide	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 27060757]
HCT-116	IC₅₀	71.3 μM Compound: vp16	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HCT-116	IC₅₀	9.5 μM Compound: Etoposide	Cytotoxicity against human HCT116 cells after 2 days Cytotoxicity against human HCT116 cells after 2 days	[PMID: 21419530]
HCT-116	IC₅₀	9.9 μg/mL Compound: Etoposide	Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 22032697]
HCT-116	IC₅₀	> 10 μM Compound: Etoposide	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by ATPlite assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by ATPlite assay	[PMID: 26793989]
HCT-116	IC₅₀	> 10 μM Compound: Etoposide	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay	[PMID: 27096049]
HCT-116	IC₅₀	> 10 μM Compound: VP-16	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 30543429]
HCT-116	IC₅₀	> 20 μM Compound: Etoposide	Antiproliferative activity against human HCT116 cells assessed as cell viability after 24 hrs by SRB assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 24 hrs by SRB assay	[PMID: 26595875]
HCT-116	IC₅₀	>= 2.91 μM Compound: Etoposide	Anticancer activity against human HCT116 cells after 48 hrs by SRB assay Anticancer activity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 30660827]
HCT-15	ED₅₀	2.2 μg/mL Compound: etoposide	Cytotoxicity against human HCT15 cells by SRB method Cytotoxicity against human HCT15 cells by SRB method	[PMID: 16252909]
HCT-15	GI₅₀	1.25 μM Compound: etoposide	Antiproliferative activity against human HCT15 cells by SRB assay Antiproliferative activity against human HCT15 cells by SRB assay	[PMID: 19394218]
HCT-15	GI₅₀	10.02 μM Compound: etoposide	Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay	[PMID: 19394218]
HCT-15	IC₅₀	0.28 μM Compound: ETO	Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 22819942]
HCT-15	IC₅₀	0.3 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 31082231]
HCT-15	IC₅₀	0.46 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 72 hrs by SRB assay Cytotoxicity against human HCT15 cells after 72 hrs by SRB assay	[PMID: 30776236]
HCT-15	IC₅₀	0.9 μM Compound: Etoposide	Anticancer activity against human HCT15 cells assessed as cell viability after 48 hrs by SRB assay Anticancer activity against human HCT15 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21074444]
HCT-15	IC₅₀	1.06 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay Cytotoxicity against human HCT15 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay	[PMID: 27484510]
HCT-15	IC₅₀	1.09 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 4 days by ELISA reader assay Cytotoxicity against human HCT15 cells after 4 days by ELISA reader assay	[PMID: 19939682]
HCT-15	IC₅₀	1.1 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 2 days by automatic ELISA reader system Cytotoxicity against human HCT15 cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
HCT-15	IC₅₀	1.1 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 2 days Cytotoxicity against human HCT15 cells after 2 days	[PMID: 21601964]
HCT-15	IC₅₀	1.1 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay	[PMID: 25481396]
HCT-15	IC₅₀	1.1 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells incubated from day 2 to day 4 by CCK8 assay Cytotoxicity against human HCT15 cells incubated from day 2 to day 4 by CCK8 assay	[PMID: 26022080]
HCT-15	IC₅₀	1.1 μM Compound: Etoposide	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 27643560]
HCT-15	IC₅₀	1.17 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
HCT-15	IC₅₀	1.27 μM Compound: Etoposide	Antiproliferative activity against human HCT15 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells measured after 72 hrs by CCK8 assay	[PMID: 27654394]
HCT-15	IC₅₀	1.27 μM Compound: Etoposide	Antiproliferative activity against human HCT15 cells measured after 72 hrs by EZ-Cytox assay Antiproliferative activity against human HCT15 cells measured after 72 hrs by EZ-Cytox assay	[PMID: 31398033]
HCT-15	IC₅₀	1.29 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells in presence of 10% fetal bovine serum Cytotoxicity against human HCT15 cells in presence of 10% fetal bovine serum	[PMID: 20188578]
HCT-15	IC₅₀	1.33 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 2 days Cytotoxicity against human HCT15 cells after 2 days	[PMID: 22318164]
HCT-15	IC₅₀	1.33 μM Compound: Etoposide	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 28384547]
HCT-15	IC₅₀	1.45 μM Compound: Etoposide	Concentration required for inhibiting proliferation of human colon tumor cell line HCT-15 after 72 hr of incubation was determined Concentration required for inhibiting proliferation of human colon tumor cell line HCT-15 after 72 hr of incubation was determined	[PMID: 15482917]
HCT-15	IC₅₀	1.48 μM Compound: 2	Cytotoxicity against human HCT-15 cells by sulforhodamine B assay Cytotoxicity against human HCT-15 cells by sulforhodamine B assay	[PMID: 17988764]
HCT-15	IC₅₀	1.6 μM Compound: etoposide	Antiproliferative activity against human HCT15 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT15 cells after 48 hrs by sulforhodamine B assay	[PMID: 20939516]
HCT-15	IC₅₀	1.8 μM Compound: Etoposide	Antiproliferative activity against human HCT-15 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-15 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
HCT-15	IC₅₀	1.97 μM Compound: Etoposide	Antiproliferative activity against human HCT-15 cells incubated for 72 hrs by microplate reader analysis Antiproliferative activity against human HCT-15 cells incubated for 72 hrs by microplate reader analysis	[PMID: 37418826]
HCT-15	IC₅₀	12.23 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay	10.1039/C4MD00325J
HCT-15	IC₅₀	18.87 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay	[PMID: 25936262]
HCT-15	IC₅₀	18.87 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 48 hrs by CCK8 assay Cytotoxicity against human HCT15 cells after 48 hrs by CCK8 assay	[PMID: 26945111]
HCT-15	IC₅₀	19.7 μM Compound: Etoposide	Antiproliferative activity against human HCT15 cells after 24 hrs by WST-1 assay Antiproliferative activity against human HCT15 cells after 24 hrs by WST-1 assay	[PMID: 28181805]
HCT-15	IC₅₀	2.03 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells by MTT assay Cytotoxicity against human HCT15 cells by MTT assay	[PMID: 21115246]
HCT-15	IC₅₀	2.38 μM Compound: Etopo	Antiproliferative activity against human HCT-15 cells after 72 hrs by EZ-Cytox colorimetric assay Antiproliferative activity against human HCT-15 cells after 72 hrs by EZ-Cytox colorimetric assay	[PMID: 34678573]
HCT-15	IC₅₀	2.43 μM Compound: etoposide	Cytotoxicity against human HCT15 cells after 48 hrs by SRB method Cytotoxicity against human HCT15 cells after 48 hrs by SRB method	[PMID: 17493824]
HCT-15	IC₅₀	2.45 μM Compound: Etoposide	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK-8 assay	[PMID: 29510948]
HCT-15	IC₅₀	2.58 μM Compound: Etoposide	Antiproliferative activity against human HCT-15 cells assessed as inhibition of cell proliferation incubated for 72 hrs by WST assay Antiproliferative activity against human HCT-15 cells assessed as inhibition of cell proliferation incubated for 72 hrs by WST assay	[PMID: 36493620]
HCT-15	IC₅₀	2.6 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay	[PMID: 26361737]
HCT-15	IC₅₀	2.8 μM Compound: etoposide	Cytotoxicity against human HCT15 cells after 3 days by SRB assay Cytotoxicity against human HCT15 cells after 3 days by SRB assay	[PMID: 18321715]
HCT-15	IC₅₀	2.82 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 3 days by CCK8 assay Cytotoxicity against human HCT15 cells after 3 days by CCK8 assay	[PMID: 26927425]
HCT-15	IC₅₀	2.94 μM Compound: Etoposide	Antiproliferative activity against human HCT15 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells incubated for 72 hrs by CCK8 assay	[PMID: 29402741]
HCT-15	IC₅₀	2.94 μM Compound: Etoposide	Antiproliferative activity against human HCT15 cells after 72 hrs by EZ-CYTOX reagent based assay Antiproliferative activity against human HCT15 cells after 72 hrs by EZ-CYTOX reagent based assay	[PMID: 30262132]
HCT-15	IC₅₀	2.95 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 26706168]
HCT-15	IC₅₀	4.5 μM Compound: etoposide	Antiproliferative activity against human HCT15 cell line Antiproliferative activity against human HCT15 cell line	[PMID: 16686539]
HCT-15	IC₅₀	4.6 μM Compound: etoposide	Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 25402632]
HCT-15	IC₅₀	5.09 μM Compound: Etoposide	Antiproliferative activity against human HCT-15 cells assessed as inhibition of cell proliferation Antiproliferative activity against human HCT-15 cells assessed as inhibition of cell proliferation	[PMID: 35123005]
HCT-15	IC₅₀	5.12 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay	[PMID: 24013413]
HCT-15	IC₅₀	5.4 μM Compound: Etoposide	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 28068603]
HCT-15	IC₅₀	5.54 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay	[PMID: 26334499]
HCT-15	IC₅₀	6.9 μM Compound: Etoposide	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 26988802]
HCT-15	IC₅₀	7.15 μM Compound: 2	Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay	[PMID: 21477899]
HCT-15	IC₅₀	7.74 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 4 days by CCK-8 assay Cytotoxicity against human HCT15 cells after 4 days by CCK-8 assay	[PMID: 25062006]
HCT-15	IC₅₀	9.27 μM Compound: Etoposide	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 28633898]
HCT-15	IC₅₀	9.45 μM Compound: Etoposide	Cytotoxicity against human HCT15 cells after 2 days Cytotoxicity against human HCT15 cells after 2 days	[PMID: 24904965]
HCT-15	IC₅₀	> 10 μM Compound: etoposide	Antiproliferative activity against human HCT15/CL02 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT15/CL02 cells after 48 hrs by sulforhodamine B assay	[PMID: 20939516]
HCT-8	ED₅₀	62.9 μM Compound: 1	Dose required for reduction in human ileocecal HCT-8 cancer cells after 3 day incubation Dose required for reduction in human ileocecal HCT-8 cancer cells after 3 day incubation	[PMID: 15456257]
HCT-8	ED₅₀	> 5 mM Compound: VP-16	The compound was tested for tumor cell growth inhibitory activity against human ileocecal carcinoma (HCT-8) cell line The compound was tested for tumor cell growth inhibitory activity against human ileocecal carcinoma (HCT-8) cell line	[PMID: 10395485]
HCT-8	IC₅₀	10 μM Compound: VP16	Cytotoxicity against human HCT8 cells measured after 48 hrs by MTT assay Cytotoxicity against human HCT8 cells measured after 48 hrs by MTT assay	[PMID: 27517805]
HCT-8	IC₅₀	10.89 μM Compound: VP16; 2	Cytotoxicity against human HCT8 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT8 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26873416]
HCT-8	IC₅₀	26.3 μM Compound: 2; VP-16	Cytotoxicity against human HCT8 cells after 48 hrs by MTT assay Cytotoxicity against human HCT8 cells after 48 hrs by MTT assay	[PMID: 28512026]
HCT-8	IC₅₀	6.4 μM Compound: etoposide	Cytotoxicity against human HCT8 cells after 5 days by MTT assay Cytotoxicity against human HCT8 cells after 5 days by MTT assay	[PMID: 8778240]
HCT-8	IC₅₀	6.54 μM Compound: VP-16	Cytotoxicity against human HCT8 cells after 48 hrs by MTT assay Cytotoxicity against human HCT8 cells after 48 hrs by MTT assay	[PMID: 24095019]
HCT-8	IC₅₀	7.06 μM Compound: 2, VP-16	Cytotoxicity against human HCT8 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT8 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23711769]
HCT-8	IC₅₀	7.06 μM Compound: 2, VP-16	Cytotoxicity against human HCT8 cells after 48 hrs by MTT assay Cytotoxicity against human HCT8 cells after 48 hrs by MTT assay	[PMID: 24140948]
HEF	IC₅₀	> 100 μM Compound: Etoposide	Cytotoxicity against HEF after 72 hrs by MTT assay Cytotoxicity against HEF after 72 hrs by MTT assay	[PMID: 30447888]
HEK-293T	IC₅₀	1.39 μM Compound: VP-16	Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay	[PMID: 35612499]
HEK-293T	IC₅₀	11.47 μM Compound: Etoposide	Cytotoxicity against HEK293T cells after 36 hrs by MTT assay Cytotoxicity against HEK293T cells after 36 hrs by MTT assay	[PMID: 27262599]
HEK-293T	IC₅₀	22 μM Compound: Etoposide	Cytotoxicity against HEK293T cells assessed as cells growth inhibition after 48 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as cells growth inhibition after 48 hrs by MTT assay	[PMID: 27994737]
HEK-293T	IC₅₀	22 μM Compound: Etoposide	Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34303812]
HEK-293T	IC₅₀	28 μM Compound: Etoposide	Antiproliferative activity against human HEK293T cells assessed as reduction in cell viability for 48 hrs by MTT assay Antiproliferative activity against human HEK293T cells assessed as reduction in cell viability for 48 hrs by MTT assay	[PMID: 35617791]
HEK293	IC₅₀	0.41 μM Compound: ETO	Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 22819942]
HEK293	IC₅₀	0.6 μM Compound: Etoposide	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27533261]
HEK293	IC₅₀	0.69 μM Compound: Etoposide	Cytotoxicity against HEK293 cells after 48 hrs by MTT assay Cytotoxicity against HEK293 cells after 48 hrs by MTT assay	[PMID: 26649766]
HEK293	IC₅₀	0.72 μM Compound: Etoposide	Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay	[PMID: 24013413]
HEK293	IC₅₀	1.04 μM Compound: Etoposide	Cytotoxicity against HEK293 cells after 4 days by CCK-8 assay Cytotoxicity against HEK293 cells after 4 days by CCK-8 assay	[PMID: 25062006]
HEK293	IC₅₀	1.21 μM Compound: Etoposide	Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
HEK293	IC₅₀	1.74 μM Compound: Etoposide	Antiproliferative activity against HEK293 cells after 72 hrs by CCK8 assay Antiproliferative activity against HEK293 cells after 72 hrs by CCK8 assay	[PMID: 27643560]
HEK293	IC₅₀	7.51 μM Compound: ETP	Antiproliferative activity against HEK293 cells after 48 hrs by SRB assay Antiproliferative activity against HEK293 cells after 48 hrs by SRB assay	[PMID: 28094224]
HEK293	IC₅₀	702.8 μM Compound: Etoposide	Cytotoxicity against Homo sapiens (human) HEK293 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) HEK293 cells after 72 hr by MTT assay	10.1007/s00044-011-9937-1
HEK293	IC₅₀	> 100 μM Compound: Etoposide	Cytotoxicity against Homo sapiens (human) HEK293 cells assessed as decrease in cell growth after 3 days by MTT assay Cytotoxicity against Homo sapiens (human) HEK293 cells assessed as decrease in cell growth after 3 days by MTT assay	10.1007/s00044-012-0245-1
HEL	ED₅₀	8.64 μM Compound: 2 (Etoposide)	Inhibitory activity against human cytomegalovirus (HCMV) in HEL cells Inhibitory activity against human cytomegalovirus (HCMV) in HEL cells	[PMID: 11311065]
HEL	IC₅₀	0.92 μM Compound: ETP	Growth inhibition of HEL cells after 72 hrs by MTT assay Growth inhibition of HEL cells after 72 hrs by MTT assay	[PMID: 30471828]
HEp-2	IC₅₀	0.9 μM Compound: Etoposide	Anticancer activity against human Hep2 cells assessed as cell viability after 48 hrs by SRB assay Anticancer activity against human Hep2 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21074444]
HEp-2	IC₅₀	2.15 μM Compound: 2	Cytotoxicity against human HEP2 cells by sulforhodamine B assay Cytotoxicity against human HEP2 cells by sulforhodamine B assay	[PMID: 17988764]
HEp-2	IC₅₀	2.15 μM Compound: 2	Cytotoxicity against human Hep2 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human Hep2 cells after 48 hrs by sulforhodamine B assay	[PMID: 21477899]
HFL1	IC₅₀	87.63 μM Compound: Etoposide	Antiproliferative activity against HFL1 cells after 72 hrs by CCK8 assay Antiproliferative activity against HFL1 cells after 72 hrs by CCK8 assay	[PMID: 27643560]
HGC-27	IC₅₀	> 150 μM Compound: vp16	Antiproliferative activity against human HGC-27 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HL-60	GI₅₀	0.4 μM Compound: Etoposide	Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis	[PMID: 25874335]
HL-60	GI₅₀	140 nM Compound: VP-16, etoposide	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 17962028]
HL-60	IC₅₀	0.025 μM Compound: Etoposide	Tested for the cytostatic activity as inhibitory concentration against leukemia HL-60 cells Tested for the cytostatic activity as inhibitory concentration against leukemia HL-60 cells	10.1016/S0960-894X(97)00071-1
HL-60	IC₅₀	0.025 μM Compound: Etoposide	Cytotoxicity against human HL60 cells assessed as reduction in cell survival Cytotoxicity against human HL60 cells assessed as reduction in cell survival	[PMID: 27234147]
HL-60	IC₅₀	0.025 μM Compound: etoposide	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 11170674]
HL-60	IC₅₀	0.03 μM Compound: Etoposide	Cytostatic activity against human HL60 cells Cytostatic activity against human HL60 cells	[PMID: 30738653]
HL-60	IC₅₀	0.042 μM Compound: VP-16	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19769341]
HL-60	IC₅₀	0.042 μM Compound: VP-16	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20415462]
HL-60	IC₅₀	0.042 μM Compound: etoposide	Cytotoxicity against human HL60 cells after 24 hrs by SRB assay Cytotoxicity against human HL60 cells after 24 hrs by SRB assay	[PMID: 19685913]
HL-60	IC₅₀	0.06 μM Compound: VP-16	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 25599951]
HL-60	IC₅₀	0.11 μM Compound: etoposide	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
HL-60	IC₅₀	0.123 μM Compound: etoposide	In vitro inhibitory concentration against proliferation of HL60 cells In vitro inhibitory concentration against proliferation of HL60 cells	[PMID: 12877593]
HL-60	IC₅₀	0.15 μg/mL Compound: Etoposide	Cytotoxic activity against human tumor HL-60 leukemia cells Cytotoxic activity against human tumor HL-60 leukemia cells	[PMID: 15056007]
HL-60	IC₅₀	0.16 μM Compound: Etoposide	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 26649766]
HL-60	IC₅₀	0.16 μM Compound: etoposide	Cytotoxicity against human HL60 cells after 5 days by MTT assay Cytotoxicity against human HL60 cells after 5 days by MTT assay	[PMID: 8778240]
HL-60	IC₅₀	0.18 μM Compound: VP-16	Cytotoxicity against human HL60 cells after 72 hrs by CCK8 method Cytotoxicity against human HL60 cells after 72 hrs by CCK8 method	[PMID: 20071056]
HL-60	IC₅₀	0.19 μM Compound: VP-16	Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29335211]
HL-60	IC₅₀	0.2 μM Compound: etoposide	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 14738377]
HL-60	IC₅₀	0.2 μM Compound: etoposide	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 18507472]
HL-60	IC₅₀	0.2 μM Compound: etoposide	Cytotoxicity against human HL60 cells by SRB assay Cytotoxicity against human HL60 cells by SRB assay	[PMID: 18651771]
HL-60	IC₅₀	0.21 μM Compound: etoposide	Antiproliferative effect against human HL60 cells after 69 hrs Antiproliferative effect against human HL60 cells after 69 hrs	[PMID: 16499324]
HL-60	IC₅₀	0.23 μg/mL Compound: etoposide	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 15497941]
HL-60	IC₅₀	0.25 μM Compound: etoposide	Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay	[PMID: 19053514]
HL-60	IC₅₀	0.25 μg/mL Compound: Etoposide	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 11520229]
HL-60	IC₅₀	0.26 μg/mL Compound: Etoposide	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19449879]
HL-60	IC₅₀	0.2 μg/mL Compound: etoposide	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 11908966]
HL-60	IC₅₀	0.3 μM Compound: Etoposide	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27598828]
HL-60	IC₅₀	0.3 μM Compound: etoposide	Cytotoxicity against human HL60 cell line by MTT assay Cytotoxicity against human HL60 cell line by MTT assay	[PMID: 17243725]
HL-60	IC₅₀	0.31 μM Compound: 2	Anticancer activity against human HL60 cells after 48 hrs by MTT assay Anticancer activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 25744190]
HL-60	IC₅₀	0.31 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human HL-60 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HL-60 cells incubated for 48 hrs by MTT assay	[PMID: 32992133]
HL-60	IC₅₀	0.33 μM Compound: Etoposide	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 23968711]
HL-60	IC₅₀	0.33 μM Compound: Etoposide	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 29545100]
HL-60	IC₅₀	0.367 μM Compound: ETP	Relative cytotoxicity against human promyelocytic leukemia(HL-60) cells Relative cytotoxicity against human promyelocytic leukemia(HL-60) cells	[PMID: 10377219]
HL-60	IC₅₀	0.37 μM Compound: etoposide	Cytotoxicity against human HL60 cells by SRB assay Cytotoxicity against human HL60 cells by SRB assay	[PMID: 17194596]
HL-60	IC₅₀	0.37 μM Compound: etoposide	Cytotoxicity against human HL60 cells after 3 days by SRB assay Cytotoxicity against human HL60 cells after 3 days by SRB assay	[PMID: 18321715]
HL-60	IC₅₀	0.39 μM Compound: etoposide	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20524638]
HL-60	IC₅₀	0.3 μg/mL Compound: Etoposide	Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay	[PMID: 9917320]
HL-60	IC₅₀	0.3 μg/mL Compound: etoposide	Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay	[PMID: 10514313]
HL-60	IC₅₀	0.3 μg/mL Compound: etoposide	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 12398536]
HL-60	IC₅₀	0.3 μg/mL Compound: etoposide	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 12398537]
HL-60	IC₅₀	0.42 μM Compound: 2, VP-16	Cytotoxicity against human HL60 cells after 48 hrs Cytotoxicity against human HL60 cells after 48 hrs	[PMID: 20053564]
HL-60	IC₅₀	0.42 μM Compound: Etoposide	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
HL-60	IC₅₀	0.47 μg/mL Compound: Etoposide	Anticancer activity against human HL60 cells after 48 hrs by MTT assay Anticancer activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 21816519]
HL-60	IC₅₀	0.486 μM Compound: Etop	Cytotoxicity against human HL60 cells after 72 hrs Cytotoxicity against human HL60 cells after 72 hrs	[PMID: 20961767]
HL-60	IC₅₀	0.486 μM Compound: Etop, etoposide	Cytotoxicity against human mitoxantrone-sensitive HL60 cells after 72 hrs Cytotoxicity against human mitoxantrone-sensitive HL60 cells after 72 hrs	[PMID: 18507368]
HL-60	IC₅₀	0.5 μM Compound: Etoposide	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27145162]
HL-60	IC₅₀	0.5 μM Compound: etoposide	In vitro inhibitory concentration against proliferation of HL60R cells along with 5 (uM) verapamil In vitro inhibitory concentration against proliferation of HL60R cells along with 5 (uM) verapamil	[PMID: 12877593]
HL-60	IC₅₀	0.5 μM Compound: etoposide	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 23865778]
HL-60	IC₅₀	0.58 μM Compound: Etoposide	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 30109008]
HL-60	IC₅₀	0.6 μM Compound: Etoposide	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 25014747]
HL-60	IC₅₀	0.61 μM Compound: Etoposide	Cytotoxicity against human HL60 cells Cytotoxicity against human HL60 cells	10.1039/C2MD20199B
HL-60	IC₅₀	0.8 μM Compound: Etoposide	Cytotoxicity against human HL-60 cells after 3 days by MTT assay Cytotoxicity against human HL-60 cells after 3 days by MTT assay	[PMID: 19013074]
HL-60	IC₅₀	0.8 μM Compound: Etoposide	Cytotoxicity against human HL60 cells after 3 days by MTT assay Cytotoxicity against human HL60 cells after 3 days by MTT assay	[PMID: 19419803]
HL-60	IC₅₀	0.8 μM Compound: etoposide	Antitumor against human HL60 cells after 72 hrs by MTT assay Antitumor against human HL60 cells after 72 hrs by MTT assay	[PMID: 18299197]
HL-60	IC₅₀	0.85 μg/mL Compound: Etoposide	Cytotoxicity against human HL60 cells after 3 days by MTT assay Cytotoxicity against human HL60 cells after 3 days by MTT assay	[PMID: 21216051]
HL-60	IC₅₀	0.86 μM Compound: Etoposide	Cytotoxicity against human HL60 cells assessed as growth inhibition after 72 hrs by ATPlite assay Cytotoxicity against human HL60 cells assessed as growth inhibition after 72 hrs by ATPlite assay	[PMID: 26793989]
HL-60	IC₅₀	0.86 μM Compound: Etoposide	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay	[PMID: 27096049]
HL-60	IC₅₀	0.93 μM Compound: Etoposide	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19836231]
HL-60	IC₅₀	0.97 μM Compound: etoposide	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 20093033]
HL-60	IC₅₀	1 μM Compound: Etoposide	Cytotoxicity against human HL60 cells after 2 days by automatic ELISA reader system Cytotoxicity against human HL60 cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
HL-60	IC₅₀	1 μM Compound: Etoposide	Cytotoxicity against human HL60 cells after 2 days Cytotoxicity against human HL60 cells after 2 days	[PMID: 21601964]
HL-60	IC₅₀	1.15 μM Compound: 2, VP-16	Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by CCK-8 assay Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by CCK-8 assay	[PMID: 23711769]
HL-60	IC₅₀	1.15 μM Compound: 2, VP-16	Cytotoxicity against human HL60 cells after 48 hrs by cell counting kit-8 assay Cytotoxicity against human HL60 cells after 48 hrs by cell counting kit-8 assay	[PMID: 24140948]
HL-60	IC₅₀	1.1 μg/mL Compound: Etoposide	Cytotoxicity against human HL60 cells assessed as decrease in cell number after 24 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as decrease in cell number after 24 hrs by MTT assay	[PMID: 22704923]
HL-60	IC₅₀	1.2 μM Compound: ETP	Cytotoxic activity against human promyelocytic leukemia HL-60 concentration of agent required to reduce cell viability by 50% Cytotoxic activity against human promyelocytic leukemia HL-60 concentration of agent required to reduce cell viability by 50%	[PMID: 10377219]
HL-60	IC₅₀	1.28 μM Compound: Etoposide	Cytotoxicity against human HL60 cells after 2 days Cytotoxicity against human HL60 cells after 2 days	[PMID: 21419530]
HL-60	IC₅₀	1.3 μM Compound: Etoposide	Cytotoxicity against human topoisomerase 2-sensitive HL60 cells after 72 hrs by MTT assay Cytotoxicity against human topoisomerase 2-sensitive HL60 cells after 72 hrs by MTT assay	[PMID: 20570510]
HL-60	IC₅₀	1.4 μM Compound: Eto, VEPESID	Cytotoxicity against human HL60 cells Cytotoxicity against human HL60 cells	[PMID: 21439821]
HL-60	IC₅₀	1.44 μM Compound: etoposide	Cytotoxicity against human HL60 cells Cytotoxicity against human HL60 cells	[PMID: 18178085]
HL-60	IC₅₀	1.8 μM Compound: Etoposide	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23454511]
HL-60	IC₅₀	1.81 μM Compound: Etoposide	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 20356735]
HL-60	IC₅₀	1.83 μM Compound: Etoposide	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19036584]
HL-60	IC₅₀	1.83 μM Compound: Etoposide	Cytotoxicity against human HL60 cells after 2 days by MTT assay Cytotoxicity against human HL60 cells after 2 days by MTT assay	[PMID: 22325897]
HL-60	IC₅₀	1.84 μM Compound: Etoposide	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay Cytotoxicity against human HL60 cells after 24 hrs by MTT assay	10.1007/s00044-013-0757-3
HL-60	IC₅₀	10.5 μM Compound: etoposide	Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay	[PMID: 16933865]
HL-60	IC₅₀	12 μM Compound: Etoposide	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth	[PMID: 36690039]
HL-60	IC₅₀	150 μM Compound: etoposide	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 15974606]
HL-60	IC₅₀	1643 ng/mL Compound: Etoposide	Cytotoxicity was assessed using drug-sensitive human leukemic cell line HL60/S Cytotoxicity was assessed using drug-sensitive human leukemic cell line HL60/S	[PMID: 11170627]
HL-60	IC₅₀	18088 ng/mL Compound: Etoposide	Cytotoxicity was assessed using vincristine-resistant human leukemic cell line HL60/Vinc Cytotoxicity was assessed using vincristine-resistant human leukemic cell line HL60/Vinc	[PMID: 11170627]
HL-60	IC₅₀	2.1 μM Compound: Etoposide	Cytotoxicity against human HL60 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 27560280]
HL-60	IC₅₀	2.1 μM Compound: Etoposide	Cytotoxicity against human HL-60 cells assessed as cell growth inhibition by MTT assay Cytotoxicity against human HL-60 cells assessed as cell growth inhibition by MTT assay	[PMID: 37676247]
HL-60	IC₅₀	2.12 μg/mL Compound: Etoposide	Cytotoxicity against human HL60 cells assessed as decrease in cell number after 24 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as decrease in cell number after 24 hrs by MTT assay	[PMID: 25978960]
HL-60	IC₅₀	2.13 μg/mL Compound: Etoposide	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 24424132]
HL-60	IC₅₀	2.16 μM Compound: Etoposide	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19782567]
HL-60	IC₅₀	2.85 μM Compound: 2, VP-16	Cytotoxicity against human HL60 cells after 48 hrs by CCK-8 assay Cytotoxicity against human HL60 cells after 48 hrs by CCK-8 assay	[PMID: 22244588]
HL-60	IC₅₀	2.85 μM Compound: 5, VP-16	Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by CCK-8 assay Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by CCK-8 assay	[PMID: 22041063]
HL-60	IC₅₀	20 μM Compound: ET	Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385594]
HL-60	IC₅₀	25 nM Compound: ETOPOSIDE	Compound was tested for its anticancer activity against HL-60 cells. Compound was tested for its anticancer activity against HL-60 cells.	10.1016/S0960-894X(96)00486-6
HL-60	IC₅₀	25 μM Compound: Etoposide	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay Cytotoxicity against human HL60 cells after 24 hrs by MTT assay	[PMID: 15974617]
HL-60	IC₅₀	3.3 μM Compound: Vp-16	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 19251420]
HL-60	IC₅₀	315 nM Compound: etoposide	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 18513974]
HL-60	IC₅₀	48.5 μM Compound: Etop	Cytotoxicity against human HL60/MX2 cells after 72 hrs Cytotoxicity against human HL60/MX2 cells after 72 hrs	[PMID: 20961767]
HL-60	IC₅₀	490 nM Compound: Etoposide	Cytotoxicity against human HL60 cells Cytotoxicity against human HL60 cells	[PMID: 20863598]
HL-60	IC₅₀	5.4 μM Compound: VP-16	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 11473438]
HL-60	IC₅₀	5.48 μM Compound: 2	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 23867385]
HL-60	IC₅₀	54940 ng/mL Compound: Etoposide	Cytotoxicity was assessed using adriamycin-resistant human leukemic cell line HL60/ADR Cytotoxicity was assessed using adriamycin-resistant human leukemic cell line HL60/ADR	[PMID: 11170627]
HL-60	IC₅₀	6.5 μM Compound: etoposide	In vitro inhibitory concentration against proliferation of HL60R cells In vitro inhibitory concentration against proliferation of HL60R cells	[PMID: 12877593]
HL-60	IC₅₀	8.12 μM Compound: Etoposide	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HL-60	IC₅₀	< 1 μM Compound: Etoposide	Activation of procaspase-3-mediated human HL60 cell death after 72 hrs by MTS/PMS assay Activation of procaspase-3-mediated human HL60 cell death after 72 hrs by MTS/PMS assay	[PMID: 16936720]
HL-60	IC₅₀	>= 2.91 μM Compound: Etoposide	Anticancer activity against human HL60 cells after 48 hrs by SRB assay Anticancer activity against human HL60 cells after 48 hrs by SRB assay	[PMID: 30660827]
HL-60(TB)	IC₅₀	0.8 μM Compound: Etoposide	Cytotoxicity against human HL-60(TB) cells after 72 hrs by MTT assay Cytotoxicity against human HL-60(TB) cells after 72 hrs by MTT assay	[PMID: 20828890]
HL60/MX2	GI₅₀	5980 nM Compound: VP-16, etoposide	Cytotoxicity against DNA topoisomerase-2 deficient human HL60/MX2 cells by MTT assay Cytotoxicity against DNA topoisomerase-2 deficient human HL60/MX2 cells by MTT assay	[PMID: 17962028]
HL60/MX2	IC₅₀	11.9 μM Compound: Etoposide	Cytotoxicity against human HL60/MX2 cells after 72 hrs by MTT assay Cytotoxicity against human HL60/MX2 cells after 72 hrs by MTT assay	[PMID: 20570510]
HL60/MX2	IC₅₀	15.75 μM Compound: Eto, VEPESID	Cytotoxicity against human HL60/MX2 cells Cytotoxicity against human HL60/MX2 cells	[PMID: 21439821]
HL60/MX2	IC₅₀	48.5 μM Compound: Etop, etoposide	Cytotoxicity against mitoxantrone-resistant human HL60/MX2 cells after 72 hrs Cytotoxicity against mitoxantrone-resistant human HL60/MX2 cells after 72 hrs	[PMID: 18507368]
HL60/MX2	IC₅₀	9.02 μM Compound: Etoposide	Antiproliferative activity against human HL60/MX2 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60/MX2 cells after 48 hrs by MTT assay	[PMID: 26649766]
HLE	ED₅₀	1.5 μg/mL Compound: VP-16	Inhibition of growth of hepatoma HLE cell line Inhibition of growth of hepatoma HLE cell line	[PMID: 8389875]
HMEC	IC₅₀	21.5 μM Compound: VP-16	Cytotoxicity against HMEC after 48 hrs by MTT assay Cytotoxicity against HMEC after 48 hrs by MTT assay	[PMID: 30265994]
HMLE	IC₅₀	0.4 μM Compound: Etoposide	Antiproliferative activity against human shGFP-fused HMLE cells after 72 hrs by MTT assay Antiproliferative activity against human shGFP-fused HMLE cells after 72 hrs by MTT assay	[PMID: 27448912]
HOP-62	GI₅₀	0.8 μM Compound: 2, Eto	Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
HOP-62	GI₅₀	0.8 μM Compound: 2, Eto	Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
HOP-62	GI₅₀	0.8 μM Compound: 2, VP-16	Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay	[PMID: 21489802]
HOP-62	GI₅₀	0.8 μM Compound: Etoposide	Cytotoxicity against human HOP62 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HOP62 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
HOS	GI₅₀	36.56 μM Compound: Ref 34, Cpd 2	Cytotoxicity against human HOS cells by MTT assay Cytotoxicity against human HOS cells by MTT assay	[PMID: 32992133]
HSC-2	IC₅₀	24 μM Compound: etoposide	Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay	[PMID: 17125230]
HSC-2	IC₅₀	24.4 μg/mL Compound: etoposide	Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay	[PMID: 12398537]
HSC-2	IC₅₀	24.4 μg/mL Compound: etoposide	Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay	[PMID: 15497941]
HSC-2	IC₅₀	24 μg/mL Compound: etoposide	Cytotoxicity against human HSC2 cells by MTT assay Cytotoxicity against human HSC2 cells by MTT assay	[PMID: 11908966]
HSC-2	IC₅₀	24 μg/mL Compound: etoposide	Cytotoxicity against human HSC2 cells by MTT assay Cytotoxicity against human HSC2 cells by MTT assay	[PMID: 12828488]
HSC-2	IC₅₀	41 μM Compound: etoposide	Cytotoxicity against human HSC2 cells assessed as cell viability after 24 hrs Cytotoxicity against human HSC2 cells assessed as cell viability after 24 hrs	[PMID: 15620262]
HT-1080	IC₅₀	0.25 μM Compound: etoposide	Cytotoxicity against human HT1080 cells by SRB assay Cytotoxicity against human HT1080 cells by SRB assay	[PMID: 17194596]
HT-1080	IC₅₀	0.25 μM Compound: etoposide	Cytotoxicity against human HT1080 cells after 3 days by SRB assay Cytotoxicity against human HT1080 cells after 3 days by SRB assay	[PMID: 18321715]
HT-1080	IC₅₀	2 μM Compound: 1	Antiproliferative activity against human HT-1080 cells assessed as inhibition of cell proliferation measured after 48 hrs by SRB assay Antiproliferative activity against human HT-1080 cells assessed as inhibition of cell proliferation measured after 48 hrs by SRB assay	[PMID: 34837817]
HT-1080	IC₅₀	750 nM Compound: VP16	Antiproliferative activity against human HT1080 cells after 96 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 96 hrs by MTT assay	[PMID: 21296467]
HT-29	GI₅₀	0.73 μM Compound: Etoposide	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 19572549]
HT-29	GI₅₀	15.13 μM Compound: Etoposide	In vitro cytotoxicity against human colon cancer HT 29 cell line In vitro cytotoxicity against human colon cancer HT 29 cell line	[PMID: 9871772]
HT-29	GI₅₀	31.6 μM Compound: Etoposide	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 25792142]
HT-29	GI₅₀	31.6 μM Compound: Etoposide	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 30071406]
HT-29	GI₅₀	31.62 μM Compound: Etoposide	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 21115210]
HT-29	GI₅₀	31.62 μM Compound: Etoposide	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 22104973]
HT-29	GI₅₀	31.62 μM Compound: Etoposide	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 23831811]
HT-29	GI₅₀	31.62 μM Compound: Etoposide	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay relative to untreated control Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay relative to untreated control	[PMID: 24389510]
HT-29	GI₅₀	31.62 μM Compound: Etoposide	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
HT-29	GI₅₀	9.4 μM Compound: Etoposide	Growth inhibition of human HT-29 cells after 72 hrs by SRB assay Growth inhibition of human HT-29 cells after 72 hrs by SRB assay	[PMID: 23153810]
HT-29	IC₅₀	0.2 μM Compound: VP-16	Antiproliferative activity against human HT-29 colon cell line Antiproliferative activity against human HT-29 colon cell line	[PMID: 10498216]
HT-29	IC₅₀	1.3 μg/mL Compound: Etoposide	Cytotoxic activity of compound against HT-29 colon human tumor cell line Cytotoxic activity of compound against HT-29 colon human tumor cell line	[PMID: 12459024]
HT-29	IC₅₀	1.42 μM Compound: etoposide	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 20093033]
HT-29	IC₅₀	1.47 μM Compound: 2	Anticancer activity against human HT-29 cells after 48 hrs by MTT assay Anticancer activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 24721832]
HT-29	IC₅₀	1.64 μM Compound: V	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 29289881]
HT-29	IC₅₀	1.7 μg/mL Compound: 1	Growth inhibition of HT-29 (human colon adenocarcinoma) cell line. Growth inhibition of HT-29 (human colon adenocarcinoma) cell line.	[PMID: 2002477]
HT-29	IC₅₀	1.8 μM Compound: Etoposide	Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 29525336]
HT-29	IC₅₀	1.81 μM Compound: 2, Etop	Anticancer activity against human HT-29 cells after 48 hrs by MTT assay Anticancer activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 22136907]
HT-29	IC₅₀	1.81 μM Compound: 2a, VP-16	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 23182091]
HT-29	IC₅₀	1.87 μM Compound: Etoposide	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 29289884]
HT-29	IC₅₀	1.98 μM Compound: 2	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 30108892]
HT-29	IC₅₀	10 μM Compound: 1	Tested for cytotoxicity against Colon carcinoma type HT-29 cell line expressing MDR-1 (-) gene; 35% of cells were affected Tested for cytotoxicity against Colon carcinoma type HT-29 cell line expressing MDR-1 (-) gene; 35% of cells were affected	[PMID: 11844671]
HT-29	IC₅₀	15 μM Compound: Etoposide	Cytotoxicity against human HT-29 cells measured after 24 to 72 hrs by SRB assay Cytotoxicity against human HT-29 cells measured after 24 to 72 hrs by SRB assay	[PMID: 29656990]
HT-29	IC₅₀	1700 nM Compound: 1a	In vitro cytotoxicity against the HT-29 (human colon carcinoma) neoplastic cell line In vitro cytotoxicity against the HT-29 (human colon carcinoma) neoplastic cell line	[PMID: 14980682]
HT-29	IC₅₀	18.5 μM Compound: Etoposide	Cytotoxicity against human HT-29 cells incubated for 24 hrs by AlamarBlue staining based analysis Cytotoxicity against human HT-29 cells incubated for 24 hrs by AlamarBlue staining based analysis	[PMID: 36857518]
HT-29	IC₅₀	2 μM Compound: Etoposide	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26920801]
HT-29	IC₅₀	2.2 μM Compound: Etoposide	Antiproliferative activity against human HT-29 cells assessed as cellular DNA content after 72 hrs by CyQUANT NF fluorescence assay Antiproliferative activity against human HT-29 cells assessed as cellular DNA content after 72 hrs by CyQUANT NF fluorescence assay	[PMID: 26731300]
HT-29	IC₅₀	2.3 μM Compound: Etoposide	Antiproliferative activity against human HT-29 cells after 5 days by sulforhodamine B assay Antiproliferative activity against human HT-29 cells after 5 days by sulforhodamine B assay	[PMID: 24864039]
HT-29	IC₅₀	2.3 μM Compound: VP-16	Cytotoxicity against human HT-29 cells after 72 hrs by methylene blue assay Cytotoxicity against human HT-29 cells after 72 hrs by methylene blue assay	[PMID: 14738395]
HT-29	IC₅₀	2.3 μM Compound: etoposide	Cytotoxicity against human HT-29 cells after 72 hrs by methylene blue dye assay Cytotoxicity against human HT-29 cells after 72 hrs by methylene blue dye assay	[PMID: 19785430]
HT-29	IC₅₀	2.5 μM Compound: VP-16	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 19053767]
HT-29	IC₅₀	2.5 μM Compound: VP-16	Antiproliferative activity against human HT-29 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human HT-29 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
HT-29	IC₅₀	21.45 μM Compound: Etoposide	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 24487188]
HT-29	IC₅₀	21.45 μM Compound: Etoposide	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HT-29	IC₅₀	2366.7 nM Compound: 1 (VP16)	In vivo antiproliferative activity against HT-29 cell line In vivo antiproliferative activity against HT-29 cell line	[PMID: 15084135]
HT-29	IC₅₀	25.63 μM Compound: Etoposide	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability by MTT assay	[PMID: 35694689]
HT-29	IC₅₀	30.38 μM Compound: etoposide	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 20405844]
HT-29	IC₅₀	4.21 μg/mL Compound: Etoposide	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	10.1039/C4MD00525B
HT-29	IC₅₀	6.32 μM Compound: Etoposide	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 19836231]
HT-29	IC₅₀	6.6 μM Compound: etoposide	Antiproliferative activity against human HT29 cell line Antiproliferative activity against human HT29 cell line	[PMID: 16686539]
HT-29	IC₅₀	7.6 μM Compound: Etoposide	Antiproliferative activity against human HT-29 cells by MTT assay Antiproliferative activity against human HT-29 cells by MTT assay	[PMID: 29072457]
HT-29	IC₅₀	9 μM Compound: 1	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation measured after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation measured after 48 hrs by SRB assay	[PMID: 34837817]
HT-29	IC₅₀	> 150 μM Compound: vp16	Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HUVEC	IC₅₀	1.25 μM Compound: VP-16	Cytotoxicity against HUVEC assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against HUVEC assessed as cell viability after 48 hrs by MTT assay	[PMID: 24012378]
HUVEC	IC₅₀	1.342 μM Compound: Etoposide	Antiproliferative activity against HUVEC assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against HUVEC assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 26615886]
HUVEC	IC₅₀	1.86 μM Compound: Etoposide	Cytotoxicity against HUVEC by sulforhodamine B assay Cytotoxicity against HUVEC by sulforhodamine B assay	[PMID: 21936523]
HUVEC	IC₅₀	29 μM Compound: Etop	Cytotoxicity against HUVEC assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against HUVEC assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34606997]
HUVEC	IC₅₀	5.2 μM Compound: Etoposide	Cytotoxicity against HUVEC assessed as reduction in cell proliferation after 72 hrs by MTS assay Cytotoxicity against HUVEC assessed as reduction in cell proliferation after 72 hrs by MTS assay	[PMID: 30776691]
HUVEC	IC₅₀	5.21 μM Compound: Etoposide	Cytotoxicity against HUVEC assessed as reduction in cell proliferation after 72 hrs by MTS assay Cytotoxicity against HUVEC assessed as reduction in cell proliferation after 72 hrs by MTS assay	[PMID: 29778894]
HUVEC	IC₅₀	> 200 μM Compound: Etop	Cytotoxicity against HUVEC assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against HUVEC assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 34606997]
HaCaT	IC₅₀	0.55 μM Compound: etoposide	Cytotoxicity against human HaCaT cells after 72 hrs by MTT assay Cytotoxicity against human HaCaT cells after 72 hrs by MTT assay	[PMID: 19919064]
HaCaT	IC₅₀	6 μM Compound: 1	Antiproliferative activity against human HaCaT cells assessed as inhibition of cell proliferation measured after 48 hrs by SRB assay Antiproliferative activity against human HaCaT cells assessed as inhibition of cell proliferation measured after 48 hrs by SRB assay	[PMID: 34837817]
HeLa	EC₅₀	0.81 μM Compound: 6 (VP-16)	Tested for inhibition of topoisomerase II isolated from HeLa cells by DNA-cleavage assay Tested for inhibition of topoisomerase II isolated from HeLa cells by DNA-cleavage assay	[PMID: 8410993]
HeLa	EC₅₀	0.81 μM Compound: VP-16	Inhibitory activity in a cell-free assay of DNA cleavage mediated by purified HeLa cell topoisomerase II. Inhibitory activity in a cell-free assay of DNA cleavage mediated by purified HeLa cell topoisomerase II.	10.1016/0960-894X(95)00043-S
HeLa	EC₅₀	0.81 μM Compound: VP-16	Compound was tested for topoisomerase II inhibition in purified HeLa cells by SDS/K+ precipitation method Compound was tested for topoisomerase II inhibition in purified HeLa cells by SDS/K+ precipitation method	10.1016/0960-894X(95)00044-T
HeLa	EC₅₀	0.81 μM Compound: VP-16	Inhibitory activity against HeLa cell Topoisomerase II Inhibitory activity against HeLa cell Topoisomerase II	10.1016/0960-894X(95)00160-U
HeLa	EC₅₀	0.81 μM Compound: VP-16	Tested for inhibitory activity against Topoisomerase II isolated from HeLa cells by using SDS-K+ precipitation method Tested for inhibitory activity against Topoisomerase II isolated from HeLa cells by using SDS-K+ precipitation method	10.1016/S0960-894X(00)80048-7
HeLa	ED₅₀	7.9 μg/mL Compound: 4	Cytotoxicity against human HeLa cells after 4 days by trypan blue assay Cytotoxicity against human HeLa cells after 4 days by trypan blue assay	[PMID: 1602298]
HeLa	GI₅₀	0.62 μM Compound: 2	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 25131956]
HeLa	GI₅₀	0.64 μM Compound: 2	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 24953821]
HeLa	GI₅₀	2 μM Compound: VP-16	Antiproliferative activity against human HeLa cells after 48 hrs incubation by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs incubation by SRB assay	[PMID: 25899335]
HeLa	GI₅₀	3 μM Compound: Etoposide	Growth inhibition of human HeLa cells Growth inhibition of human HeLa cells	[PMID: 21986585]
HeLa	GI₅₀	3 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay	[PMID: 27023255]
HeLa	GI₅₀	3 μM Compound: VP-16	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 29129514]
HeLa	GI₅₀	3.3 μM Compound: Etoposide	Growth inhibition of human HeLa cells after 48 hrs by SRB assay Growth inhibition of human HeLa cells after 48 hrs by SRB assay	[PMID: 24211632]
HeLa	GI₅₀	3.3 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 30840453]
HeLa	GI₅₀	3.3 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
HeLa	GI₅₀	3.3 μM Compound: VP-16	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27765506]
HeLa	GI₅₀	3.56 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 22682920]
HeLa	GI₅₀	40 μM Compound: Etoposide	Growth inhibitory concentration of compound was determined against HeLa cells by alamar blue assay Growth inhibitory concentration of compound was determined against HeLa cells by alamar blue assay	[PMID: 15026047]
HeLa	GI₅₀	8 μM Compound: 2	Growth inhibition of HeLa cells after 48 hrs by MTT assay Growth inhibition of HeLa cells after 48 hrs by MTT assay	[PMID: 17894480]
HeLa	IC₅₀	0.08 μM Compound: etoposide	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 23092389]
HeLa	IC₅₀	0.18 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 3 days by CCK8 assay Cytotoxicity against human HeLa cells after 3 days by CCK8 assay	[PMID: 26927425]
HeLa	IC₅₀	0.18 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 27643560]
HeLa	IC₅₀	0.31 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 32992133]
HeLa	IC₅₀	0.38 μg/mL Compound: Etoposide	Cytotoxicity against human HeLa cells after 3 days by MTT assay Cytotoxicity against human HeLa cells after 3 days by MTT assay	[PMID: 21216051]
HeLa	IC₅₀	0.4 μM Compound: Etoposide	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 19788270]
HeLa	IC₅₀	0.47 μM Compound: etoposide	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 20093033]
HeLa	IC₅₀	0.54 μM Compound: VP-16	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25599951]
HeLa	IC₅₀	1 μM Compound: Etoposide	Cytotoxicity against human HeLa cells incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 33421712]
HeLa	IC₅₀	1.2 μM Compound: Etoposide	Antiproliferation activity against human Hela cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferation activity against human Hela cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33079544]
HeLa	IC₅₀	1.2 μM Compound: VP16	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 33191085]
HeLa	IC₅₀	1.26 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay	[PMID: 25481396]
HeLa	IC₅₀	1.29 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 4 days by ELISA reader assay Cytotoxicity against human HeLa cells after 4 days by ELISA reader assay	[PMID: 19939682]
HeLa	IC₅₀	1.4 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 2 days by automatic ELISA reader system Cytotoxicity against human HeLa cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
HeLa	IC₅₀	1.4 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 2 days Cytotoxicity against human HeLa cells after 2 days	[PMID: 21601964]
HeLa	IC₅₀	1.41 μM Compound: Etoposide	Cytotoxicity against human HeLa cells incubated from day 2 to day 4 by CCK8 assay Cytotoxicity against human HeLa cells incubated from day 2 to day 4 by CCK8 assay	[PMID: 26022080]
HeLa	IC₅₀	1.5 μM Compound: VP-16	Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK8 assay	[PMID: 36063665]
HeLa	IC₅₀	1.52 μM Compound: 2a, VP-16	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 23182091]
HeLa	IC₅₀	1.57 μM Compound: Etoposide	Cytotoxicity against human HeLa cells in presence of 10% fetal bovine serum Cytotoxicity against human HeLa cells in presence of 10% fetal bovine serum	[PMID: 20188578]
HeLa	IC₅₀	1.58 μM Compound: 2	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 28757065]
HeLa	IC₅₀	1.605 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 26615886]
HeLa	IC₅₀	1.71 μM Compound: Ref 34, Cpd 2	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 32992133]
HeLa	IC₅₀	1.93 μM Compound: V	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29289881]
HeLa	IC₅₀	10.03 μM Compound: Etoposide	Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by CCK8 assay	[PMID: 27484510]
HeLa	IC₅₀	10.03 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay	[PMID: 29510948]
HeLa	IC₅₀	10.4 μM Compound: Etoposide	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay	10.1039/C4MD00325J
HeLa	IC₅₀	11.2 μM Compound: 2; VP-16	Cytotoxicity against human HeLa cells assessed as reduction in inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 29248296]
HeLa	IC₅₀	12.12 μM Compound: VP16; 2	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26873416]
HeLa	IC₅₀	12.2 μM Compound: 2; VP-16	Cytotoxicity against human HeLa cells incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 31278032]
HeLa	IC₅₀	13.5 μM Compound: VP16	Cytotoxicity against human HeLa cells measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells measured after 48 hrs by MTT assay	[PMID: 27517805]
HeLa	IC₅₀	15 μM Compound: Etoposide	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 28571311]
HeLa	IC₅₀	15.93 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28462840]
HeLa	IC₅₀	16 μM Compound: Etoposide	Growth inhibition of human HeLa cells assessed as inhibition of cell viability after 72 hrs by MTT assay Growth inhibition of human HeLa cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 24527835]
HeLa	IC₅₀	17.68 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 23369687]
HeLa	IC₅₀	18.2 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 4 days by MTT assay Cytotoxicity against human HeLa cells after 4 days by MTT assay	[PMID: 20619511]
HeLa	IC₅₀	18.24 μM Compound: etoposide	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 18178085]
HeLa	IC₅₀	2.03 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29269253]
HeLa	IC₅₀	2.15 μM Compound: Etoposide	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 19836231]
HeLa	IC₅₀	2.24 μM Compound: 2	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30108892]
HeLa	IC₅₀	2.35 μg/mL Compound: Etoposide	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	10.1039/C4MD00525B
HeLa	IC₅₀	2.36 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 2 days Cytotoxicity against human HeLa cells after 2 days	[PMID: 21419530]
HeLa	IC₅₀	2.4 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29077404]
HeLa	IC₅₀	2.4 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 32196342]
HeLa	IC₅₀	2.56 μM Compound: VP-16	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth Antiproliferative activity against human HeLa cells assessed as reduction in cell growth	[PMID: 38107170]
HeLa	IC₅₀	2.66 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31227365]
HeLa	IC₅₀	2.7 μM Compound: Etoposide	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 33831559]
HeLa	IC₅₀	2.71 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29289884]
HeLa	IC₅₀	2.75 μM Compound: 2	Anticancer activity against human HeLa cells after 48 hrs by MTT assay Anticancer activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24721832]
HeLa	IC₅₀	2.76 μM Compound: 5, VP-16	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by CCK-8 assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by CCK-8 assay	[PMID: 22041063]
HeLa	IC₅₀	2.9 μM Compound: etoposide	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 17482821]
HeLa	IC₅₀	2.9 μM Compound: etoposide	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 18258438]
HeLa	IC₅₀	2.91 μM Compound: 2, VP-16	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23711769]
HeLa	IC₅₀	2.91 μM Compound: 2, VP-16	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24140948]
HeLa	IC₅₀	2.97 μM Compound: Vp-16	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	10.1039/C4MD00209A
HeLa	IC₅₀	21.4 μM Compound: VP-16	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30265994]
HeLa	IC₅₀	22.35 μM Compound: VP-16	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29335211]
HeLa	IC₅₀	225.5 μM Compound: VP16	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay	[PMID: 26649907]
HeLa	IC₅₀	23.33 μM Compound: Etoposide	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 21983445]
HeLa	IC₅₀	24.9 μM Compound: 2; VP-16	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28512026]
HeLa	IC₅₀	28.61 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30109008]
HeLa	IC₅₀	3 μM Compound: Eto	Antitumor activity against human HeLa cells after 72 hrs by MTT assay Antitumor activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 17935309]
HeLa	IC₅₀	3 μM Compound: VP-16	Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay	[PMID: 19053767]
HeLa	IC₅₀	3 μM Compound: VP-16	Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
HeLa	IC₅₀	3.2 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 2 days Cytotoxicity against human HeLa cells after 2 days	[PMID: 22318164]
HeLa	IC₅₀	3.2 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 28384547]
HeLa	IC₅₀	3.2 μM Compound: VP16	Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by SRB assay	[PMID: 26618211]
HeLa	IC₅₀	3.23 μM Compound: Etoposide	Anticancer activity against human HeLa cells after 48 hrs by MTT assay Anticancer activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25615796]
HeLa	IC₅₀	3.38 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells incubated for 72 hrs by microplate reader analysis Antiproliferative activity against human HeLa cells incubated for 72 hrs by microplate reader analysis	[PMID: 37418826]
HeLa	IC₅₀	3.4 μM Compound: etoposide	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25402632]
HeLa	IC₅₀	3.6 μM Compound: etoposide	Antiproliferative effect against human HeLa cells after 69 hrs by MTT assay Antiproliferative effect against human HeLa cells after 69 hrs by MTT assay	[PMID: 16499324]
HeLa	IC₅₀	3.9 μM Compound: VP-16	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19394829]
HeLa	IC₅₀	3.9 μM Compound: VP-16	Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
HeLa	IC₅₀	32.05 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29545100]
HeLa	IC₅₀	32.45 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26649766]
HeLa	IC₅₀	4 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 21570846]
HeLa	IC₅₀	4.12 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 28633898]
HeLa	IC₅₀	4.13 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells measured after 72 hrs by EZ-Cytox assay Antiproliferative activity against human HeLa cells measured after 72 hrs by EZ-Cytox assay	[PMID: 31398033]
HeLa	IC₅₀	4.36 μM Compound: VP-16	Cytotoxicity against human HeLa cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HeLa cells after 72 hrs by sulforhodamine B assay	[PMID: 25240702]
HeLa	IC₅₀	4.39 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 36 hrs by MTT assay Cytotoxicity against human HeLa cells after 36 hrs by MTT assay	[PMID: 27262599]
HeLa	IC₅₀	4.71 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24487188]
HeLa	IC₅₀	4.71 μM Compound: Etoposide	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HeLa	IC₅₀	4.71 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25453799]
HeLa	IC₅₀	4.73 μM Compound: VP-16	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24095019]
HeLa	IC₅₀	40.4 μM Compound: 2, VP-16	Cytotoxicity against human HeLa cells after 48 hrs by CCK-8 assay Cytotoxicity against human HeLa cells after 48 hrs by CCK-8 assay	[PMID: 22244588]
HeLa	IC₅₀	41.21 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27060757]
HeLa	IC₅₀	5.35 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 32502865]
HeLa	IC₅₀	5.7 nM Compound: VP-16	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 24422592]
HeLa	IC₅₀	50.6 μM Compound: VP-16	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21733601]
HeLa	IC₅₀	59.38 μM Compound: VP-16	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24775914]
HeLa	IC₅₀	6.27 μM Compound: VP-16	Cytotoxicity against human HeLa cells after 2 days by MTT assay Cytotoxicity against human HeLa cells after 2 days by MTT assay	[PMID: 21821321]
HeLa	IC₅₀	6.27 μM Compound: VP-16	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25113878]
HeLa	IC₅₀	63.71 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 23968711]
HeLa	IC₅₀	7.01 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation	[PMID: 35123005]
HeLa	IC₅₀	7.21 μM Compound: Etoposide	Cytotoxic activity against human HeLa cells after 72 hrs by MTT assay Cytotoxic activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 28733083]
HeLa	IC₅₀	7.32 μM Compound: Etoposide	Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay	[PMID: 25936262]
HeLa	IC₅₀	7.32 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 48 hrs by CCK8 assay Cytotoxicity against human HeLa cells after 48 hrs by CCK8 assay	[PMID: 26945111]
HeLa	IC₅₀	7.43 μM Compound: VP-16	Cytotoxicity against human HeLa cells assessed as reduction in cell growth measured after 48 hrs by sulforhodamine B assay Cytotoxicity against human HeLa cells assessed as reduction in cell growth measured after 48 hrs by sulforhodamine B assay	[PMID: 31239178]
HeLa	IC₅₀	7.6 μM Compound: Etoposide	Cytotoxicity against human HeLa cells measured after 2 days by MTT assay Cytotoxicity against human HeLa cells measured after 2 days by MTT assay	[PMID: 26334499]
HeLa	IC₅₀	7.89 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 28431878]
HeLa	IC₅₀	8 μM Compound: ET	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385594]
HeLa	IC₅₀	8.09 μM Compound: Etopo	Antiproliferative activity against human HeLa cells after 72 hrs by EZ-Cytox colorimetric assay Antiproliferative activity against human HeLa cells after 72 hrs by EZ-Cytox colorimetric assay	[PMID: 34678573]
HeLa	IC₅₀	8.12 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 32992133]
HeLa	IC₅₀	8.2 μM Compound: Etoposide	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 27560280]
HeLa	IC₅₀	8.3 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Ez-cytoX based microplate reader method Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Ez-cytoX based microplate reader method	[PMID: 34597897]
HeLa	IC₅₀	8.32 μM Compound: Etoposide	Antitumor activity against human HeLa cells assessed as growth inhibition measured after 48 hrs by MTT assay Antitumor activity against human HeLa cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23313635]
HeLa	IC₅₀	8.43 μM Compound: Etoposide	Cytotoxicity against human HeLa cells after 3 days Cytotoxicity against human HeLa cells after 3 days	[PMID: 19954977]
HeLa	IC₅₀	8.93 μM Compound: Etoposide	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 20356735]
HeLa	IC₅₀	9.1 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 28068603]
HeLa	IC₅₀	9.21 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK8 assay	[PMID: 29402741]
HeLa	IC₅₀	9.21 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells after 72 hrs by EZ-CYTOX reagent based assay Antiproliferative activity against human HeLa cells after 72 hrs by EZ-CYTOX reagent based assay	[PMID: 30262132]
HeLa	IC₅₀	96.26 μM Compound: 2	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 22687745]
HeLa	IC₅₀	96.26 μM Compound: Etoposideg	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25462233]
HeLa	IC₅₀	> 50 μM Compound: Etoposide	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by SRB assay	[PMID: 31404864]
HeLa	IC₅₀	> 50 μM Compound: Etoposide	Anticancer activity against human HeLa cells assessed as inhibition of cell growth Anticancer activity against human HeLa cells assessed as inhibition of cell growth	[PMID: 32531682]
HeLa	IC₅₀	>= 2.91 μM Compound: Etoposide	Anticancer activity against human HeLa cells after 48 hrs by SRB assay Anticancer activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 30660827]
HeLa	IC₅₀	>= 6.94 μM Compound: Etoposide	Antiproliferative activity against human HeLa cells by SRB assay Antiproliferative activity against human HeLa cells by SRB assay	[PMID: 31546197]
HeLa S3	IC₅₀	0.5 μM Compound: Etoposide	Antiproliferative activity against human HeLaS3 cells by MTT assay Antiproliferative activity against human HeLaS3 cells by MTT assay	[PMID: 29072457]
HeLa S3	IC₅₀	43.1 μM Compound: Etoposide	Antiproliferative activity against human HeLaS3 cells after 24 hrs by WST-1 assay Antiproliferative activity against human HeLaS3 cells after 24 hrs by WST-1 assay	[PMID: 28181805]
Hep 3B2	IC₅₀	6.7 μM Compound: Etoposide	Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay	[PMID: 22342101]
HepG2	CC₅₀	0.7 μM Compound: Etoposide	Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 21741130]
HepG2	EC₅₀	15.9 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by Cell Titer-Glo assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by Cell Titer-Glo assay	[PMID: 28080063]
HepG2	EC₅₀	60.5 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31096154]
HepG2	EC₅₀	9.8 μM Compound: etoposide	Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter Glo assay Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter Glo assay	10.1039/C4MD00409D
HepG2	IC₅₀	0.31 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 32992133]
HepG2	IC₅₀	0.83 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28169166]
HepG2	IC₅₀	1.15 μM Compound: VP-16	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 24775914]
HepG2	IC₅₀	1.4 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay	[PMID: 25644672]
HepG2	IC₅₀	1.748 μM Compound: Etoposide	Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 26615886]
HepG2	IC₅₀	10.5 μM Compound: 2; VP-16	Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 31278032]
HepG2	IC₅₀	103.81 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 23369687]
HepG2	IC₅₀	11.52 μM Compound: VP-16	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24095019]
HepG2	IC₅₀	11.8 μM Compound: Etoposide	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 31546197]
HepG2	IC₅₀	12 μg/mL Compound: Etoposide	Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay	10.1007/s00044-011-9903-y
HepG2	IC₅₀	13.4 μM Compound: 2; VP-16	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28512026]
HepG2	IC₅₀	13.65 μM Compound: Etoposide	Antiproliferative against human HepG2 cells after 48 hrs by MTT assay Antiproliferative against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24996136]
HepG2	IC₅₀	15.32 μM Compound: VP-16	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24775914]
HepG2	IC₅₀	15.32 μM Compound: VP16	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33191085]
HepG2	IC₅₀	15.8 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 27759375]
HepG2	IC₅₀	15.8 μM Compound: etoposide	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21174408]
HepG2	IC₅₀	16.1 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 28571311]
HepG2	IC₅₀	16 μg/mL Compound: Etoposide	Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as survival after 3 days by crystal violet staining Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as survival after 3 days by crystal violet staining	10.1007/s00044-012-0025-y
HepG2	IC₅₀	2.02 μM Compound: Ref 34, Cpd 2	Antitumor activity against human HepG2 cells xenografted in BALB/c nude mouse assessed as tumor weight suppression at 1 mg/kg, ip administered every 6 days for 20 days and measured every 2 days by digital caliper method relative to control Antitumor activity against human HepG2 cells xenografted in BALB/c nude mouse assessed as tumor weight suppression at 1 mg/kg, ip administered every 6 days for 20 days and measured every 2 days by digital caliper method relative to control	[PMID: 32992133]
HepG2	IC₅₀	2.114 μM Compound: Etoposide	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 38784476]
HepG2	IC₅₀	2.45 μM Compound: Etoposide	Anticancer activity against human HepG2 cells after 48 hrs by MTT assay Anticancer activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25615796]
HepG2	IC₅₀	2.66 μM Compound: vp16	Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HepG2	IC₅₀	2.84 μM Compound: Etoposide	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29289884]
HepG2	IC₅₀	20 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells assessed as reduction in cell proliferation after 72 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell proliferation after 72 hrs by MTS assay	[PMID: 30776691]
HepG2	IC₅₀	20 μM Compound: VP-16	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30265994]
HepG2	IC₅₀	20.1 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells assessed as reduction in cell proliferation after 72 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell proliferation after 72 hrs by MTS assay	[PMID: 29778894]
HepG2	IC₅₀	20.1 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells measured after 72 hrs by MTS assay Cytotoxicity against human HepG2 cells measured after 72 hrs by MTS assay	[PMID: 37329714]
HepG2	IC₅₀	20.389 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25019480]
HepG2	IC₅₀	20.9 μM Compound: Etop	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 26216018]
HepG2	IC₅₀	20.9 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells incubated for 24 hrs by AlamarBlue staining based analysis Cytotoxicity against human HepG2 cells incubated for 24 hrs by AlamarBlue staining based analysis	[PMID: 36857518]
HepG2	IC₅₀	21 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition by MTT assay	[PMID: 37676247]
HepG2	IC₅₀	21 μg/mL Compound: Etoposide	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 21216051]
HepG2	IC₅₀	22.11 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	10.1039/C3MD00166K
HepG2	IC₅₀	24.32 μg/mL Compound: Etoposide	Cytotoxic activity against human HepG2 cells by MTT assay Cytotoxic activity against human HepG2 cells by MTT assay	[PMID: 28366267]
HepG2	IC₅₀	27.07 μM Compound: VP16; 2	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26873416]
HepG2	IC₅₀	27.18 μM Compound: Etoposide	Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay	10.1007/s00044-012-0402-6
HepG2	IC₅₀	3.6 μM Compound: etoposide	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 25402632]
HepG2	IC₅₀	30 μM Compound: VP16	Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 26291037]
HepG2	IC₅₀	30.16 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24836071]
HepG2	IC₅₀	30.16 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25078311]
HepG2	IC₅₀	30.16 μM Compound: etoposide	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	10.1007/s00044-013-0777-z
HepG2	IC₅₀	30.2 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 37329714]
HepG2	IC₅₀	33.98 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26397393]
HepG2	IC₅₀	4 μM Compound: VP16	Cytotoxicity against human HepG2 cells after 96 hrs Cytotoxicity against human HepG2 cells after 96 hrs	[PMID: 22276775]
HepG2	IC₅₀	4.1 μM Compound: VP-16	Growth inhibition of human HepG2 cells after 72 hrs by sulforhodamine B assay Growth inhibition of human HepG2 cells after 72 hrs by sulforhodamine B assay	[PMID: 20346660]
HepG2	IC₅₀	4.76 μM Compound: Etoposide	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22578452]
HepG2	IC₅₀	4.9 μM Compound: etoposide	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 3 days by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 3 days by MTT assay	[PMID: 21277655]
HepG2	IC₅₀	40.47 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 25747499]
HepG2	IC₅₀	427 μM Compound: VP16	Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay	10.1007/s00044-009-9172-1
HepG2	IC₅₀	5.21 μM Compound: VP16	Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 27517805]
HepG2	IC₅₀	5.48 μM Compound: 2	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22687745]
HepG2	IC₅₀	5.48 μM Compound: Etoposideg	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25462233]
HepG2	IC₅₀	5.52 μM Compound: 2	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 28757065]
HepG2	IC₅₀	5.62 μM Compound: Etoposide	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26804229]
HepG2	IC₅₀	5.9 μM Compound: Etoposide	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by CCK8 assay	[PMID: 38408342]
HepG2	IC₅₀	6.2 μg/mL Compound: Etoposide	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29335206]
HepG2	IC₅₀	6.2 μg/mL Compound: Etoposide	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 29908441]
HepG2	IC₅₀	6.41 μM Compound: Etoposide	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23668986]
HepG2	IC₅₀	6.94 μM Compound: Etoposide	Anticancer activity against human HepG2 cells assessed as inhibition of cell growth Anticancer activity against human HepG2 cells assessed as inhibition of cell growth	[PMID: 32531682]
HepG2	IC₅₀	8.1 μM Compound: VP-16	Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 assay	[PMID: 36063665]
HepG2	IC₅₀	9.14 μM Compound: Etoposide	Antitumor activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay Antitumor activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23313635]
HepG2	IC₅₀	9.2 μM Compound: 2; VP-16	Cytotoxicity against human HepG2 cells assessed as reduction in inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 29248296]
HepG2	IC₅₀	> 0.91 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human HepG2 cells incubated for 48 to 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 to 72 hrs by MTT assay	[PMID: 32992133]
HepG2	IC₅₀	> 50000 nM Compound: VP-16	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29886322]
HepG2	IC₅₀	>= 2.91 μM Compound: Etoposide	Anticancer activity against human HepG2 cells after 48 hrs by SRB assay Anticancer activity against human HepG2 cells after 48 hrs by SRB assay	[PMID: 30660827]
HepG2	IC₅₀	>= 6.94 μM Compound: Etoposide	Antiproliferative activity against human HepG2 cells by SRB assay Antiproliferative activity against human HepG2 cells by SRB assay	[PMID: 31546197]
Hs 683	GI₅₀	1.5 μM Compound: Etoposide	Growth inhibition of human Hs683 cells after 72 hrs by MTT assay Growth inhibition of human Hs683 cells after 72 hrs by MTT assay	[PMID: 28406636]
Hs 683	IC₅₀	1 μM Compound: Etoposide	Growth inhibition of human Hs683 cells after 72 hrs by MTT assay Growth inhibition of human Hs683 cells after 72 hrs by MTT assay	[PMID: 24950030]
Hs 683	IC₅₀	2 μM Compound: Etoposide	Growth inhibition of human Hs683 cells after 72 hrs by MTT assay Growth inhibition of human Hs683 cells after 72 hrs by MTT assay	[PMID: 24180210]
Hs-578T	GI₅₀	8 μM Compound: Etoposide	In vitro cytotoxicity against human breast cancer Hs 578.T cell line In vitro cytotoxicity against human breast cancer Hs 578.T cell line	[PMID: 9871772]
Hs-578T	IC₅₀	> 50 μM Compound: Etoposide	Activation of procaspase-3-mediated human Hs 578T cell death after 72 hrs by MTS/PMS assay Activation of procaspase-3-mediated human Hs 578T cell death after 72 hrs by MTS/PMS assay	[PMID: 16936720]
Hs746T	IC₅₀	3.29 μg/mL Compound: Etoposide	Cytotoxic activity against human tumor Hs 746.T stomach cells Cytotoxic activity against human tumor Hs 746.T stomach cells	[PMID: 15056007]
HuCC-A1	IC₅₀	4 μg/mL Compound: Etoposide	Cytotoxicity against human HuCCa1 cells after 3 days by MTT assay Cytotoxicity against human HuCCa1 cells after 3 days by MTT assay	[PMID: 21216051]
HuCC-A1	IC₅₀	5.1 μM Compound: Etoposide	Cytotoxicity against human HuCCa1 cells Cytotoxicity against human HuCCa1 cells	[PMID: 19788270]
HuCC-A1	IC₅₀	6.8 μM Compound: Etoposide	Antiproliferative activity against human HuCC-A1 cells assessed as reduction in cell proliferation Antiproliferative activity against human HuCC-A1 cells assessed as reduction in cell proliferation	[PMID: 33276991]
Huh-7	IC₅₀	17.3 μM Compound: Vp-16	Antiproliferative activity against human Huh-7 cells after 72 hrs by SRB assay Antiproliferative activity against human Huh-7 cells after 72 hrs by SRB assay	[PMID: 33979690]
Huh-7	IC₅₀	3.8 μM Compound: 3; Etop	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
Huh-7	IC₅₀	7.4 μM Compound: VP-16	Cytotoxicity against human HuH7 cells by MTT assay Cytotoxicity against human HuH7 cells by MTT assay	[PMID: 30543429]
Huh-7	IC₅₀	8.9 μM Compound: vp16	Antiproliferative activity against human Huh-7 cells measured after 72 hrs by MTT assay Antiproliferative activity against human Huh-7 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
IGROV-1	IC₅₀	984.5 nM Compound: 1 (VP16)	In vivo antiproliferative activity against IGROV1 cell line In vivo antiproliferative activity against IGROV1 cell line	[PMID: 15084135]
IMR-32	IC₅₀	6.3 μM Compound: Etoposide	Anticancer activity against human IMR32 cells assessed as cell viability after 48 hrs by SRB assay Anticancer activity against human IMR32 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21074444]
Ishikawa	GI₅₀	11 μM Compound: Etoposide	Growth inhibition of human Ishikawa cells Growth inhibition of human Ishikawa cells	[PMID: 21986585]
J774	IC₅₀	576.7 nM Compound: VP-16	Inhibitory concentration required for cytotoxicity in J774.2 murine macrophage-like cells Inhibitory concentration required for cytotoxicity in J774.2 murine macrophage-like cells	10.1016/0960-894X(95)00300-I
J774.2	IC₅₀	2133.3 nM Compound: VP-16	Inhibitory concentration required for cytotoxicity in hydroxyrubicin-resistant (WP159/R) cells Inhibitory concentration required for cytotoxicity in hydroxyrubicin-resistant (WP159/R) cells	10.1016/0960-894X(95)00300-I
J774.2	IC₅₀	3667.2 nM Compound: VP-16	Inhibitory concentration required for cytotoxicity in DOX-resistant (DOX/R) cells Inhibitory concentration required for cytotoxicity in DOX-resistant (DOX/R) cells	10.1016/0960-894X(95)00300-I
J82	IC₅₀	0.8 μM Compound: Etoposide	Anticancer activity against human J82 cells after 3 days by MTT assay Anticancer activity against human J82 cells after 3 days by MTT assay	[PMID: 21621882]
J82	IC₅₀	2.5 μM Compound: Etoposide	Cytotoxicity against human J82 cells after 3 days by MTT assay Cytotoxicity against human J82 cells after 3 days by MTT assay	[PMID: 19419803]
J82	IC₅₀	2.8 μM Compound: Etoposide	Cytotoxicity against human J82 cells after 3 days by MTT assay Cytotoxicity against human J82 cells after 3 days by MTT assay	[PMID: 19013074]
J82	IC₅₀	2.8 μM Compound: Etoposide	Cytotoxicity against human J82 cells after 72 hrs by MTT assay Cytotoxicity against human J82 cells after 72 hrs by MTT assay	[PMID: 19269832]
J82	IC₅₀	2.8 μM Compound: Etoposide	Cytotoxicity against human J82 cells after 72 hrs by MTT assay Cytotoxicity against human J82 cells after 72 hrs by MTT assay	[PMID: 20828890]
J82	IC₅₀	2.8 μM Compound: Etoposide	Cytotoxicity against human J82 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human J82 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23454511]
J82	IC₅₀	2.8 μM Compound: etoposide	Antitumor against human J82 cells after 72 hrs by MTT assay Antitumor against human J82 cells after 72 hrs by MTT assay	[PMID: 18299197]
Jurkat	IC₅₀	1.2 μM Compound: VP-16	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 19394829]
Jurkat	IC₅₀	1.2 μM Compound: VP-16	Antiproliferative activity against human Jurkat cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
Jurkat	IC₅₀	1.4 μM Compound: Etoposide	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 30447888]
Jurkat	IC₅₀	160 nM Compound: Etoposide	Growth inhibitory activity against human Jurkat leukemia cell line (JLC) Growth inhibitory activity against human Jurkat leukemia cell line (JLC)	[PMID: 12620081]
Jurkat	IC₅₀	2.8 μg/mL Compound: Etoposide	Anticancer activity against human Jurkat cells after 48 hrs by MTT assay Anticancer activity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 21816519]
Jurkat	IC₅₀	5.35 μM Compound: Etoposide	Cytotoxicity against human Jurkat cells after 2 days by MTT assay Cytotoxicity against human Jurkat cells after 2 days by MTT assay	[PMID: 22325897]
K562	GI₅₀	12.59 μM Compound: Etoposide	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 21115210]
K562	GI₅₀	12.59 μM Compound: Etoposide	Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
K562	IC₅₀	0.163 μM Compound: 1	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 29870668]
K562	IC₅₀	0.163 μM Compound: Etoposide	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 25922181]
K562	IC₅₀	0.183 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human K562 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells incubated for 48 hrs by MTT assay	[PMID: 32992133]
K562	IC₅₀	0.3 μM Compound: Etoposide	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 29871847]
K562	IC₅₀	0.32 μM Compound: etoposide	Growth inhibition of K562 cells by XTT assay after 5 days Growth inhibition of K562 cells by XTT assay after 5 days	[PMID: 17411092]
K562	IC₅₀	0.32 μM Compound: etoposide	Cytotoxicity against human K562 cells after 5 days by XTT assay Cytotoxicity against human K562 cells after 5 days by XTT assay	[PMID: 18076140]
K562	IC₅₀	0.345 μM Compound: Etoposide	Antiproliferative activity against human K562 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells measured after 72 hrs by CCK8 assay	[PMID: 27484511]
K562	IC₅₀	0.4 μM Compound: Etoposide	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 37672645]
K562	IC₅₀	0.413 μM Compound: 2	Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay	[PMID: 27503681]
K562	IC₅₀	0.413 μM Compound: Etoposide	Antiproliferative activity against human K562 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 26615886]
K562	IC₅₀	0.42 μM Compound: 1	Cytotoxicity against human K562 cells after 72 hrs by MTS assay Cytotoxicity against human K562 cells after 72 hrs by MTS assay	[PMID: 20006518]
K562	IC₅₀	0.51 μM Compound: Etoposide	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 26649766]
K562	IC₅₀	0.54 μM Compound: Etoposide	Cytostatic activity against human K562 cells Cytostatic activity against human K562 cells	[PMID: 30738653]
K562	IC₅₀	0.76 μM Compound: Etoposide	Growth inhibition of human K562 cells incubated for 72 hrs by sulforhodamine B assay Growth inhibition of human K562 cells incubated for 72 hrs by sulforhodamine B assay	[PMID: 28625715]
K562	IC₅₀	0.76 μM Compound: Etoposide	Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30041947]
K562	IC₅₀	0.764 μM Compound: 2	Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay	[PMID: 29678463]
K562	IC₅₀	0.98 μM Compound: Etoposide	Antiproliferative activity against human K562 cells assessed as reduction in cell viability by sulforhodamine B assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability by sulforhodamine B assay	[PMID: 32073848]
K562	IC₅₀	1.06 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 method Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 method	[PMID: 32992133]
K562	IC₅₀	1.21 μM Compound: Etoposide	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 21115246]
K562	IC₅₀	1.22 μM Compound: Etoposide	Cytotoxicity against human etoposide-sensitive K562 cells after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay Cytotoxicity against human etoposide-sensitive K562 cells after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay	[PMID: 29656990]
K562	IC₅₀	1.27 μM Compound: Etoposide	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 18514972]
K562	IC₅₀	1.3 μM Compound: Etoposide	Cytotoxicity against human K562 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human K562 cells after 72 hrs by sulforhodamine B assay	[PMID: 29893558]
K562	IC₅₀	1.64 μM Compound: VP-16	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 25599951]
K562	IC₅₀	1.72 μM Compound: VP-16	Antiproliferative activity against human K562 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition by MTT assay	[PMID: 38107170]
K562	IC₅₀	1.77 μM Compound: Etoposide	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
K562	IC₅₀	1.79 μM Compound: Etoposide	Cytotoxicity in human K562 cells by sulforhodamine B colorimetric assay Cytotoxicity in human K562 cells by sulforhodamine B colorimetric assay	[PMID: 27933890]
K562	IC₅₀	1.87 μM Compound: Etoposide	Cytotoxicity against human K-562 cells after 72 hrs by MTT assay Cytotoxicity against human K-562 cells after 72 hrs by MTT assay	[PMID: 16872135]
K562	IC₅₀	1.98 μM Compound: Ref 34, Cpd 2	Cytotoxicity against human K562 cells by SRB assay Cytotoxicity against human K562 cells by SRB assay	[PMID: 32992133]
K562	IC₅₀	10.79 μM Compound: VP16	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33191085]
K562	IC₅₀	11.3 μM Compound: Etoposide	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 35182774]
K562	IC₅₀	12 μM Compound: ET	Cytotoxicity against human K562 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385594]
K562	IC₅₀	2.09 μM Compound: Etoposide	Cytotoxicity against human K562 cells after 2 days Cytotoxicity against human K562 cells after 2 days	[PMID: 22318164]
K562	IC₅₀	2.11 μM Compound: VP-16	Cytotoxicity against human K562 cells after 2 days by MTT assay Cytotoxicity against human K562 cells after 2 days by MTT assay	[PMID: 21821321]
K562	IC₅₀	2.3 μM Compound: etoposide	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
K562	IC₅₀	2.41 μM Compound: Etoposide	Cytotoxicity against human K562 cells after 4 days by ELISA reader assay Cytotoxicity against human K562 cells after 4 days by ELISA reader assay	[PMID: 19939682]
K562	IC₅₀	2.84 μM Compound: Etoposide	Cytotoxicity against human K562 cells in presence of 10% fetal bovine serum Cytotoxicity against human K562 cells in presence of 10% fetal bovine serum	[PMID: 20188578]
K562	IC₅₀	2.85 μM Compound: Etoposide	Cytotoxicity against human K562 cells after 24 hrs by MTT assay Cytotoxicity against human K562 cells after 24 hrs by MTT assay	[PMID: 23369687]
K562	IC₅₀	22.81 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 32992133]
K562	IC₅₀	242.8 μM Compound: VP-16	Cytotoxicity against adriamycin-selected multi drug-resistant human K562 cells after 72 hrs by sulforhodamine B and MTT assay Cytotoxicity against adriamycin-selected multi drug-resistant human K562 cells after 72 hrs by sulforhodamine B and MTT assay	[PMID: 22119124]
K562	IC₅₀	3.1 μM Compound: Etoposide	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 17459529]
K562	IC₅₀	3.1 μM Compound: etoposide	Cytotoxicity against human K562 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human K562 cells after 72 hrs by sulforhodamine B assay	[PMID: 25495422]
K562	IC₅₀	3.1 μM Compound: etoposide	Antiproliferative activity against human K562 cells after 3 days by sulforhodamine B assay Antiproliferative activity against human K562 cells after 3 days by sulforhodamine B assay	[PMID: 25700232]
K562	IC₅₀	3.39 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 assay	[PMID: 32992133]
K562	IC₅₀	3.39 μM Compound: VP-16	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 25113878]
K562	IC₅₀	4.39 μM Compound: Etoposide	Cytotoxicity against human K562 cells assessed as reduction in viable cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in viable cells after 48 hrs by MTT assay	[PMID: 26916436]
K562	IC₅₀	4.9 μM Compound: Etoposide	Cytotoxicity against human K562 ATCC CCL 243 cells after 72 hrs by MTT assay Cytotoxicity against human K562 ATCC CCL 243 cells after 72 hrs by MTT assay	[PMID: 18558490]
K562	IC₅₀	5.16 μM Compound: VP-16	Cytotoxicity against human K562 cells after 72 hrs by sulforhodamine B and MTT assay Cytotoxicity against human K562 cells after 72 hrs by sulforhodamine B and MTT assay	[PMID: 22119124]
K562	IC₅₀	522.2 nM Compound: 1 (VP16)	In vivo antiproliferative activity against K-562 cell line In vivo antiproliferative activity against K-562 cell line	[PMID: 15084135]
K562	IC₅₀	6.7 μM Compound: Etoposide	Antiproliferative activity against human K562 cells after 24 to 72 hrs by SRB assay Antiproliferative activity against human K562 cells after 24 to 72 hrs by SRB assay	[PMID: 26595875]
K562	IC₅₀	66 μM Compound: Etop	Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34606997]
K562	IC₅₀	8.45 μM Compound: Etoposide	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 23968711]
K562	IC₅₀	8.45 μM Compound: Etoposide	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 29545100]
K562	IC₅₀	9.23 μM Compound: ETP	Growth inhibition of human K562 cells after 72 hrs by MTT assay Growth inhibition of human K562 cells after 72 hrs by MTT assay	[PMID: 30471828]
K562	IC₅₀	9.4 μM Compound: Etoposide	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 30447888]
K562	IC₅₀	> 200 μM Compound: Etop	Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 34606997]
K562/A02	GI₅₀	1.08 μM Compound: Ref 34, Cpd 2	Cytotoxicity against human K562/A02 cells by SRB assay Cytotoxicity against human K562/A02 cells by SRB assay	[PMID: 32992133]
K562/A02	IC₅₀	1.98 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human K562/A02 cells by MTT assay Antiproliferative activity against human K562/A02 cells by MTT assay	[PMID: 32992133]
K562/A02	IC₅₀	10.58 μM Compound: Etoposide	Antiproliferative activity against human K562/A02 cells assessed as reduction in cell viability measured after 2 days by MTT assay Antiproliferative activity against human K562/A02 cells assessed as reduction in cell viability measured after 2 days by MTT assay	[PMID: 32531682]
K562/A02	IC₅₀	151.69 μM Compound: VP-16	Cytotoxicity against human K562/A02 cells after 2 days by MTT assay Cytotoxicity against human K562/A02 cells after 2 days by MTT assay	[PMID: 21821321]
K562/A02	IC₅₀	234.7 μM Compound: VP-16	Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay	[PMID: 25113878]
K562/Adr	IC₅₀	0.413 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human K562/ADR cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human K562/ADR cells incubated for 72 hrs by CCK8 assay	[PMID: 32992133]
K562/Adr	IC₅₀	2.025 μM Compound: 2	Antiproliferative activity against human K562/ADR cells after 72 hrs by CCK8 assay Antiproliferative activity against human K562/ADR cells after 72 hrs by CCK8 assay	[PMID: 27503681]
K562/Adr	IC₅₀	2.025 μM Compound: Etoposide	Antiproliferative activity against human K562/ADR cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human K562/ADR cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 26615886]
K562/Adr	IC₅₀	2.211 μM Compound: Etoposide	Antiproliferative activity against human K562/ADR cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human K562/ADR cells measured after 72 hrs by CCK8 assay	[PMID: 27484511]
K562/VCR	IC₅₀	11.84 μM Compound: 2	Antiproliferative activity against human K562/VCR cells after 72 hrs by CCK8 assay Antiproliferative activity against human K562/VCR cells after 72 hrs by CCK8 assay	[PMID: 29678463]
KB	CC₅₀	0.1 μM Compound: VP-16	Compound concentration required to reduce the exponential growth of KB cells by 50% Compound concentration required to reduce the exponential growth of KB cells by 50%	[PMID: 9767632]
KB	EC₅₀	1.1 μM Compound: Etoposide	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 20102168]
KB	EC₅₀	3.9 μg/mL Compound: Etoposide	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 23043462]
KB	EC₅₀	3.9 μg/mL Compound: etoposide	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 20073490]
KB	EC₅₀	4.5 μM Compound: etoposide	Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay	[PMID: 21028898]
KB	ED₅₀	0.12 μg/mL Compound: 1 (Etoposide)	Compound was tested for in vitro cytotoxicity in KB cells after 3 days of incubation Compound was tested for in vitro cytotoxicity in KB cells after 3 days of incubation	[PMID: 2537424]
KB	ED₅₀	0.16 μg/mL Compound: 1	Cytotoxicity against human KB cells assessed as reduction in cell number after 3 days by crystal violet staining Cytotoxicity against human KB cells assessed as reduction in cell number after 3 days by crystal violet staining	[PMID: 2550587]
KB	ED₅₀	0.1 μg/mL Compound: etoposide	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 2095375]
KB	ED₅₀	0.1 μg/mL Compound: etoposide	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 2849640]
KB	ED₅₀	0.2 mM Compound: VP-16	The compound was tested for tumor cell growth inhibitory activity against human nasopharynx carcinoma(KB) cell line. The compound was tested for tumor cell growth inhibitory activity against human nasopharynx carcinoma(KB) cell line.	[PMID: 10395485]
KB	ED₅₀	0.2 μM Compound: Etoposide	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 20187635]
KB	ED₅₀	0.3 μM Compound: 1	Dose required to cause reduction in human nasopharyngeal KB cancer cells after 3 days incubation Dose required to cause reduction in human nasopharyngeal KB cancer cells after 3 days incubation	[PMID: 15456257]
KB	ED₅₀	0.5 μg/mL Compound: 1	Dose required to cause reduction in human nasopharyngeal KB cancer cells after 3 days incubation Dose required to cause reduction in human nasopharyngeal KB cancer cells after 3 days incubation	[PMID: 15456257]
KB	ED₅₀	11 μM Compound: 1	Effective dose required for inhibition of KB-7d cell replication after 3 days of continuous treatment Effective dose required for inhibition of KB-7d cell replication after 3 days of continuous treatment	[PMID: 15125972]
KB	ED₅₀	17.2 μM Compound: 1	Dose required for reduction in etoposide resistant human nasopharyngeal KB-7d cancer cells after 3 days incubation Dose required for reduction in etoposide resistant human nasopharyngeal KB-7d cancer cells after 3 days incubation	[PMID: 15456257]
KB	ED₅₀	23.8 mM Compound: VP-16	The compound was tested for tumor cell growth inhibitory activity against human KB-7d cell line resistant to etoposide The compound was tested for tumor cell growth inhibitory activity against human KB-7d cell line resistant to etoposide	[PMID: 10395485]
KB	ED₅₀	30.6 mM Compound: VP-16	The compound was tested for tumor cell growth inhibitory activity against human KB-vin20c cell line resistant to vincristine The compound was tested for tumor cell growth inhibitory activity against human KB-vin20c cell line resistant to vincristine	[PMID: 10395485]
KB	ED₅₀	7 μM Compound: 1	Dose required for reduction in camptothecin resistant human nasopharyngeal KB cancer cells after 3 days incubation Dose required for reduction in camptothecin resistant human nasopharyngeal KB cancer cells after 3 days incubation	[PMID: 15456257]
KB	ED₅₀	> 100 μM Compound: 1	Dose required for reduction in vincristine resistant human nasopharyngeal KB-VIN cancer cells after 3 days incubation Dose required for reduction in vincristine resistant human nasopharyngeal KB-VIN cancer cells after 3 days incubation	[PMID: 15456257]
KB	ED₅₀	> 10 μg/mL Compound: 1	Dose required to cause reduction in human nasopharyngeal KB-7d cancer cells after 3 days incubation Dose required to cause reduction in human nasopharyngeal KB-7d cancer cells after 3 days incubation	[PMID: 15456257]
KB	GI₅₀	0.3 μM Compound: 2	Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B based ELISA Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B based ELISA	[PMID: 21402478]
KB	GI₅₀	0.3 μM Compound: 2, VP-16	Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay	[PMID: 21489802]
KB	GI₅₀	0.31 μM Compound: 2, Eto	Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
KB	GI₅₀	0.31 μM Compound: 2, Eto	Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
KB	GI₅₀	8.392 μM Compound: VP-16	Antiproliferative activity against human KB cells incubated for 48 hrs by SRB assay Antiproliferative activity against human KB cells incubated for 48 hrs by SRB assay	[PMID: 32171161]
KB	IC₅₀	0.12 μg/mL Compound: Etoposide	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 9214732]
KB	IC₅₀	0.164 μM Compound: Etoposide	Growth inhibitory activity (antiproliferative) against KB cell lines Growth inhibitory activity (antiproliferative) against KB cell lines	[PMID: 8691469]
KB	IC₅₀	0.2 μM Compound: 1	Concentration required for 50% reduction in KB cell number after 3-day incubation Concentration required for 50% reduction in KB cell number after 3-day incubation	[PMID: 1312600]
KB	IC₅₀	0.2 μM Compound: 1	Concentration required for 50% reduction in KB cell number after 3-day incubation Concentration required for 50% reduction in KB cell number after 3-day incubation	[PMID: 1312601]
KB	IC₅₀	0.201 μg/mL Compound: Etoposide	Cytotoxic activity against human KB nasopha tumor cell line Cytotoxic activity against human KB nasopha tumor cell line	[PMID: 15149673]
KB	IC₅₀	0.25 μg/mL Compound: Etoposide	Cytotoxicity against human KB cells after 3 days by MTT assay Cytotoxicity against human KB cells after 3 days by MTT assay	[PMID: 21216051]
KB	IC₅₀	0.42 μM Compound: Etoposide	Antiproliferative activity against human KB cells after 48 hrs by MTT assay Antiproliferative activity against human KB cells after 48 hrs by MTT assay	[PMID: 18514972]
KB	IC₅₀	0.5 μM Compound: Etoposide	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 19788270]
KB	IC₅₀	0.6 μM Compound: Etoposide	Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50% Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50%	[PMID: 12431048]
KB	IC₅₀	0.6 μM Compound: Etoposide	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 20187635]
KB	IC₅₀	0.8 μM Compound: Etoposide	Concentration required to reduce proliferation of KB human nasopharyngeal carcinoma (KBWT) cell line by 50% as determined by the MTT method Concentration required to reduce proliferation of KB human nasopharyngeal carcinoma (KBWT) cell line by 50% as determined by the MTT method	[PMID: 14761187]
KB	IC₅₀	0.85 μM Compound: VP-16	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B and MTT assay Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B and MTT assay	[PMID: 22119124]
KB	IC₅₀	1.02 μM Compound: Etoposide	Antiproliferative activity against human KB cells assessed as reduction in cell growth incubated for 2 days by MTT assay Antiproliferative activity against human KB cells assessed as reduction in cell growth incubated for 2 days by MTT assay	[PMID: 32531682]
KB	IC₅₀	1.1 μM Compound: VP-16	Cytotoxicity against human KB cells after 72 hrs by methylene blue assay Cytotoxicity against human KB cells after 72 hrs by methylene blue assay	[PMID: 14738395]
KB	IC₅₀	1.1 μM Compound: VP-16	Growth inhibition of human KB cells after 72 hrs by methylene blue dye assay Growth inhibition of human KB cells after 72 hrs by methylene blue dye assay	[PMID: 19053773]
KB	IC₅₀	1.1 μM Compound: VP-16	Growth inhibition of human KB cells after 72 hrs by methylene blue assay Growth inhibition of human KB cells after 72 hrs by methylene blue assay	[PMID: 22060033]
KB	IC₅₀	1.1 μM Compound: VP-16	Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay	[PMID: 24106982]
KB	IC₅₀	1.1 μM Compound: VP-16	Antiproliferative activity against human KB cells Antiproliferative activity against human KB cells	[PMID: 25059503]
KB	IC₅₀	1.25 μM Compound: Etoposide	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 18844422]
KB	IC₅₀	1.3 μM Compound: etoposide	Antiproliferative activity against drug-resistant tumor cell line KBCamp. Antiproliferative activity against drug-resistant tumor cell line KBCamp.	[PMID: 10411476]
KB	IC₅₀	1.3 μM Compound: etoposide	Cytotoxicity against human KB cells after 72 hrs by methylene blue dye assay Cytotoxicity against human KB cells after 72 hrs by methylene blue dye assay	[PMID: 19785430]
KB	IC₅₀	1.45 μM Compound: etoposide	Antiproliferative activity against drug-resistant tumor cell line KBwt. Antiproliferative activity against drug-resistant tumor cell line KBwt.	[PMID: 10411476]
KB	IC₅₀	1.5 μM Compound: VP-16	Antiproliferative activity against human KB cells after 72 hrs by methylene blue assay Antiproliferative activity against human KB cells after 72 hrs by methylene blue assay	[PMID: 26160020]
KB	IC₅₀	1.71 μM Compound: Ref 34, Cpd 2	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 32992133]
KB	IC₅₀	1.737 μM Compound: Ref 34, Cpd 2	Cytotoxicity against human KB cells incubated for 72 hrs by SRB method Cytotoxicity against human KB cells incubated for 72 hrs by SRB method	[PMID: 32992133]
KB	IC₅₀	10 μM Compound: Etoposide	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 21570846]
KB	IC₅₀	11.8 μM Compound: Etoposide	Antiproliferative activity against human KB cells by MTT assay Antiproliferative activity against human KB cells by MTT assay	[PMID: 31546197]
KB	IC₅₀	14.2 μM Compound: Etoposide	Cytotoxicity against human KB cells assessed as reduction of cell growth by SRB method Cytotoxicity against human KB cells assessed as reduction of cell growth by SRB method	[PMID: 18782668]
KB	IC₅₀	1500 nM Compound: VP-16	Cytotoxicity against human KB cells after 72 hrs by methylene blue assay Cytotoxicity against human KB cells after 72 hrs by methylene blue assay	[PMID: 24657567]
KB	IC₅₀	153.26 μM Compound: VP-16	Cytotoxicity against vincristine-selected multi drug-resistant human KB cells after 72 hrs by sulforhodamine B and MTT assay Cytotoxicity against vincristine-selected multi drug-resistant human KB cells after 72 hrs by sulforhodamine B and MTT assay	[PMID: 22119124]
KB	IC₅₀	2 μM Compound: VP-16	Cytotoxicity against human KB cells after 72 hrs Cytotoxicity against human KB cells after 72 hrs	[PMID: 17125231]
KB	IC₅₀	2.27 μM Compound: Ref 34, Cpd 2	Cytotoxicity against human Vincristine-resistant KB cells incubated for 72 hrs by SRB method Cytotoxicity against human Vincristine-resistant KB cells incubated for 72 hrs by SRB method	[PMID: 32992133]
KB	IC₅₀	2.4 μM Compound: Etoposide	Concentration required to reduce proliferation of KB subclones passaged in the presence of vincristine 0.02 uM (KB7D) cell line by 50% as determined by the MTT method Concentration required to reduce proliferation of KB subclones passaged in the presence of vincristine 0.02 uM (KB7D) cell line by 50% as determined by the MTT method	[PMID: 14761187]
KB	IC₅₀	23 μM Compound: VP-16	Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-VIN10 cells after 72 hrs by methylene blue dye assay Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-VIN10 cells after 72 hrs by methylene blue dye assay	[PMID: 19053773]
KB	IC₅₀	23.8 μM Compound: Etoposide	Growth inhibitory activity (antiproliferative) against KB/7d cell lines Growth inhibitory activity (antiproliferative) against KB/7d cell lines	[PMID: 8691469]
KB	IC₅₀	26.2 μM Compound: etoposide	Antiproliferative activity against drug-resistant tumor cell line KBMDR. Antiproliferative activity against drug-resistant tumor cell line KBMDR.	[PMID: 10411476]
KB	IC₅₀	28.7 μM Compound: Etoposide	Cytotoxicity against human vincristine-resistant KB cells after 72 hrs by MTT assay Cytotoxicity against human vincristine-resistant KB cells after 72 hrs by MTT assay	[PMID: 20187635]
KB	IC₅₀	3.5 μM Compound: VP-16	Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-TAX50 cells after 72 hrs by methylene blue dye assay Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-TAX50 cells after 72 hrs by methylene blue dye assay	[PMID: 19053773]
KB	IC₅₀	3.88 μM Compound: 2	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 24553146]
KB	IC₅₀	3.88 μM Compound: 3	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 23490151]
KB	IC₅₀	3.88 μM Compound: 3	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 24332656]
KB	IC₅₀	4.61 nM Compound: 1, VP-16	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 21145139]
KB	IC₅₀	4.8 μM Compound: etoposide	Cytotoxicity against human KB cells by SRB microtiter plate assay Cytotoxicity against human KB cells by SRB microtiter plate assay	[PMID: 17585747]
KB	IC₅₀	475 nM Compound: VP-16	Antiproliferative activity against human KB cells after 72 hrs by ethylene blue dye assay Antiproliferative activity against human KB cells after 72 hrs by ethylene blue dye assay	[PMID: 22698783]
KB	IC₅₀	54 μM Compound: VP-16	Growth inhibition of human KB-7D cells overexpressing multidrug resistant associated protein after 72 hrs by methylene blue dye assay Growth inhibition of human KB-7D cells overexpressing multidrug resistant associated protein after 72 hrs by methylene blue dye assay	[PMID: 19053773]
KB	IC₅₀	8.3 μM Compound: Etoposide	Cytotoxicity against Homo sapiens (human) KB cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) KB cells after 72 hr by MTT assay	10.1007/s00044-011-9937-1
KB	IC₅₀	8.3 μM Compound: Etoposide	Anticancer activity against Homo sapiens (human) KB cells assessed as decrease in cell growth after 3 days by MTT assay Anticancer activity against Homo sapiens (human) KB cells assessed as decrease in cell growth after 3 days by MTT assay	10.1007/s00044-012-0245-1
KB	IC₅₀	> 20 μM Compound: Etoposide	Concentration required to reduce proliferation of KB subclones passaged in the presence of doxorubicin 0.09 uM (KBMDR) cell line by 50% as determined by the MTT method Concentration required to reduce proliferation of KB subclones passaged in the presence of doxorubicin 0.09 uM (KBMDR) cell line by 50% as determined by the MTT method	[PMID: 14761187]
KB	IC₅₀	> 20 μM Compound: Etoposide	Concentration required to reduce proliferation of KB subclones passaged in the presence of etoposide 7 uM (KB7D) cell line by 50% as determined by the MTT method Concentration required to reduce proliferation of KB subclones passaged in the presence of etoposide 7 uM (KB7D) cell line by 50% as determined by the MTT method	[PMID: 14761187]
KB	IC₅₀	> 50 μM Compound: etoposide	Antiproliferative activity against drug-resistant tumor cell line KB7D. Antiproliferative activity against drug-resistant tumor cell line KB7D.	[PMID: 10411476]
KB	IC₅₀	> 50 μM Compound: etoposide	Antiproliferative activity against drug-resistant tumor cell line KBV20C. Antiproliferative activity against drug-resistant tumor cell line KBV20C.	[PMID: 10411476]
KB 3-1	IC₅₀	566.5 nM Compound: 1 (VP16)	In vivo antiproliferative activity against KB-3-1 cell line In vivo antiproliferative activity against KB-3-1 cell line	[PMID: 15084135]
KM12	GI₅₀	5.62 μM Compound: Etoposide	In vitro cytotoxicity against human colon cancer KM 12 cell line In vitro cytotoxicity against human colon cancer KM 12 cell line	[PMID: 9871772]
L02	IC₅₀	1.22 μM Compound: VP-16	Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay	[PMID: 35612499]
L02	IC₅₀	13 μM Compound: Etoposide	Antiproliferative activity against human L02 cells after 48 hrs by MTT assay Antiproliferative activity against human L02 cells after 48 hrs by MTT assay	[PMID: 18514972]
L02	IC₅₀	24.6 μM Compound: VP-16	Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay	[PMID: 30265994]
L02	IC₅₀	24.61 μM Compound: VP-16	Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 24775914]
L02	IC₅₀	3.78 μM Compound: Etoposide	Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28169166]
L02	IC₅₀	3480.5 nM Compound: VP-16	Cytotoxicity against human L02 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29886322]
L02	IC₅₀	39.1 μM Compound: VP-16	Antiproliferative activity against human HL7702 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HL7702 cells incubated for 72 hrs by CCK8 assay	[PMID: 36063665]
L02	IC₅₀	47.74 μM Compound: vp16	Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
L02	IC₅₀	49.6 μM Compound: Etoposide	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability measured after 48 hrs by CCK8 assay Cytotoxicity against human HL7702 cells assessed as reduction in cell viability measured after 48 hrs by CCK8 assay	[PMID: 38408342]
L02	IC₅₀	7.75 μM Compound: 2	Cytotoxicity against human L02 cells after 24 hrs by MTT assay Cytotoxicity against human L02 cells after 24 hrs by MTT assay	[PMID: 28757065]
L1210	ED₅₀	1.58 μg/mL Compound: Etoposide	Compound was tested for its antitumor activity and the cytotoxicity against L1210 lymphoid leukemia screen Compound was tested for its antitumor activity and the cytotoxicity against L1210 lymphoid leukemia screen	[PMID: 3820231]
L1210	ED₅₀	1.6 μg/mL Compound: etoposide	Cytotoxicity against mouse L1210 cells Cytotoxicity against mouse L1210 cells	[PMID: 2095375]
L1210	IC₅₀	0.2 μM Compound: etoposide	In vitro cytotoxic activity against murine L1210 leukemia cells. In vitro cytotoxic activity against murine L1210 leukemia cells.	[PMID: 9804687]
L1210	IC₅₀	0.23 μM Compound: VP 16	Antiproliferative activity was evaluated against murine L1210 leukemia cell line Antiproliferative activity was evaluated against murine L1210 leukemia cell line	[PMID: 11128630]
L1210	IC₅₀	0.5 μM Compound: Etoposide	Cytotoxicity against mouse L1210 ATCC CCL 219 cells after 48 hrs by MTT assay Cytotoxicity against mouse L1210 ATCC CCL 219 cells after 48 hrs by MTT assay	[PMID: 18558490]
L1210	IC₅₀	0.83 μM Compound: 1 (VP16)	Inhibitory concentration required to reduce 50 percent L1210 cell growth Inhibitory concentration required to reduce 50 percent L1210 cell growth	[PMID: 15084135]
L1210	IC₅₀	0.83 μM Compound: VP-16	Inhibition of L1210 cell proliferation in cytotoxic assay Inhibition of L1210 cell proliferation in cytotoxic assay	[PMID: 15658872]
L1210	IC₅₀	0.834 μM Compound: 2	Inhibitory activity against L1210 cell line Inhibitory activity against L1210 cell line	[PMID: 14592517]
L1210	IC₅₀	201.4 nM Compound: 1 (VP16)	In vivo antiproliferative activity against L1210 cell line In vivo antiproliferative activity against L1210 cell line	[PMID: 15084135]
L132	GI₅₀	10.38 μM Compound: Etoposide	Growth inhibition of human L-132 cells by MTT assay Growth inhibition of human L-132 cells by MTT assay	[PMID: 27503682]
L6	IC₅₀	18.99 μM Compound: Etoposide	Cytotoxicity against rat L6 cells after 71.5 hrs by Presto Blue assay Cytotoxicity against rat L6 cells after 71.5 hrs by Presto Blue assay	[PMID: 25466187]
L929	IC₅₀	1 μM Compound: 2	Cytotoxicity against mouse L929 cells after 72 hrs by MTT assay Cytotoxicity against mouse L929 cells after 72 hrs by MTT assay	[PMID: 22687745]
LAMA-84	IC₅₀	0.79 μM Compound: Etoposide	Cytotoxicity against human LAMA-84 cells after 72 hrs by MTT assay Cytotoxicity against human LAMA-84 cells after 72 hrs by MTT assay	[PMID: 16872135]
LLC-PK1	IC₅₀	> 50 μM Compound: Etoposide	Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	> 50 μM Compound: Etoposide	Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	> 50 μM Compound: Etoposide	Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	> 50 μM Compound: Etoposide (VP-16)	TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells	[PMID: 12699389]
LLC-PK1	IC₅₀	> 50 μM Compound: Etoposide (VP-16)	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells	[PMID: 12699389]
LLC-PK1	IC₅₀	> 50 μM Compound: Etoposide (VP-16)	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells	[PMID: 12699389]
LN-229	IC₅₀	0.43 μM Compound: Etoposide	Antiproliferative activity against human LN-229 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Antiproliferative activity against human LN-229 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
LNCaP	IC₅₀	31.21 μM Compound: Etoposide	Cytotoxicity against human LNCAP cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32199733]
LNCaP	IC₅₀	50.33 μM Compound: Etoposide	Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay	[PMID: 26292628]
LS174T	IC₅₀	0.48 μM Compound: Etoposide	Antiproliferative activity against human LS174T cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human LS174T cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33398999]
LS174T	IC₅₀	0.9 μM Compound: Etoposide	Antiproliferative activity against human LS174T cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human LS174T cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
LoVo	IC₅₀	1.71 μM Compound: Ref 34, Cpd 2	Cytotoxicity against human LoVo cells by MTT assay Cytotoxicity against human LoVo cells by MTT assay	[PMID: 32992133]
LoVo	IC₅₀	14.9 μM Compound: 2; VP-16	Cytotoxicity against human LoVo cells incubated for 48 hrs by MTT assay Cytotoxicity against human LoVo cells incubated for 48 hrs by MTT assay	[PMID: 31278032]
LoVo	IC₅₀	18.7 μM Compound: 2; VP-16	Cytotoxicity against human LoVo cells assessed as reduction in inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human LoVo cells assessed as reduction in inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 29248296]
LoVo	IC₅₀	2.3 μM Compound: ETP	Cytotoxic activity against solid tumor, LoVo, (human colon adenocarcinoma) concentration of agent required to reduce cell viability by 50% Cytotoxic activity against solid tumor, LoVo, (human colon adenocarcinoma) concentration of agent required to reduce cell viability by 50%	[PMID: 10377219]
M059J	IC₅₀	58.9 μM Compound: VP16	Cytotoxicity against human M059J cells assessed as cell growth inhibition after 24 hrs by XTT assay Cytotoxicity against human M059J cells assessed as cell growth inhibition after 24 hrs by XTT assay	[PMID: 26649907]
M14	GI₅₀	< 0.01 μM Compound: 2	In vitro cytotoxic activity against melanoma (M 14) cancer cell line. In vitro cytotoxic activity against melanoma (M 14) cancer cell line.	[PMID: 10465531]
M21	IC₅₀	0.2 μM Compound: 1	Antiproliferative activity against human M21 cells assessed as inhibition of cell proliferation measured after 48 hrs by SRB assay Antiproliferative activity against human M21 cells assessed as inhibition of cell proliferation measured after 48 hrs by SRB assay	[PMID: 34837817]
MCF-10A	GI₅₀	> 5 μM Compound: Etoposide	Growth inhibition of human MCF10A cells after 72 hrs by celltiter-blue viability assay Growth inhibition of human MCF10A cells after 72 hrs by celltiter-blue viability assay	[PMID: 21348461]
MCF-10A	IC₅₀	10.14 μM Compound: Etoposide	Cytotoxicity against human MCF10A cells after 2 days by CCK8 assay Cytotoxicity against human MCF10A cells after 2 days by CCK8 assay	[PMID: 26361737]
MCF-10A	IC₅₀	102 μM Compound: Etoposide	Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability for 48 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability for 48 hrs by MTT assay	[PMID: 35617791]
MCF-10A	IC₅₀	12.23 μM Compound: Etoposide	Cytotoxicity against human MCF10A cells after 2 days Cytotoxicity against human MCF10A cells after 2 days	[PMID: 24904965]
MCF-10A	IC₅₀	36.26 μM Compound: Eto	Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay	[PMID: 23999041]
MCF-10A	IC₅₀	84.7 μM Compound: Etoposide	Cytotoxicity against human MCF10A cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MCF10A cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 34791873]
MCF-10A	IC₅₀	> 120 μM Compound: Etoposide	Cytotoxicity against human MCF-10A cells Cytotoxicity against human MCF-10A cells	[PMID: 34303812]
MCF7	CC₅₀	1 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 21741130]
MCF7	EC₅₀	16.4 μg/mL Compound: Etoposide	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 23043462]
MCF7	EC₅₀	16.4 μg/mL Compound: etoposide	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 20073490]
MCF7	EC₅₀	2.8 μg/mL Compound: Etoposide	Cytotoxicity against human MCF7 cells after 2 days Cytotoxicity against human MCF7 cells after 2 days	[PMID: 17629328]
MCF7	EC₅₀	2.8 μg/mL Compound: etoposide	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 17672504]
MCF7	ED₅₀	62.2 μM Compound: 1	Dose required for reduction in human breast MCF-7 cancer cells after 3 day incubation Dose required for reduction in human breast MCF-7 cancer cells after 3 day incubation	[PMID: 15456257]
MCF7	ED₅₀	> 5 mM Compound: VP-16	The compound was tested for tumor cell growth inhibitory activity against human breast cancer (MCF-7) cell line. The compound was tested for tumor cell growth inhibitory activity against human breast cancer (MCF-7) cell line.	[PMID: 10395485]
MCF7	GI₅₀	0.25 μM Compound: 2	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 24953821]
MCF7	GI₅₀	0.25 μM Compound: 2	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 25131956]
MCF7	GI₅₀	0.56 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 22682920]
MCF7	GI₅₀	0.56 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 28041801]
MCF7	GI₅₀	0.83 μM Compound: ET	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 22889556]
MCF7	GI₅₀	0.87 μM Compound: Eto	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 23999041]
MCF7	GI₅₀	1 μM Compound: Etoposide	Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31718941]
MCF7	GI₅₀	19.9 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25792142]
MCF7	GI₅₀	19.9 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30071406]
MCF7	GI₅₀	19.95 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 21115210]
MCF7	GI₅₀	19.95 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 22104973]
MCF7	GI₅₀	19.95 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23831811]
MCF7	GI₅₀	19.95 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay relative to untreated control Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay relative to untreated control	[PMID: 24389510]
MCF7	GI₅₀	19.95 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
MCF7	GI₅₀	2.1 μM Compound: 2	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B based ELISA Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B based ELISA	[PMID: 21402478]
MCF7	GI₅₀	2.1 μM Compound: 2, VP-16	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 21489802]
MCF7	GI₅₀	2.1 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
MCF7	GI₅₀	2.11 μM Compound: 2, Eto	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
MCF7	GI₅₀	2.11 μM Compound: 2, Eto	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
MCF7	GI₅₀	25 μM Compound: Etoposide	Compound was evaluated for in vitro cytotoxicity data against human breast cancer MCF-7 ADR cell line Compound was evaluated for in vitro cytotoxicity data against human breast cancer MCF-7 ADR cell line	[PMID: 9871772]
MCF7	GI₅₀	4 μM Compound: Etoposide	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 28406636]
MCF7	GI₅₀	55.6 μM Compound: etoposide	Cytotoxicity against human MCF7 cells after 72 hrs by Cell Titer 96 Aqueous Non-Radioactive assay Cytotoxicity against human MCF7 cells after 72 hrs by Cell Titer 96 Aqueous Non-Radioactive assay	[PMID: 18321710]
MCF7	GI₅₀	7.5 μg/mL Compound: Etoposide	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
MCF7	GI₅₀	> 5 μM Compound: Etoposide	Growth inhibition of human MCF7 cells after 72 hrs by celltiter-blue viability assay Growth inhibition of human MCF7 cells after 72 hrs by celltiter-blue viability assay	[PMID: 21348461]
MCF7	IC₅₀	0.008 μM Compound: Etoposide	Anticancer activity against human MCF7 cells by MTT assay Anticancer activity against human MCF7 cells by MTT assay	10.1039/C4MD00279B
MCF7	IC₅₀	0.03 μg/mL Compound: Etoposide	Anticancer activity against human MCF7 cells after 48 hrs by sulforhodamine B assay Anticancer activity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 21816519]
MCF7	IC₅₀	0.06 μM Compound: Etoposide	Synergistic cytotoxicity against human MCF7 cells measured after 6 days in presence of 5 uM KU60019 by SRB assay Synergistic cytotoxicity against human MCF7 cells measured after 6 days in presence of 5 uM KU60019 by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	0.085 μM Compound: Etoposide	Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53) Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53)	[PMID: 10780913]
MCF7	IC₅₀	0.11 μM Compound: Etoposide	Synergistic cytotoxicity against human MCF7 cells measured after 6 days in presence of 50 nM AZD0156 by SRB assay Synergistic cytotoxicity against human MCF7 cells measured after 6 days in presence of 50 nM AZD0156 by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	0.19 μM Compound: etoposide	Antiproliferative effect against human MCF7 cells after 72 hrs by MTT assay Antiproliferative effect against human MCF7 cells after 72 hrs by MTT assay	[PMID: 16499324]
MCF7	IC₅₀	0.21 μM Compound: Eto	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 37438997]
MCF7	IC₅₀	0.31 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
MCF7	IC₅₀	0.31 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 32992133]
MCF7	IC₅₀	0.5 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells after 96 hrs by crystal violet assay Antiproliferative activity against human MCF7 cells after 96 hrs by crystal violet assay	[PMID: 18434163]
MCF7	IC₅₀	0.54 μM Compound: Etoposide	Growth inhibition against human MCF-7 cell lines Growth inhibition against human MCF-7 cell lines	[PMID: 15189040]
MCF7	IC₅₀	0.56 μM Compound: Etoposide	Additive cytotoxicity against human MCF7 cells in presence of 10 uM 3-Chloro-4-methoxy-N-((4-(oxazolo[4,5-b]pyridin-2-yl)phenyl)carbamothioyl)benzamide measured after 6 days by SRB assay Additive cytotoxicity against human MCF7 cells in presence of 10 uM 3-Chloro-4-methoxy-N-((4-(oxazolo[4,5-b]pyridin-2-yl)phenyl)carbamothioyl)benzamide measured after 6 days by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	0.59 μM Compound: Etoposide	Synergistic cytotoxicity against human MCF7 cells measured after 6 days in presence of 5 uM KU55933 by SRB assay Synergistic cytotoxicity against human MCF7 cells measured after 6 days in presence of 5 uM KU55933 by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	0.65 μM Compound: Etoposide	Antagonistic cytotoxicity against human MCF7 cells in presence of 10 uM 3-Chloro-4-methoxy-N-((4-(oxazolo[4,5-b]pyridin-2-yl)phenyl)carbamothioyl)benzamide measured after 6 days by SRB assay Antagonistic cytotoxicity against human MCF7 cells in presence of 10 uM 3-Chloro-4-methoxy-N-((4-(oxazolo[4,5-b]pyridin-2-yl)phenyl)carbamothioyl)benzamide measured after 6 days by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	0.66 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells measured after 6 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay Cytotoxicity against human MCF7 cells measured after 6 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	0.68 μM Compound: 2, Etop	Anticancer activity against human MCF7 cells after 48 hrs by MTT assay Anticancer activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22136907]
MCF7	IC₅₀	0.7 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 48 hrs Cytotoxicity against human MCF7 cells after 48 hrs	[PMID: 19115839]
MCF7	IC₅₀	0.73 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 2 days by CCK-8 assay Cytotoxicity against human MCF7 cells after 2 days by CCK-8 assay	[PMID: 25481396]
MCF7	IC₅₀	0.79 μM Compound: VP-16	Cytotoxicity against human MCF7 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
MCF7	IC₅₀	0.8 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells assessed as cellular DNA content after 96 hrs by CyQUANT NF fluorescence assay Antiproliferative activity against human MCF7 cells assessed as cellular DNA content after 96 hrs by CyQUANT NF fluorescence assay	[PMID: 26731300]
MCF7	IC₅₀	0.83 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 27010926]
MCF7	IC₅₀	0.83 μM Compound: Etoposide	Anticancer activity against human MCF7 cells Anticancer activity against human MCF7 cells	[PMID: 31945642]
MCF7	IC₅₀	1 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 24780599]
MCF7	IC₅₀	1 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27448912]
MCF7	IC₅₀	1 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33751978]
MCF7	IC₅₀	1 μM Compound: VP-16	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 19053767]
MCF7	IC₅₀	1 μM Compound: VP-16	Antiproliferative activity against human MCF7 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
MCF7	IC₅₀	1.09 μM Compound: VP-16	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B and MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B and MTT assay	[PMID: 22119124]
MCF7	IC₅₀	1.18 μM Compound: 3; Etop	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
MCF7	IC₅₀	1.2 μM Compound: Eto	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23999041]
MCF7	IC₅₀	1.264 μM Compound: 2	Antiproliferative activity against human MCF7 cells after 96 hrs by propidium iodide-based monolayer assay Antiproliferative activity against human MCF7 cells after 96 hrs by propidium iodide-based monolayer assay	[PMID: 26854430]
MCF7	IC₅₀	1.36 μM Compound: 2	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30108892]
MCF7	IC₅₀	1.45 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 32502865]
MCF7	IC₅₀	1.6 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 33421712]
MCF7	IC₅₀	1.62 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29289884]
MCF7	IC₅₀	1.71 μM Compound: Ref 34, Cpd 2	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 32992133]
MCF7	IC₅₀	1.74 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 36 hrs by MTT assay Cytotoxicity against human MCF7 cells after 36 hrs by MTT assay	[PMID: 27262599]
MCF7	IC₅₀	1.89 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 4 days by ELISA reader assay Cytotoxicity against human MCF7 cells after 4 days by ELISA reader assay	[PMID: 19939682]
MCF7	IC₅₀	1.97 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 34838335]
MCF7	IC₅₀	1.98 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21115246]
MCF7	IC₅₀	10.5 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 29077404]
MCF7	IC₅₀	10.9 μM Compound: VP-16	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19394829]
MCF7	IC₅₀	10.9 μM Compound: VP-16	Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
MCF7	IC₅₀	100 μM Compound: VP-16	Antiproliferative activity against human MCF-7 breast cell line Antiproliferative activity against human MCF-7 breast cell line	[PMID: 10498216]
MCF7	IC₅₀	11.8 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30660827]
MCF7	IC₅₀	11.95 μg/mL Compound: Etoposide	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	10.1039/C4MD00525B
MCF7	IC₅₀	12.2 μM Compound: Etoposide	Cytotoxicity against human MCF7 ATCC HTB 22 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 ATCC HTB 22 cells after 72 hrs by MTT assay	[PMID: 18558490]
MCF7	IC₅₀	12.3 μM Compound: VP-16	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 11473438]
MCF7	IC₅₀	12.4 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26890115]
MCF7	IC₅₀	12.4 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 28886509]
MCF7	IC₅₀	12.6 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 34791873]
MCF7	IC₅₀	15.8 nM Compound: Ref 34, Cpd 2	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
MCF7	IC₅₀	16.3 μM Compound: Etoposide	Cytotoxicity against human breast cancer cell line MCF7 assessed as inhibition of cell viability measured after 24 hrs by MTT assay Cytotoxicity against human breast cancer cell line MCF7 assessed as inhibition of cell viability measured after 24 hrs by MTT assay	[PMID: 23305918]
MCF7	IC₅₀	17 μM Compound: Etoposide	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 24950030]
MCF7	IC₅₀	17.5 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 4 days by MTT assay Cytotoxicity against human MCF7 cells after 4 days by MTT assay	[PMID: 20619511]
MCF7	IC₅₀	17.76 μg/mL Compound: Etoposide	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25016373]
MCF7	IC₅₀	18.01 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 3 days Cytotoxicity against human MCF7 cells after 3 days	[PMID: 19954977]
MCF7	IC₅₀	18.43 μg/mL Compound: Etoposide	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 22341788]
MCF7	IC₅₀	18.75 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells by CCK-8 assay Antiproliferative activity against human MCF7 cells by CCK-8 assay	[PMID: 35598793]
MCF7	IC₅₀	18.9 μM Compound: Vp-16	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 33979690]
MCF7	IC₅₀	19 μM Compound: 2	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 21477899]
MCF7	IC₅₀	2.03 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29269253]
MCF7	IC₅₀	2.03 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 29525336]
MCF7	IC₅₀	2.08 μM Compound: 2	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 28757065]
MCF7	IC₅₀	2.11 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 31281022]
MCF7	IC₅₀	2.2 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26920801]
MCF7	IC₅₀	2.56 μM Compound: VP-16	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay	[PMID: 38107170]
MCF7	IC₅₀	2.69 μM Compound: Etoposide	Anticancer activity against human MCF7 cells after 48 hrs by MTT assay Anticancer activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25615796]
MCF7	IC₅₀	20.9 μM Compound: Eto	Cytotoxicity against human MCF7 cells assessed as growth inhibition by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition by MTT assay	[PMID: 23920485]
MCF7	IC₅₀	23.62 μM Compound: Etoposide	Synergistic cytotoxicity against human MCF7 cells in presence of 10 uM 3-Chloro-4-methoxy-N-((4-(oxazolo[4,5-b]pyridin-2-yl)phenyl)carbamothioyl)benzamide measured after 2 days by SRB assay Synergistic cytotoxicity against human MCF7 cells in presence of 10 uM 3-Chloro-4-methoxy-N-((4-(oxazolo[4,5-b]pyridin-2-yl)phenyl)carbamothioyl)benzamide measured after 2 days by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	23.9 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24487188]
MCF7	IC₅₀	23.9 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MCF7	IC₅₀	23.9 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25453799]
MCF7	IC₅₀	24.01 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28462840]
MCF7	IC₅₀	27.41 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27863370]
MCF7	IC₅₀	29.49 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	10.1007/s00044-013-0757-3
MCF7	IC₅₀	29.66 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36996717]
MCF7	IC₅₀	3.1 μg/mL Compound: Etoposide	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29335206]
MCF7	IC₅₀	3.1 μg/mL Compound: Etoposide	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 29908441]
MCF7	IC₅₀	3.2 μM Compound: etoposide	Cytotoxic activity against human MCF7 cells after 48 hrs by MTT reduction assay Cytotoxic activity against human MCF7 cells after 48 hrs by MTT reduction assay	[PMID: 17316916]
MCF7	IC₅₀	3.25 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 2 days Cytotoxicity against human MCF7 cells after 2 days	[PMID: 22318164]
MCF7	IC₅₀	32.82 μM Compound: 2	Anticancer activity against human MCF7 cells after 48 hrs by MTT assay Anticancer activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25744190]
MCF7	IC₅₀	35.55 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK8 assay	[PMID: 27654394]
MCF7	IC₅₀	35.6 μM Compound: etoposide	Cytotoxicity against human MCF7 cells by XTT assay Cytotoxicity against human MCF7 cells by XTT assay	[PMID: 17368022]
MCF7	IC₅₀	35.6 μM Compound: etoposide	Cytotoxicity against human MCF7 cells by XTT assay Cytotoxicity against human MCF7 cells by XTT assay	[PMID: 18093835]
MCF7	IC₅₀	4 μM Compound: Etoposide	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 24180210]
MCF7	IC₅₀	45 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34303812]
MCF7	IC₅₀	45 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 35617791]
MCF7	IC₅₀	45 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 38516586]
MCF7	IC₅₀	46.2 μM Compound: Etoposide	Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	4716.5 nM Compound: VP-16	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29886322]
MCF7	IC₅₀	480 nM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22564383]
MCF7	IC₅₀	5.7 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31669850]
MCF7	IC₅₀	50 μM Compound: Eto	Antitumor activity against human MCF7 cells after 72 hrs by MTT assay Antitumor activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 17935309]
MCF7	IC₅₀	50 μM Compound: Etop	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34606997]
MCF7	IC₅₀	50 μM Compound: etoposide	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 17482821]
MCF7	IC₅₀	53.8 μM Compound: VP-16	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30265994]
MCF7	IC₅₀	58.8 μM Compound: Etoposide	Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 5 uM KU55933 by SRB assay Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 5 uM KU55933 by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	59.75 μM Compound: Etoposide	Antitumor activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23313635]
MCF7	IC₅₀	62.7 μM Compound: Etoposide	Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 50 nM AZD0156 by SRB assay Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 50 nM AZD0156 by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	67000 nM Compound: VP16	Antiproliferative activity measured against MCF-7-mdr cells. Antiproliferative activity measured against MCF-7-mdr cells.	[PMID: 9876111]
MCF7	IC₅₀	7.6 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 48 hrs by WST-8 assay Cytotoxicity against human MCF7 cells after 48 hrs by WST-8 assay	[PMID: 19072209]
MCF7	IC₅₀	7.6 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 48 hrs by SRB method Cytotoxicity against human MCF7 cells after 48 hrs by SRB method	[PMID: 19425589]
MCF7	IC₅₀	7.6 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 25847767]
MCF7	IC₅₀	8.9 μM Compound: Etoposide	Antiproliferation activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferation activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33079544]
MCF7	IC₅₀	81.09 μM Compound: Etoposide	Antiproliferative against human MCF7 cells after 48 hrs by MTT assay Antiproliferative against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24996136]
MCF7	IC₅₀	82.6 μM Compound: VP16	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by XTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by XTT assay	[PMID: 26649907]
MCF7	IC₅₀	87.4 μM Compound: Etoposide	Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 5 uM KU60019 by SRB assay Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 5 uM KU60019 by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	877.5 nM Compound: etoposide	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 16309315]
MCF7	IC₅₀	9.4 μg/mL Compound: Etoposide	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24219991]
MCF7	IC₅₀	9.6 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30447888]
MCF7	IC₅₀	> 10 μM Compound: ETP	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 30471828]
MCF7	IC₅₀	> 100 μM Compound: Etop	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 34606997]
MCF7	IC₅₀	> 30 μM Compound: ETP	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 28094224]
MCF7	IC₅₀	>= 2.91 μM Compound: Etoposide	Anticancer activity against human MCF7 cells after 48 hrs by SRB assay Anticancer activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 30660827]
MCF7	IC₅₀	>= 2.91 μM Compound: Etoposide	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30660827]
MCF7	IC₅₀	>= 6.94 μM Compound: Etoposide	Antiproliferative activity against human MCF7 cells by SRB assay Antiproliferative activity against human MCF7 cells by SRB assay	[PMID: 31546197]
MCF7-DOX	IC₅₀	>= 2.91 μM Compound: Etoposide	Anticancer activity against human MCF7/Dox cells after 48 hrs by SRB assay Anticancer activity against human MCF7/Dox cells after 48 hrs by SRB assay	[PMID: 30660827]
MCF7-DOX	IC₅₀	>= 6.94 μM Compound: Etoposide	Antiproliferative activity against human MCF7/Dox cells by SRB assay Antiproliferative activity against human MCF7/Dox cells by SRB assay	[PMID: 31546197]
MDA-MB-231	GI₅₀	1.67 μM Compound: Eto	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 23999041]
MDA-MB-231	GI₅₀	2 μM Compound: Etoposide	In vitro cytotoxicity against human breast cancer MDA-MB 231 cell line In vitro cytotoxicity against human breast cancer MDA-MB 231 cell line	[PMID: 9871772]
MDA-MB-231	GI₅₀	7.2 μM Compound: Etoposide	Growth inhibition of human MDA-MB-231 cells after 72 hrs by SRB assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 23153810]
MDA-MB-231	IC₅₀	0.15 μM Compound: Etoposide	Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53) Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53)	[PMID: 10780913]
MDA-MB-231	IC₅₀	0.24 μg/mL Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay	[PMID: 21216051]
MDA-MB-231	IC₅₀	0.3 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 19788270]
MDA-MB-231	IC₅₀	0.4 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 37672645]
MDA-MB-231	IC₅₀	0.51 μM Compound: VP-16	Cytotoxicity against human MDA-MB-231 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
MDA-MB-231	IC₅₀	0.7 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells after 2 days by automatic ELISA reader system Cytotoxicity against human MDA-MB-231 cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
MDA-MB-231	IC₅₀	1.23 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells after 2 days Cytotoxicity against human MDA-MB-231 cells after 2 days	[PMID: 21419530]
MDA-MB-231	IC₅₀	1.5 μM Compound: Eto	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 23999041]
MDA-MB-231	IC₅₀	1.53 μM Compound: Etoposide	Growth inhibition of human MDA-MB-231 cells incubated for 72 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells incubated for 72 hrs by sulforhodamine B assay	[PMID: 28625715]
MDA-MB-231	IC₅₀	1.53 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30041947]
MDA-MB-231	IC₅₀	1.91 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 31281022]
MDA-MB-231	IC₅₀	1.91 μM Compound: V	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29289881]
MDA-MB-231	IC₅₀	1.97 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 34838335]
MDA-MB-231	IC₅₀	10.3 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 25847767]
MDA-MB-231	IC₅₀	10.6 μM Compound: etoposide	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 25495422]
MDA-MB-231	IC₅₀	11 μM Compound: etoposide	Antiproliferative activity against human MDA-MB-231 cells after 3 days by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells after 3 days by sulforhodamine B assay	[PMID: 25700232]
MDA-MB-231	IC₅₀	11.8 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30660827]
MDA-MB-231	IC₅₀	13.35 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27863370]
MDA-MB-231	IC₅₀	15.7 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 26890115]
MDA-MB-231	IC₅₀	16.25 μM Compound: etoposide	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 18178085]
MDA-MB-231	IC₅₀	16.27 μM Compound: Etoposide	Cytotoxic activity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxic activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28733083]
MDA-MB-231	IC₅₀	16.3 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay	[PMID: 20619511]
MDA-MB-231	IC₅₀	16.85 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells after 3 days Cytotoxicity against human MDA-MB-231 cells after 3 days	[PMID: 19954977]
MDA-MB-231	IC₅₀	2.3 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30457333]
MDA-MB-231	IC₅₀	2.8 μM Compound: Etoposide	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hr by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hr by SRB assay	[PMID: 34931849]
MDA-MB-231	IC₅₀	2.87 μM Compound: 3; Etop	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
MDA-MB-231	IC₅₀	2.87 μM Compound: etoposide	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 20093033]
MDA-MB-231	IC₅₀	20.3 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28068602]
MDA-MB-231	IC₅₀	20.52 μg/mL Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 22341788]
MDA-MB-231	IC₅₀	21.2 μM Compound: VP-16	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 19394829]
MDA-MB-231	IC₅₀	21.2 μM Compound: VP-16	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
MDA-MB-231	IC₅₀	23.22 μM Compound: etoposide	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 20405844]
MDA-MB-231	IC₅₀	24.22 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24487188]
MDA-MB-231	IC₅₀	24.22 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MDA-MB-231	IC₅₀	29.27 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28431878]
MDA-MB-231	IC₅₀	3.32 μM Compound: Etoposide	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability by sulforhodamine B assay	[PMID: 32073848]
MDA-MB-231	IC₅₀	3.38 μM Compound: Etoposide	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 30755350]
MDA-MB-231	IC₅₀	3.5 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 19836231]
MDA-MB-231	IC₅₀	3.6 μM Compound: VP16	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 26291037]
MDA-MB-231	IC₅₀	3.66 μM Compound: Etoposide	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay	[PMID: 36786551]
MDA-MB-231	IC₅₀	3.67 μM Compound: VP-16	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 25240702]
MDA-MB-231	IC₅₀	3.85 μM Compound: Etoposide	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 31894983]
MDA-MB-231	IC₅₀	30.28 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 30109008]
MDA-MB-231	IC₅₀	30.63 μM Compound: Etoposide	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability by MTT assay	[PMID: 35694689]
MDA-MB-231	IC₅₀	4.2 μM Compound: VP16	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by SRB assay	[PMID: 26618211]
MDA-MB-231	IC₅₀	4.4 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 29893558]
MDA-MB-231	IC₅₀	42 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell survival by clonogenic assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell survival by clonogenic assay	[PMID: 34303812]
MDA-MB-231	IC₅₀	48 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34303812]
MDA-MB-231	IC₅₀	48 μM Compound: Etoposide	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability for 48 hrs by MTT assay	[PMID: 35617791]
MDA-MB-231	IC₅₀	48 μM Compound: Etoposide	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 38516586]
MDA-MB-231	IC₅₀	49.35 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 26292628]
MDA-MB-231	IC₅₀	5.6 μM Compound: VP-16	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by CCK8 assay	[PMID: 36063665]
MDA-MB-231	IC₅₀	600 nM Compound: 1 (VP16)	In vivo antiproliferative activity against MDA-MB-231 cell line In vivo antiproliferative activity against MDA-MB-231 cell line	[PMID: 15084135]
MDA-MB-231	IC₅₀	7.2 μg/mL Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24219991]
MDA-MB-231	IC₅₀	7.35 μM Compound: Etoposide	Cytotoxicity in human MDA-MB-231 cells by sulforhodamine B colorimetric assay Cytotoxicity in human MDA-MB-231 cells by sulforhodamine B colorimetric assay	[PMID: 27933890]
MDA-MB-231	IC₅₀	7.7 μM Compound: etoposide	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
MDA-MB-231	IC₅₀	8.7 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability by SRB assay	[PMID: 33636429]
MDA-MB-231	IC₅₀	9.13 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay	[PMID: 27707625]
MDA-MB-231	IC₅₀	9.7 μM Compound: Etoposide	Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by SRB assay	[PMID: 35362983]
MDA-MB-231	IC₅₀	> 10 μM Compound: ETP	Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30471828]
MDA-MB-231	IC₅₀	> 50 μM Compound: Etoposide	Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by Ez-cytox assay Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by Ez-cytox assay	[PMID: 31398033]
MDA-MB-435	GI₅₀	0.9 μM Compound: Etoposide	In vitro cytotoxicity against human breast cancer MDA-MB 435 cell line In vitro cytotoxicity against human breast cancer MDA-MB 435 cell line	[PMID: 9871772]
MDA-MB-435	IC₅₀	1.7 μM Compound: VP16	Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by SRB assay	[PMID: 26291037]
MDA-MB-435	IC₅₀	2.81 μM Compound: VP-16	Cytotoxicity against human MDA-MB-435 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25800514]
MDA-MB-436	IC₅₀	39.42 μM Compound: Etoposide	Antiproliferative activity against human MDA-MB-436 cells measured after 72 hrs by Ez-cytox assay Antiproliferative activity against human MDA-MB-436 cells measured after 72 hrs by Ez-cytox assay	[PMID: 31398033]
MDA-MB-453	IC₅₀	12.5 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MDA-MB-468	IC₅₀	0.6 μM Compound: Etoposide	Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53) Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53)	[PMID: 10780913]
MDA-MB-468	IC₅₀	0.86 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay	[PMID: 27707625]
MDA-MB-468	IC₅₀	13.6 μM Compound: etoposide	Cytotoxicity against human MDA-MB468 cells by XTT assay Cytotoxicity against human MDA-MB468 cells by XTT assay	[PMID: 17368022]
MDA-MB-468	IC₅₀	2.1 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30457333]
MDA-MB-468	IC₅₀	6.69 μM Compound: Etoposide	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay	[PMID: 25644672]
MDA-N	GI₅₀	< 0.01 μM Compound: Etoposide	In vitro cytotoxicity against human breast cancer MDA-N cell line In vitro cytotoxicity against human breast cancer MDA-N cell line	[PMID: 9871772]
ME-180	IC₅₀	8.9 μM Compound: Etoposide	Cytotoxicity against human ME180 cells after 48 hrs by MTT assay Cytotoxicity against human ME180 cells after 48 hrs by MTT assay	[PMID: 24487188]
ME-180	IC₅₀	8.9 μM Compound: Etoposide	Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
ME-180	IC₅₀	8.9 μM Compound: Etoposide	Cytotoxicity against human ME180 cells after 72 hrs by MTT assay Cytotoxicity against human ME180 cells after 72 hrs by MTT assay	[PMID: 25453799]
MES-SA	GI₅₀	0.21 μM Compound: etoposide	Antiproliferative activity against human MESSA cells by SRB assay Antiproliferative activity against human MESSA cells by SRB assay	[PMID: 19394218]
MES-SA	IC₅₀	0.3 μM Compound: etoposide	Antiproliferative activity against human MESSA cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MESSA cells after 48 hrs by sulforhodamine B assay	[PMID: 20939516]
MES-SA/Dx5	GI₅₀	9.72 μM Compound: etoposide	Antiproliferative activity against multidrug resistant human MES-SA/Dx5 cells by SRB assay Antiproliferative activity against multidrug resistant human MES-SA/Dx5 cells by SRB assay	[PMID: 19394218]
MES-SA/Dx5	IC₅₀	> 10 μM Compound: etoposide	Antiproliferative activity against human MESSA/DX5 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MESSA/DX5 cells after 48 hrs by sulforhodamine B assay	[PMID: 20939516]
MGC-803	IC₅₀	1.06 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human MGC-803 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells incubated for 48 hrs by MTT assay	[PMID: 32992133]
MGC-803	IC₅₀	10.76 μM Compound: Etoposide	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36996717]
MGC-803	IC₅₀	11.18 μM Compound: Etoposide	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 32502865]
MGC-803	IC₅₀	20.91 μM Compound: Etoposide	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 28462840]
MGC-803	IC₅₀	> 10 μM Compound: Etoposide	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 26804229]
MGC-803	IC₅₀	> 150 μM Compound: vp16	Antiproliferative activity against human MGC-803 cells measured after 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
MIA PaCa-2	GI₅₀	1.1 μM Compound: 2	Antiproliferative activity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 25131956]
MIA PaCa-2	IC₅₀	15 μM Compound: Eto	Antitumor activity against human MiaPaCa2 cells after 72 hrs by MTT assay Antitumor activity against human MiaPaCa2 cells after 72 hrs by MTT assay	[PMID: 17935309]
MIA PaCa-2	IC₅₀	15.4 μM Compound: etoposide	Growth inhibition of human MiaPaCa2 cells by MTT assay Growth inhibition of human MiaPaCa2 cells by MTT assay	[PMID: 17482821]
MKN-45	IC₅₀	0.49 μg/mL Compound: Etoposide	Cytotoxic activity against human MKN45 stomach tumor cell line Cytotoxic activity against human MKN45 stomach tumor cell line	[PMID: 15149673]
MKN-45	IC₅₀	> 0.91 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human MKN-45 cells incubated for 48 to 72 hrs by MTT assay Antiproliferative activity against human MKN-45 cells incubated for 48 to 72 hrs by MTT assay	[PMID: 32992133]
MOLT-3	IC₅₀	0.019 μg/mL Compound: Etoposide	Cytotoxicity against Homo sapiens (human) MOLT3 cells after 3 days by crystal violet staining Cytotoxicity against Homo sapiens (human) MOLT3 cells after 3 days by crystal violet staining	10.1007/s00044-011-9903-y
MOLT-3	IC₅₀	0.02 μM Compound: Etoposide	Cytotoxicity against human MOLT3 cells Cytotoxicity against human MOLT3 cells	10.1039/C2MD20199B
MOLT-3	IC₅₀	0.024 μg/mL Compound: Etoposide	Cytotoxicity against Homo sapiens (human) MOLT3 cells assessed as survival after 3 days by crystal violet staining Cytotoxicity against Homo sapiens (human) MOLT3 cells assessed as survival after 3 days by crystal violet staining	10.1007/s00044-012-0025-y
MOLT-3	IC₅₀	0.03 μM Compound: Etoposide	Cytotoxicity against human MOLT3 cells by XTT assay Cytotoxicity against human MOLT3 cells by XTT assay	10.1039/C3MD00166K
MOLT-3	IC₅₀	0.03 μM Compound: etoposide	Cytotoxicity against human MOLT3 cells by XTT assay Cytotoxicity against human MOLT3 cells by XTT assay	[PMID: 21174408]
MOLT-3	IC₅₀	0.041 μM Compound: Etoposide	Cytotoxicity against Homo sapiens (human) MOLT3 cells assessed as inhibition of cell growth after 3 days by crystal violet staining Cytotoxicity against Homo sapiens (human) MOLT3 cells assessed as inhibition of cell growth after 3 days by crystal violet staining	10.1007/s00044-012-0402-6
MOLT-3	IC₅₀	0.041 μM Compound: Etoposide	Cytotoxicity against human MOLT3 cells after 48 hrs by XTT assay Cytotoxicity against human MOLT3 cells after 48 hrs by XTT assay	[PMID: 26397393]
MOLT-3	IC₅₀	0.04 μg/mL Compound: Etoposide	Cytotoxic activity against human MOLT3 cells by XTT assay Cytotoxic activity against human MOLT3 cells by XTT assay	[PMID: 28366267]
MOLT-3	IC₅₀	0.051 μM Compound: Etoposide	Cytotoxicity against human MOLT3 cells after 48 hrs by MTT assay Cytotoxicity against human MOLT3 cells after 48 hrs by MTT assay	[PMID: 24836071]
MOLT-3	IC₅₀	0.051 μM Compound: Etoposide	Cytotoxicity against human MOLT3 cells after 48 hrs by MTT assay Cytotoxicity against human MOLT3 cells after 48 hrs by MTT assay	[PMID: 25019480]
MOLT-3	IC₅₀	0.051 μM Compound: Etoposide	Cytotoxicity against human MOLT3 cells assessed as reduction in cell viability after 48 hrs by XTT assay Cytotoxicity against human MOLT3 cells assessed as reduction in cell viability after 48 hrs by XTT assay	[PMID: 25078311]
MOLT-3	IC₅₀	0.051 μM Compound: etoposide	Cytotoxicity against human MOLT3 cells after 48 hrs by XTT assay Cytotoxicity against human MOLT3 cells after 48 hrs by XTT assay	10.1007/s00044-013-0777-z
MOLT-3	IC₅₀	0.065 μM Compound: 1	Tested for cytotoxicity against parental T-cell leukemia type Molt 3 cell line expressing MDR-1 (-) gene Tested for cytotoxicity against parental T-cell leukemia type Molt 3 cell line expressing MDR-1 (-) gene	[PMID: 11844671]
MOLT-3	IC₅₀	0.11 μM Compound: Etoposide	Cytotoxicity against human MOLT3 cells by XTT assay Cytotoxicity against human MOLT3 cells by XTT assay	[PMID: 25747499]
MOLT-3	IC₅₀	0.7 μM Compound: Etoposide	Cytotoxicity against human MOLT3 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MOLT3 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27145162]
MOLT-4	IC₅₀	38 nM Compound: ETOPOSIDE	Compound was tested for its anticancer activity against human T-lymphocytic leukemia MOLT-4 cells. Compound was tested for its anticancer activity against human T-lymphocytic leukemia MOLT-4 cells.	10.1016/S0960-894X(96)00486-6
MONO-MAC-6	IC₅₀	2.2 μM Compound: Etoposide	Cytotoxicity against human MONO-MAC-6 cells incubated for 24 hrs by AlamarBlue staining based analysis Cytotoxicity against human MONO-MAC-6 cells incubated for 24 hrs by AlamarBlue staining based analysis	[PMID: 36857518]
MOVP-3	IC₅₀	7.55 μM Compound: 1	Tested for cytotoxicity against VP 16 resistant Molt3 type MOVP-3 cell line expressing MDR-1 (++) gene Tested for cytotoxicity against VP 16 resistant Molt3 type MOVP-3 cell line expressing MDR-1 (++) gene	[PMID: 11844671]
MRC5	IC₅₀	11.23 μM Compound: Etoposide	Antiproliferative activity against human MRC5 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MRC5 cells after 72 hrs by sulforhodamine B assay	[PMID: 31894983]
MRC5	IC₅₀	11.73 μM Compound: Etoposide	Growth inhibition of human MRC5 cells incubated for 72 hrs by sulforhodamine B assay Growth inhibition of human MRC5 cells incubated for 72 hrs by sulforhodamine B assay	[PMID: 28625715]
MRC5	IC₅₀	11.73 μM Compound: Etoposide	Cytotoxicity against human MRC5 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MRC5 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30041947]
MRC5	IC₅₀	12.7 μM Compound: Etoposide	Cytotoxicity in human MRC5 cells by sulforhodamine B colorimetric assay Cytotoxicity in human MRC5 cells by sulforhodamine B colorimetric assay	[PMID: 27933890]
MRC5	IC₅₀	12.72 μM Compound: Etoposide	Antiproliferative activity against human MRC5 cells after 72 hrs by SRB assay Antiproliferative activity against human MRC5 cells after 72 hrs by SRB assay	[PMID: 30755350]
MRC5	IC₅₀	13.48 μM Compound: Etoposide	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay	[PMID: 36786551]
MRC5	IC₅₀	3.9 μM Compound: Etoposide	Cytotoxicity against human MRC5 cells after 3 days by MTT assay Cytotoxicity against human MRC5 cells after 3 days by MTT assay	[PMID: 19013074]
MRC5	IC₅₀	3.9 μM Compound: Etoposide	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 19269832]
MRC5	IC₅₀	3.9 μM Compound: Etoposide	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 20828890]
MRC5	IC₅₀	3.9 μM Compound: Etoposide	Anticancer activity against human MRC5 cells after 3 days by MTT assay Anticancer activity against human MRC5 cells after 3 days by MTT assay	[PMID: 21621882]
MRC5	IC₅₀	3.9 μM Compound: Etoposide	Cytotoxicity against human MRC5 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23454511]
MRC5	IC₅₀	3.9 μM Compound: VP-16	Antiproliferative activity against human MRC5 cells after 96 hrs by MTT assay Antiproliferative activity against human MRC5 cells after 96 hrs by MTT assay	[PMID: 19053767]
MRC5	IC₅₀	3.9 μM Compound: etoposide	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 18299197]
MRC5	IC₅₀	3.93 μM Compound: Etoposide	Cytotoxicity against human MRC5 cells after 3 days by MTT assay Cytotoxicity against human MRC5 cells after 3 days by MTT assay	[PMID: 19419803]
MRC5	IC₅₀	33.5 μM Compound: VP-16	Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay	[PMID: 30265994]
MRC5	IC₅₀	> 20 μM Compound: Etoposide	Cytotoxicity against human MRC5 cells after 24 to 72 hrs by SRB assay Cytotoxicity against human MRC5 cells after 24 to 72 hrs by SRB assay	[PMID: 26595875]
MRC5	IC₅₀	> 20 μM Compound: Etoposide	Antiproliferative activity against human MRC5 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MRC5 cells measured after 72 hrs by SRB assay	[PMID: 35362983]
MRC5	IC₅₀	> 20 μM Compound: Etoposide	Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 39151060]
MT4	CC₅₀	0.08 μM Compound: VP-16	Compound concentration required to reduce the exponential growth of MT-4 cells by 50% Compound concentration required to reduce the exponential growth of MT-4 cells by 50%	[PMID: 9767632]
MT4	CC₅₀	0.09 μM Compound: Etoposide	Cytotoxicity against human MT4 cells infected with HTLV-1 after 96 hrs by MTT assay Cytotoxicity against human MT4 cells infected with HTLV-1 after 96 hrs by MTT assay	[PMID: 21741130]
MT4	IC₅₀	0.09 μM Compound: VP16	Cytotoxicity against human MT4 cells after 96 hrs Cytotoxicity against human MT4 cells after 96 hrs	[PMID: 22276775]
MT4	IC₅₀	1.25 μM Compound: VP-16	Antiproliferative activity against human MT4 cells after 96 hrs by MTT assay Antiproliferative activity against human MT4 cells after 96 hrs by MTT assay	[PMID: 19053767]
MT4	IC₅₀	1.25 μM Compound: VP-16	Antiproliferative activity against human MT-4 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human MT-4 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
Medulloblastoma cell	EC₅₀	0.208 μM Compound: 2	Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay	[PMID: 17417631]
N592	IC₅₀	0.5 μM Compound: VP-16 (Etoposide)	Cytotoxicity against human small-cell lung cancer (SCLC) Cytotoxicity against human small-cell lung cancer (SCLC)	[PMID: 8258835]
N9	IC₅₀	1.95 μM Compound: Etoposide	Cytotoxicity against mouse N9 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay Cytotoxicity against mouse N9 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay	[PMID: 25644672]
NALM-6	IC₅₀	0.134 μM Compound: VP-16	Cytotoxicity against wild type human NALM6 cells assessed as growth inhibition after 5 days by XTT assay Cytotoxicity against wild type human NALM6 cells assessed as growth inhibition after 5 days by XTT assay	[PMID: 25945730]
NALM-6	IC₅₀	0.182 μM Compound: VP-16	Cytotoxicity against TOP2B double knockout human NALM6 cells assessed as growth inhibition after 5 days by XTT assay Cytotoxicity against TOP2B double knockout human NALM6 cells assessed as growth inhibition after 5 days by XTT assay	[PMID: 25945730]
NALM-6	IC₅₀	0.234 μM Compound: VP-16	Cytotoxicity against human NALM6 cells expressing 50% TOP2A assessed as growth inhibition after 5 days by XTT assay Cytotoxicity against human NALM6 cells expressing 50% TOP2A assessed as growth inhibition after 5 days by XTT assay	[PMID: 25945730]
NB-4	IC₅₀	1.3 μM Compound: Etoposide	Cytotoxicity against human NB4 cells after 48 hrs by WST-8 assay Cytotoxicity against human NB4 cells after 48 hrs by WST-8 assay	[PMID: 19072209]
NB-4	IC₅₀	1.3 μM Compound: Etoposide	Cytotoxicity against human NB4 cells after 48 hrs by SRB method Cytotoxicity against human NB4 cells after 48 hrs by SRB method	[PMID: 19425589]
NCI-H1299	IC₅₀	0.23 μM Compound: Etoposide	Synergistic cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU60019 after 6 days by SRB assay Synergistic cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU60019 after 6 days by SRB assay	[PMID: 35231830]
NCI-H1299	IC₅₀	0.24 μM Compound: Etoposide	Synergistic cytotoxicity against human NCI-H1299 cells measured in presence of 50 nM AZD0156 after 6 days by SRB assay Synergistic cytotoxicity against human NCI-H1299 cells measured in presence of 50 nM AZD0156 after 6 days by SRB assay	[PMID: 35231830]
NCI-H1299	IC₅₀	0.46 μM Compound: Etoposide	Additive cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU55933 after 6 days by SRB assay Additive cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU55933 after 6 days by SRB assay	[PMID: 35231830]
NCI-H1299	IC₅₀	0.71 μM Compound: Etoposide	Cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM 2(((2-(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol after 6 days by SRB assay Cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM 2(((2-(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol after 6 days by SRB assay	[PMID: 35231830]
NCI-H1299	IC₅₀	11.13 μM Compound: Etoposide	Cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM 2(((2-(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol after 2 days by SRB assay Cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM 2(((2-(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol after 2 days by SRB assay	[PMID: 35231830]
NCI-H1299	IC₅₀	229.7 μM Compound: Etoposide	Anticancer activity against human H1299 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Anticancer activity against human H1299 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 34425478]
NCI-H1299	IC₅₀	5.75 μM Compound: Etoposide	Synergistic cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU60019 after 2 days by SRB assay Synergistic cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU60019 after 2 days by SRB assay	[PMID: 35231830]
NCI-H1299	IC₅₀	8.86 μM Compound: Etoposide	Synergistic cytotoxicity against human NCI-H1299 cells measured in presence of 50 nM AZD0156 after 2 days by SRB assay Synergistic cytotoxicity against human NCI-H1299 cells measured in presence of 50 nM AZD0156 after 2 days by SRB assay	[PMID: 35231830]
NCI-H1299	IC₅₀	9.37 μM Compound: Etoposide	Additive cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU55933 after 2 days by SRB assay Additive cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU55933 after 2 days by SRB assay	[PMID: 35231830]
NCI-H1650	IC₅₀	2.65 μM Compound: 3; Etop	Antiproliferative activity against human NCI-H1650 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human NCI-H1650 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
NCI-H1975	IC₅₀	0.34 μM Compound: 3; Etop	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
NCI-H1975	IC₅₀	95 μM Compound: ET	Cytotoxicity against human NCI-H1975 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385594]
NCI-H1993	IC₅₀	> 0.91 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human NCI-H1993 cells incubated for 48 to 72 hrs by MTT assay Antiproliferative activity against human NCI-H1993 cells incubated for 48 to 72 hrs by MTT assay	[PMID: 32992133]
NCI-H2228	IC₅₀	2.51 μM Compound: 3; Etop	Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
NCI-H226	IC₅₀	0.24 μM Compound: Etoposide	Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H226	IC₅₀	> 50 μM Compound: Etoposide	Activation of procaspase-3-mediated human NCI-H226 cell death after 72 hrs by MTS/PMS assay Activation of procaspase-3-mediated human NCI-H226 cell death after 72 hrs by MTS/PMS assay	[PMID: 16936720]
NCI-H322M	IC₅₀	1.59 μM Compound: Etoposide	Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H358	IC₅₀	1.5 μM Compound: Etoposide	Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H446	IC₅₀	0.24 μM Compound: 3; Etop	Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
NCI-H446	IC₅₀	17.59 nM Compound: Etoposide	Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35932565]
NCI-H446	IC₅₀	192.16 nM Compound: Etoposide	Antiproliferative activity against Irinotecan-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against Irinotecan-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35932565]
NCI-H446	IC₅₀	192.16 nM Compound: Etoposide	Antiproliferative activity against etoposide/cisplatin combination-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against etoposide/cisplatin combination-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35932565]
NCI-H460	GI₅₀	0.1 μM Compound: Etoposide	Growth inhibition of human H460 cells incubated for 72 hrs by MTT assay Growth inhibition of human H460 cells incubated for 72 hrs by MTT assay	[PMID: 31718941]
NCI-H460	IC₅₀	0.1 μM Compound: Etoposide	Inhibitory activity against NCI-H460 cell line using MTT assay Inhibitory activity against NCI-H460 cell line using MTT assay	[PMID: 10780913]
NCI-H460	IC₅₀	0.1 μM Compound: Etoposide	Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53) Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53)	[PMID: 10780913]
NCI-H460	IC₅₀	0.1 μM Compound: Etoposide	Antiproliferative activity against human H460 cells after 72 hrs by MTT assay Antiproliferative activity against human H460 cells after 72 hrs by MTT assay	[PMID: 24780599]
NCI-H460	IC₅₀	0.1 μM Compound: Etoposide	Antiproliferative activity against human H460 cells after 72 hrs by MTT assay Antiproliferative activity against human H460 cells after 72 hrs by MTT assay	[PMID: 27448912]
NCI-H460	IC₅₀	0.1 μM Compound: Etoposide	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33751978]
NCI-H460	IC₅₀	0.2 μM Compound: etoposide	Growth inhibition of human H460 cells by MTT assay Growth inhibition of human H460 cells by MTT assay	[PMID: 17482821]
NCI-H460	IC₅₀	0.39 μM Compound: Etoposide	Inhibitory activity against H460pv8 cell line using MTT assay Inhibitory activity against H460pv8 cell line using MTT assay	[PMID: 10780913]
NCI-H460	IC₅₀	1 μM Compound: 2	Cytotoxicity against human H460 cells after 48 hrs by MTT assay Cytotoxicity against human H460 cells after 48 hrs by MTT assay	[PMID: 23867385]
NCI-H460	IC₅₀	1.35 μM Compound: Etoposide	Cytostatic activity against human NCI-H460 cells Cytostatic activity against human NCI-H460 cells	[PMID: 30738653]
NCI-H460	IC₅₀	3.65 μM Compound: Etoposide	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
NCI-H460	IC₅₀	90 nM Compound: Etoposide	Cytotoxicity against human NCI-H460 cells after 48 hrs by [3H]thymidine incorporation assay Cytotoxicity against human NCI-H460 cells after 48 hrs by [3H]thymidine incorporation assay	[PMID: 20210346]
NCI-H460	IC₅₀	< 30 μM Compound: Eto	Cytotoxicity against human H460 cells assessed as growth inhibition by MTT assay Cytotoxicity against human H460 cells assessed as growth inhibition by MTT assay	[PMID: 23920485]
NCI-H460	IC₅₀	> 30 μM Compound: Etop	Antiproliferative activity against human H460 cells by MTT assay Antiproliferative activity against human H460 cells by MTT assay	[PMID: 26216018]
NCI-H520	GI₅₀	0.9 μM Compound: 2	In vitro cytotoxic activity against lung (H 522) cancer cell line. In vitro cytotoxic activity against lung (H 522) cancer cell line.	[PMID: 10465531]
NCI-H520	GI₅₀	13.5 μM Compound: etoposide	Growth inhibition of human NCI-H520 cells Growth inhibition of human NCI-H520 cells	[PMID: 18502124]
NCI-H647	IC₅₀	0.08 μM Compound: Etoposide	Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H69	IC₅₀	1192.2 nM Compound: 1 (VP16)	In vivo antiproliferative activity against NCI-H69 cell line In vivo antiproliferative activity against NCI-H69 cell line	[PMID: 15084135]
NCI-H69	IC₅₀	46 μM Compound: Etoposide	Cytotoxicity against human adriamycin resistant H69 cells Cytotoxicity against human adriamycin resistant H69 cells	[PMID: 19788270]
NCI-H838	IC₅₀	> 100 μM Compound: Etoposide	Cytotoxicity against human NCI-H838 cells incubated for 24 hrs by AlamarBlue staining based analysis Cytotoxicity against human NCI-H838 cells incubated for 24 hrs by AlamarBlue staining based analysis	[PMID: 36857518]
NCI-H929	IC₅₀	0.9 μM Compound: Etoposide	Cytotoxicity against human NCI-H929 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H929 cells after 72 hrs by MTT assay	[PMID: 30447888]
NCI-N87	IC₅₀	1.29 μM Compound: Etoposide	Cytotoxicity against human NCI-N87 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay Cytotoxicity against human NCI-N87 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay	[PMID: 27484510]
NCI/ADR-RES	GI₅₀	25 μM Compound: 2	In vitro cytotoxic activity against ADR resistant breast cancer (MCF-7-ADR) cell line. In vitro cytotoxic activity against ADR resistant breast cancer (MCF-7-ADR) cell line.	[PMID: 10465531]
NHDF	IC₅₀	> 100 μM Compound: Etoposide	Cytotoxicity against human HDF cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HDF cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32199733]
NIH3T3	IC₅₀	62.97 μM Compound: etoposide	Cytotoxicity against mouse 3T3 cells after 48 hrs by MTT assay Cytotoxicity against mouse 3T3 cells after 48 hrs by MTT assay	[PMID: 20405844]
OVCAR-3	IC₅₀	2.9 μM Compound: Etoposide	Cytotoxicity against human OVCAR3 cells measured after 24 to 72 hrs by SRB assay Cytotoxicity against human OVCAR3 cells measured after 24 to 72 hrs by SRB assay	[PMID: 29656990]
P388	ED₅₀	1.71 μg/mL Compound: Etoposide	Compound was tested for its antitumor activity and the cytotoxicity against P-388 lymphocytic leukemia screen Compound was tested for its antitumor activity and the cytotoxicity against P-388 lymphocytic leukemia screen	[PMID: 3820231]
P388	ED₅₀	2.6 μg/mL Compound: etoposide	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 2095375]
P388	ED₅₀	5 mg/kg Compound: etoposide	compound was tested in vivo for inhibition of P388 murine leukemia cells after iv / ip administration. compound was tested in vivo for inhibition of P388 murine leukemia cells after iv / ip administration.	[PMID: 9804687]
P388	IC₅₀	0.0085 μg/mL Compound: Etoposide	Cytotoxic activity of compound against Murine P388 Leukemia Cytotoxic activity of compound against Murine P388 Leukemia	[PMID: 12459024]
P388	IC₅₀	0.0085 μg/mL Compound: Etoposide	Cytotoxic activity against murine P388 leukemia cells Cytotoxic activity against murine P388 leukemia cells	[PMID: 15056007]
P388	IC₅₀	0.0085 μg/mL Compound: Etoposide	In vitro cytotoxicity was measured towards murine lymphocytic leukemia P388 cells In vitro cytotoxicity was measured towards murine lymphocytic leukemia P388 cells	[PMID: 15149673]
P388	IC₅₀	0.05 μM Compound: etoposide	Cytotoxicity against mouse P388 cells after 24 hrs by SRB assay Cytotoxicity against mouse P388 cells after 24 hrs by SRB assay	[PMID: 19685913]
P388	IC₅₀	0.063 μg/mL Compound: 1	Growth inhibition of P388-D1 (murine leukemia) cell line. Growth inhibition of P388-D1 (murine leukemia) cell line.	[PMID: 2002477]
P388	IC₅₀	0.08 μM Compound: etoposide	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 23092389]
P388	IC₅₀	0.1 μM Compound: VP-16	Cytotoxicity against mouse P388 cells by MTT assay Cytotoxicity against mouse P388 cells by MTT assay	[PMID: 11473438]
P388	IC₅₀	0.12 μM Compound: VP-16	In vitro cytotoxicity was determined by quantitating P388 murine leukemia cells on a Coulter Counter following a 48 hour exposure of cells to the test compound In vitro cytotoxicity was determined by quantitating P388 murine leukemia cells on a Coulter Counter following a 48 hour exposure of cells to the test compound	10.1016/0960-894X(95)00043-S
P388	IC₅₀	0.12 μg/mL Compound: Etoposide	Cytotoxicity against mouse P388 cells after 3 days by MTT assay Cytotoxicity against mouse P388 cells after 3 days by MTT assay	[PMID: 21216051]
P388	IC₅₀	0.24 μM Compound: ETP	Cytotoxic activity against murine lymphocytic leukemia P388 concentration of agent required to reduce cell viability by 50% Cytotoxic activity against murine lymphocytic leukemia P388 concentration of agent required to reduce cell viability by 50%	[PMID: 10377219]
P388	IC₅₀	0.3 μM Compound: 6 (VP-16)	In vitro cytotoxicity against P388 murine leukemia cells in culture in a clonogenic assay after 1 hour exposure to drug In vitro cytotoxicity against P388 murine leukemia cells in culture in a clonogenic assay after 1 hour exposure to drug	[PMID: 8410993]
P388	IC₅₀	0.3 μM Compound: VP-16	In vitro cytotoxicity was evaluated following 1 hour transient exposure of P388 mouse leukemia cells to the compound In vitro cytotoxicity was evaluated following 1 hour transient exposure of P388 mouse leukemia cells to the compound	10.1016/0960-894X(95)00044-T
P388	IC₅₀	0.3 μM Compound: VP-16	In vitro cytotoxicity against P388 mouse leukemia cells In vitro cytotoxicity against P388 mouse leukemia cells	10.1016/0960-894X(95)00160-U
P388	IC₅₀	1.3 μM Compound: Etoposide	Cytotoxicity against mouse P388 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against mouse P388 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26920801]
P388	IC₅₀	150 nM Compound: Etoposide	Growth inhibitory activity against murine P388 leukemia cells Growth inhibitory activity against murine P388 leukemia cells	[PMID: 12620081]
P388	IC₅₀	170 nM Compound: 1a	In vitro cytotoxicity against the P-388 (from DBA/2 mouse) neoplastic cell line In vitro cytotoxicity against the P-388 (from DBA/2 mouse) neoplastic cell line	[PMID: 14980682]
P388	IC₅₀	2.62 μg/mL Compound: Etoposide	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 9214732]
P388	IC₅₀	29.8 nM Compound: 1 (VP16)	In vivo antiproliferative activity against P388 cell line In vivo antiproliferative activity against P388 cell line	[PMID: 15084135]
P388	IC₅₀	1.0 x 10^-8 M Compound: VP-16	Cytotoxicity against P388 leukemia Cytotoxicity against P388 leukemia	[PMID: 8389875]
PAM	IC₅₀	180 μM Compound: Etoposide	Inhibitory activity against PAM cell line Inhibitory activity against PAM cell line	[PMID: 9554873]
PANC-1	IC₅₀	1.6 μg/mL Compound: Etoposide	Cytotoxic activity against human tumor PANC-1 pancreas cells Cytotoxic activity against human tumor PANC-1 pancreas cells	[PMID: 15056007]
PANC-1	IC₅₀	18.26 μM Compound: Etoposide	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 39151060]
PANC-1	IC₅₀	24.35 μM Compound: Etoposide	Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability by MTT assay	[PMID: 35694689]
PANC-1	IC₅₀	>= 2.91 μM Compound: Etoposide	Anticancer activity against human PANC1 cells after 48 hrs by SRB assay Anticancer activity against human PANC1 cells after 48 hrs by SRB assay	[PMID: 30660827]
PC-12	IC₅₀	< 1 μM Compound: Etoposide	Activation of procaspase-3-mediated human PC12 cell death after 72 hrs by MTS/PMS assay Activation of procaspase-3-mediated human PC12 cell death after 72 hrs by MTS/PMS assay	[PMID: 16936720]
PC-3	ED₅₀	> 100 μM Compound: 1	Dose required for reduction in human prostate PC-3 cancer cells after 3 days incubation Dose required for reduction in human prostate PC-3 cancer cells after 3 days incubation	[PMID: 15456257]
PC-3	GI₅₀	0.6 μM Compound: Etoposide	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 25792142]
PC-3	GI₅₀	0.6 μM Compound: Etoposide	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 30071406]
PC-3	GI₅₀	0.63 μM Compound: Etoposide	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21115210]
PC-3	GI₅₀	0.63 μM Compound: Etoposide	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay relative to untreated control Cytotoxicity against human PC3 cells after 72 hrs by MTT assay relative to untreated control	[PMID: 24389510]
PC-3	GI₅₀	0.63 μM Compound: Etoposide	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
PC-3	GI₅₀	11.1 μM Compound: etoposide	Cytotoxicity against human PC3 cells after 72 hrs by Cell Titer 96 Aqueous Non-Radioactive assay Cytotoxicity against human PC3 cells after 72 hrs by Cell Titer 96 Aqueous Non-Radioactive assay	[PMID: 18321710]
PC-3	GI₅₀	12.5 μM Compound: etoposide	Growth inhibition of human PC3 cells Growth inhibition of human PC3 cells	[PMID: 18502124]
PC-3	GI₅₀	2.6 μM Compound: 2, VP-16	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 21489802]
PC-3	IC₅₀	1 μM Compound: VP16	Antiproliferative activity against human PC3 cells after 72 hrs by SRB assay Antiproliferative activity against human PC3 cells after 72 hrs by SRB assay	[PMID: 26291037]
PC-3	IC₅₀	1.1 μM Compound: Etoposide	Antiproliferative activity against human PC3 cells assessed as cellular DNA content after 72 hrs by CyQUANT NF fluorescence assay Antiproliferative activity against human PC3 cells assessed as cellular DNA content after 72 hrs by CyQUANT NF fluorescence assay	[PMID: 26731300]
PC-3	IC₅₀	1.59 μM Compound: 3; Etop	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
PC-3	IC₅₀	1.7 μM Compound: Etoposide	Cytotoxicity against human PC3 cells after 48 hrs Cytotoxicity against human PC3 cells after 48 hrs	[PMID: 19115839]
PC-3	IC₅₀	13.18 μM Compound: Etoposide	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 30109008]
PC-3	IC₅₀	13.6 μM Compound: Etoposide	Cytotoxicity against human PC3 cells after 48 hrs by WST-8 assay Cytotoxicity against human PC3 cells after 48 hrs by WST-8 assay	[PMID: 19072209]
PC-3	IC₅₀	13.6 μM Compound: Etoposide	Cytotoxicity against human PC3 cells after 48 hrs by SRB method Cytotoxicity against human PC3 cells after 48 hrs by SRB method	[PMID: 19425589]
PC-3	IC₅₀	13.9 μM Compound: Etoposide	Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28068602]
PC-3	IC₅₀	14.4 μM Compound: Etoposide	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 24487188]
PC-3	IC₅₀	14.4 μM Compound: Etoposide	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
PC-3	IC₅₀	14.4 μM Compound: Etoposide	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 25453799]
PC-3	IC₅₀	15.8 nM Compound: Ref 34, Cpd 2	Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
PC-3	IC₅₀	17.4 μM Compound: 2	Cytotoxicity against human PC-3 cells by sulforhodamine B assay Cytotoxicity against human PC-3 cells by sulforhodamine B assay	[PMID: 17988764]
PC-3	IC₅₀	17.5 μM Compound: 2	Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 21477899]
PC-3	IC₅₀	18.2 μM Compound: Eto	Cytotoxicity against human PC3 cells assessed as growth inhibition by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition by MTT assay	[PMID: 23920485]
PC-3	IC₅₀	2 μM Compound: Etoposide	Growth inhibition of human PC3 cells after 72 hrs by MTT assay Growth inhibition of human PC3 cells after 72 hrs by MTT assay	[PMID: 24950030]
PC-3	IC₅₀	2.39 μM Compound: Etoposide	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 38784476]
PC-3	IC₅₀	2.6 μM Compound: Etoposide	Anticancer activity against human PC3 cells assessed as cell viability after 48 hrs by SRB assay Anticancer activity against human PC3 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21074444]
PC-3	IC₅₀	2.7 μM Compound: Etoposide	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 30447888]
PC-3	IC₅₀	2300 nM Compound: VP16	Antiproliferative activity measured against PC-3 human prostate adenocarcinoma Antiproliferative activity measured against PC-3 human prostate adenocarcinoma	[PMID: 9876111]
PC-3	IC₅₀	3 μM Compound: VP-16	Antiproliferative activity against human PC-3 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human PC-3 cells incubated for 72 hrs by CCK8 assay	[PMID: 36063665]
PC-3	IC₅₀	30 μM Compound: Etoposide	Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32199733]
PC-3	IC₅₀	31.5 μM Compound: Etoposide	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth	[PMID: 33722739]
PC-3	IC₅₀	4.33 μM Compound: VP-16	Antiproliferative activity against human PC3 cells assessed as cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as cell viability incubated for 72 hrs by MTT assay	[PMID: 25799376]
PC-3	IC₅₀	5.4 μM Compound: Etoposide	Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 29525336]
PC-3	IC₅₀	5.73 μM Compound: VP-16	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29335211]
PC-3	IC₅₀	69.54 μM Compound: etoposide	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 20405844]
PC-3	IC₅₀	7.2 μg/mL Compound: Etoposide	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	10.1039/C4MD00525B
PC-3	IC₅₀	7.8 μM Compound: etoposide	Antiproliferative activity against human PC3 cell line Antiproliferative activity against human PC3 cell line	[PMID: 16686539]
PC-3	IC₅₀	8 μM Compound: Etoposide	Cytotoxicity against human PC-3 cells incubated for 24 hrs by AlamarBlue staining based analysis Cytotoxicity against human PC-3 cells incubated for 24 hrs by AlamarBlue staining based analysis	[PMID: 36857518]
PC-3	IC₅₀	> 100 μM Compound: Etoposide	Growth inhibition of human PC3 cells after 72 hrs by MTT assay Growth inhibition of human PC3 cells after 72 hrs by MTT assay	[PMID: 24180210]
PC-9	IC₅₀	2.22 μM Compound: 3; Etop	Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	12 μM Compound: 1	Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay	[PMID: 29870668]
RAW264.7	IC₅₀	0.82 μM Compound: Etoposide	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay	[PMID: 25644672]
RKO	IC₅₀	1.9 μM Compound: Etoposide	Antiproliferative activity against human RKO cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human RKO cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
RKO	IC₅₀	1.96 μM Compound: Etoposide	Antiproliferative activity against human RKO cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human RKO cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33398999]
RKO	IC₅₀	> 150 μM Compound: vp16	Antiproliferative activity against human RKO cells measured after 72 hrs by MTT assay Antiproliferative activity against human RKO cells measured after 72 hrs by MTT assay	[PMID: 35462164]
RPMI-8226	IC₅₀	0.14 μM Compound: 2, VP-16	Cytotoxicity against human RPMI8226 cells after 48 hrs Cytotoxicity against human RPMI8226 cells after 48 hrs	[PMID: 20053564]
RPMI-8226	IC₅₀	0.7 μM Compound: VP-16	Cytotoxicity against human RPMI8226 cells after 72 hrs by CCK8 method Cytotoxicity against human RPMI8226 cells after 72 hrs by CCK8 method	[PMID: 20071056]
RPMI-8226	IC₅₀	4.8 μM Compound: Etoposide	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 30447888]
RT-112	IC₅₀	0.22 μM Compound: Etoposide	Growth inhibition against human RT-112 cell lines Growth inhibition against human RT-112 cell lines	[PMID: 15189040]
RT-4	IC₅₀	1.33 μM Compound: Etoposide	Growth inhibition against human RT-4 cell lines Growth inhibition against human RT-4 cell lines	[PMID: 15189040]
RWPE-1	GI₅₀	0.9 μM Compound: Etoposide	Cytotoxicity against human RWPE1 cells after 72 hrs by MTT assay relative to untreated control Cytotoxicity against human RWPE1 cells after 72 hrs by MTT assay relative to untreated control	[PMID: 24389510]
RWPE-1	IC₅₀	27.64 μM Compound: Etoposide	Cytotoxicity against human RWPE1 cells after 48 hrs by MTT assay Cytotoxicity against human RWPE1 cells after 48 hrs by MTT assay	[PMID: 26292628]
Raji	IC₅₀	1.21 μM Compound: Etoposide	Cytotoxicity against human Raji cells after 48 hrs by MTT assay Cytotoxicity against human Raji cells after 48 hrs by MTT assay	[PMID: 30109008]
Raji	IC₅₀	1.68 μM Compound: Etoposide	Antiproliferative activity against human Raji cells after 48 hrs by MTT assay Antiproliferative activity against human Raji cells after 48 hrs by MTT assay	[PMID: 26649766]
Renca	IC₅₀	2.9 μM Compound: etoposide	Antiproliferative activity against mouse Renca cell line Antiproliferative activity against mouse Renca cell line	[PMID: 16686539]
SBC-3	ED₅₀	1.6 μg/mL Compound: VP-16	Inhibition of growth of lung small cell carcinoma SBC-3 cell line Inhibition of growth of lung small cell carcinoma SBC-3 cell line	[PMID: 8389875]
SBC-3	IC₅₀	0.0676 μg/mL Compound: Etoposide	Cytotoxic activity against human tumor SBC-3 lung cells Cytotoxic activity against human tumor SBC-3 lung cells	[PMID: 15056007]
SCLC	IC₅₀	1.3 μM Compound: VP-16 (Etoposide)	Cytotoxicity against human SCLC cells resistant to cisplatin (SCLC/CDDP) Cytotoxicity against human SCLC cells resistant to cisplatin (SCLC/CDDP)	[PMID: 8258835]
SCaBER	IC₅₀	0.276 μg/mL Compound: Etoposide	Cytotoxic activity against human tumor SCaBER bladder cells Cytotoxic activity against human tumor SCaBER bladder cells	[PMID: 15056007]
SCaBER	IC₅₀	0.31 μg/mL Compound: Etoposide	Cytotoxic activity of compound against SCaBER bladder squamous human tumor cell line Cytotoxic activity of compound against SCaBER bladder squamous human tumor cell line	[PMID: 12459024]
SF-268	GI₅₀	4.21 μM Compound: ETO	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	10.1007/s00044-013-0798-7
SF-268	IC₅₀	3.25 μM Compound: VP-16	Antiproliferative activity against human SF-268 cells after 96 hrs by MTT assay Antiproliferative activity against human SF-268 cells after 96 hrs by MTT assay	[PMID: 19053767]
SF-295	IC₅₀	13.3 μM Compound: 2	Cytotoxicity against human SF295 cells by sulforhodamine B assay Cytotoxicity against human SF295 cells by sulforhodamine B assay	[PMID: 17988764]
SF-295	IC₅₀	13.5 μM Compound: 2	Cytotoxicity against human SF295 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human SF295 cells after 48 hrs by sulforhodamine B assay	[PMID: 21477899]
SGC-7901	IC₅₀	0.08 μM Compound: etoposide	Cytotoxicity against human SGC7901 cells Cytotoxicity against human SGC7901 cells	[PMID: 23092389]
SGC-7901	IC₅₀	12.09 μM Compound: 2	Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 22687745]
SGC-7901	IC₅₀	5.26 μM Compound: vp16	Antiproliferative activity against human SGC-7901 cells measured after 72 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
SGC-7901	IC₅₀	6.56 μM Compound: Vp-16	Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	10.1039/C4MD00209A
SH-SY5Y	IC₅₀	0.89 μM Compound: VP-16	Cytotoxicity against human SH-SY5Y cells expressing low level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells expressing low level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
SH-SY5Y	IC₅₀	1.7 μM Compound: Etoposide	Cytotoxicity against human SH-SY5Y cells after 48 hrs by WST-8 assay Cytotoxicity against human SH-SY5Y cells after 48 hrs by WST-8 assay	[PMID: 19072209]
SH-SY5Y	IC₅₀	1.7 μM Compound: Etoposide	Cytotoxicity against human SH-SY5Y cells after 48 hrs by SRB method Cytotoxicity against human SH-SY5Y cells after 48 hrs by SRB method	[PMID: 19425589]
SH-SY5Y	IC₅₀	5.37 μM Compound: 2	Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 22687745]
SISO	IC₅₀	0.15 μM Compound: Etoposide	Growth inhibition against human SISO cell lines Growth inhibition against human SISO cell lines	[PMID: 15189040]
SK-BR-3	IC₅₀	0.3 μM Compound: Etoposide	Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53) Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53)	[PMID: 10780913]
SK-HEP1	IC₅₀	0.22 μM Compound: Etoposide	Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hr by SRB assay Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hr by SRB assay	[PMID: 34931849]
SK-HEP1	IC₅₀	0.25 μM Compound: Etoposide	Cytotoxicity in human SK-HEP1 cells by sulforhodamine B colorimetric assay Cytotoxicity in human SK-HEP1 cells by sulforhodamine B colorimetric assay	[PMID: 27933890]
SK-HEP1	IC₅₀	0.38 μM Compound: Etoposide	Antiproliferative activity against human SKHEP1 cells assessed as reduction in cell viability by sulforhodamine B assay Antiproliferative activity against human SKHEP1 cells assessed as reduction in cell viability by sulforhodamine B assay	[PMID: 32073848]
SK-HEP1	IC₅₀	0.4 μM Compound: Etoposide	Cytotoxicity against human SK-HEP1 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human SK-HEP1 cells assessed as reduction in cell viability by SRB assay	[PMID: 33636429]
SK-HEP1	IC₅₀	0.4 μM Compound: Etoposide	Cytotoxicity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 37672645]
SK-HEP1	IC₅₀	0.41 μM Compound: Etoposide	Antiproliferative activity against human SKHEP1 cells after 72 hrs by SRB assay Antiproliferative activity against human SKHEP1 cells after 72 hrs by SRB assay	[PMID: 30755350]
SK-HEP1	IC₅₀	0.63 μM Compound: Etoposide	Growth inhibition of human SKHEP1 cells incubated for 72 hrs by sulforhodamine B assay Growth inhibition of human SKHEP1 cells incubated for 72 hrs by sulforhodamine B assay	[PMID: 28625715]
SK-HEP1	IC₅₀	0.63 μM Compound: Etoposide	Cytotoxicity against human SKHEP1 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human SKHEP1 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30041947]
SK-HEP1	IC₅₀	0.7 μM Compound: Etoposide	Antiproliferative activity against human SK-HEP1 cells measured after 72 hrs by SRB assay Antiproliferative activity against human SK-HEP1 cells measured after 72 hrs by SRB assay	[PMID: 35362983]
SK-HEP1	IC₅₀	0.78 μM Compound: Etoposide	Antiproliferative activity against human SKHEP1 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human SKHEP1 cells after 72 hrs by sulforhodamine B assay	[PMID: 31894983]
SK-HEP1	IC₅₀	0.93 μM Compound: Etoposide	Cytotoxicity against human SKHEP1 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human SKHEP1 cells after 72 hrs by sulforhodamine B assay	[PMID: 29893558]
SK-HEP1	IC₅₀	1.1 μM Compound: etoposide	Cytotoxicity against human SKHEP1 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human SKHEP1 cells after 72 hrs by sulforhodamine B assay	[PMID: 25495422]
SK-HEP1	IC₅₀	1.1 μM Compound: etoposide	Antiproliferative activity against human SKHEP1 cells after 3 days by sulforhodamine B assay Antiproliferative activity against human SKHEP1 cells after 3 days by sulforhodamine B assay	[PMID: 25700232]
SK-HEP1	IC₅₀	2.8 μM Compound: etoposide	Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
SK-HEP1	IC₅₀	49.6 μM Compound: etoposide	Cytotoxicity against human SK-Hep1 cells by MTT assay Cytotoxicity against human SK-Hep1 cells by MTT assay	[PMID: 18637688]
SK-HEP1	IC₅₀	62 nM Compound: Etoposide	Cytotoxicity against human SKHEP1 cells after 48 hrs by [3H]thymidine incorporation assay Cytotoxicity against human SKHEP1 cells after 48 hrs by [3H]thymidine incorporation assay	[PMID: 20210346]
SK-MEL-1	IC₅₀	8 μM Compound: Etoposide	Cytotoxicity against human SK-MEL-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29032930]
SK-MEL-1	IC₅₀	> 30 μM Compound: etoposide	Cytotoxicity against human SK-MEL-1 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-1 cells after 72 hrs by MTT assay	[PMID: 19053514]
SK-MEL-2	ED₅₀	0.08 μg/mL Compound: etoposide	Cytotoxicity against human SK-MEL-2 cells by SRB method Cytotoxicity against human SK-MEL-2 cells by SRB method	[PMID: 16252909]
SK-MEL-2	IC₅₀	0.2 μM Compound: Etoposide	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 28841320]
SK-MEL-2	IC₅₀	0.3 μM Compound: Etoposide	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 31082231]
SK-MEL-2	IC₅₀	0.3 μM Compound: etoposide	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB method Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB method	[PMID: 17493824]
SK-MEL-2	IC₅₀	0.41 μM Compound: Etoposide	Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay	[PMID: 21936523]
SK-MEL-2	IC₅₀	0.79 μM Compound: Etoposide	Cytotoxicity against human SK-MEL-2 cells after 72 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 72 hrs by SRB assay	[PMID: 30776236]
SK-MEL-2	IC₅₀	1.1 μM Compound: Etoposide	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 28165740]
SK-MEL-2	IC₅₀	1.17 μM Compound: Etoposide	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 21182258]
SK-MEL-2	IC₅₀	1.17 μM Compound: Etoposide	Anticancer activity against human SK-MEL-2 cells by SRB assay Anticancer activity against human SK-MEL-2 cells by SRB assay	[PMID: 21420296]
SK-MEL-2	IC₅₀	1.17 μM Compound: Etoposide	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 26988298]
SK-MEL-2	IC₅₀	1.33 μM Compound: Etoposide	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 26706168]
SK-MEL-2	IC₅₀	1.5 μM Compound: Etoposide	Cytotoxicity in human SK-MEL-2 cells by SRB assay Cytotoxicity in human SK-MEL-2 cells by SRB assay	[PMID: 26812172]
SK-MEL-2	IC₅₀	4.13 μM Compound: Etoposide	Concentration required for inhibiting proliferation of human melanoma tumor cell line SK-MEL-2 by 50% after 72 hr of incubation was determined Concentration required for inhibiting proliferation of human melanoma tumor cell line SK-MEL-2 by 50% after 72 hr of incubation was determined	[PMID: 15482917]
SK-MEL-2	IC₅₀	5.72 μM Compound: etoposide	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 17194596]
SK-MEL-2	IC₅₀	5.72 μM Compound: etoposide	Cytotoxicity against human SK-MEL-2 cells after 3 days by SRB assay Cytotoxicity against human SK-MEL-2 cells after 3 days by SRB assay	[PMID: 18321715]
SK-MEL-28	CC₅₀	1.2 μM Compound: Etoposide	Antiproliferative activity against human SK-MEL-28 cells after 96 hrs by MTT assay Antiproliferative activity against human SK-MEL-28 cells after 96 hrs by MTT assay	[PMID: 21741130]
SK-MEL-28	GI₅₀	3.2 μM Compound: Etoposide	Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTT assay Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 28406636]
SK-MEL-28	IC₅₀	1 μM Compound: Etoposide	Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTT assay Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 24950030]
SK-MEL-28	IC₅₀	1.1 μM Compound: VP-16	Antiproliferative activity against human SKMEL-28 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human SKMEL-28 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
SK-MEL-28	IC₅₀	3 μM Compound: Etoposide	Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTT assay Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 24180210]
SK-MEL-28	IC₅₀	850 nM Compound: 1a	In vitro cytotoxicity against MEL-28 (human malign melanoma) neoplastic cell line In vitro cytotoxicity against MEL-28 (human malign melanoma) neoplastic cell line	[PMID: 14980682]
SK-MES-1	CC₅₀	0.3 μM Compound: Etoposide	Antiproliferative activity against human SKMES1 cells after 96 hrs by MTT assay Antiproliferative activity against human SKMES1 cells after 96 hrs by MTT assay	[PMID: 21741130]
SK-MES-1	IC₅₀	1.83 μM Compound: Etoposide	Cytotoxicity against human SKMES1 cells Cytotoxicity against human SKMES1 cells	[PMID: 25440884]
SK-MES-1	IC₅₀	2.5 μM Compound: Etoposide	Cytotoxicity against human SK-MES-1 cells after 3 days by MTT assay Cytotoxicity against human SK-MES-1 cells after 3 days by MTT assay	[PMID: 19013074]
SK-MES-1	IC₅₀	2.5 μM Compound: Etoposide	Cytotoxicity against human SKMES1 cells after 72 hrs by MTT assay Cytotoxicity against human SKMES1 cells after 72 hrs by MTT assay	[PMID: 19269832]
SK-MES-1	IC₅₀	2.5 μM Compound: Etoposide	Cytotoxicity against human SKMES1 cells after 72 hrs by MTT assay Cytotoxicity against human SKMES1 cells after 72 hrs by MTT assay	[PMID: 20828890]
SK-MES-1	IC₅₀	2.5 μM Compound: Etoposide	Cytotoxicity against human SKMES1 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human SKMES1 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23454511]
SK-MES-1	IC₅₀	2.5 μM Compound: etoposide	Antitumor against human SK-MES1 cells after 72 hrs by MTT assay Antitumor against human SK-MES1 cells after 72 hrs by MTT assay	[PMID: 18299197]
SK-MES-1	IC₅₀	2.8 μM Compound: Etoposide	Cytotoxicity against human SKMES1 cells after 3 days by MTT assay Cytotoxicity against human SKMES1 cells after 3 days by MTT assay	[PMID: 19419803]
SK-MES-1	IC₅₀	2.8 μM Compound: Etoposide	Anticancer activity against human SKMES1 cells after 3 days by MTT assay Anticancer activity against human SKMES1 cells after 3 days by MTT assay	[PMID: 21621882]
SK-N-MC	IC₅₀	14.04 μg/mL Compound: Etoposide	Cytotoxicity against human SK-N-MC cells by MTT assay Cytotoxicity against human SK-N-MC cells by MTT assay	[PMID: 22341788]
SK-N-MC	IC₅₀	275 nM Compound: 1 (VP16)	In vivo antiproliferative activity against SK-N-MC cell line In vivo antiproliferative activity against SK-N-MC cell line	[PMID: 15084135]
SK-N-SH	IC₅₀	9.03 μM Compound: Etoposide	Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 48 hrs by SRB assay	10.1039/C4MD00325J
SK-N-SH	IC₅₀	< 1 μM Compound: Etoposide	Activation of procaspase-3-mediated human SK-N-SH cell death after 72 hrs by MTS/PMS assay Activation of procaspase-3-mediated human SK-N-SH cell death after 72 hrs by MTS/PMS assay	[PMID: 16936720]
SK-OV-3	ED₅₀	2.7 μg/mL Compound: etoposide	Cytotoxicity against human SKOV3 cells by SRB method Cytotoxicity against human SKOV3 cells by SRB method	[PMID: 16252909]
SK-OV-3	GI₅₀	< 0.01 μM Compound: 2	In vitro cytotoxic activity against Ovarian (SK-OV3) cell line. In vitro cytotoxic activity against Ovarian (SK-OV3) cell line.	[PMID: 10465531]
SK-OV-3	IC₅₀	0.84 μM Compound: Etoposide	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 26988298]
SK-OV-3	IC₅₀	0.95 μg/mL Compound: Etoposide	Cytotoxic activity of compound against SK-OV-3 ovary human tumor cell line Cytotoxic activity of compound against SK-OV-3 ovary human tumor cell line	[PMID: 12459024]
SK-OV-3	IC₅₀	1.06 μg/mL Compound: Etoposide	Cytotoxic activity against human tumor SK-OV-3 ovary cells Cytotoxic activity against human tumor SK-OV-3 ovary cells	[PMID: 15056007]
SK-OV-3	IC₅₀	1.31 μM Compound: Etoposide	Cytotoxicity against human SKOV3 cells by sulforhodamine B assay Cytotoxicity against human SKOV3 cells by sulforhodamine B assay	[PMID: 21936523]
SK-OV-3	IC₅₀	1.72 μM Compound: etoposide	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB method Cytotoxicity against human SKOV3 cells after 48 hrs by SRB method	[PMID: 17493824]
SK-OV-3	IC₅₀	1.8 μM Compound: Etoposide	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 31082231]
SK-OV-3	IC₅₀	1.81 μM Compound: Etoposide	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 21182258]
SK-OV-3	IC₅₀	1.81 μM Compound: Etoposide	Anticancer activity against human SKOV3 cells by SRB assay Anticancer activity against human SKOV3 cells by SRB assay	[PMID: 21420296]
SK-OV-3	IC₅₀	1.83 μM Compound: Etoposide	Cytotoxicity against human SKOV3 cells after 72 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 72 hrs by SRB assay	[PMID: 30776236]
SK-OV-3	IC₅₀	1.95 μM Compound: Etoposide	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 28165740]
SK-OV-3	IC₅₀	1.96 μM Compound: Etoposide	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 26706168]
SK-OV-3	IC₅₀	14.8 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by MTT assay	[PMID: 32992133]
SK-OV-3	IC₅₀	2.39 μM Compound: VP-16	Cytotoxicity against human SKOV3 cells assessed as reduction in cell growth measured after 48 hrs by sulforhodamine B assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell growth measured after 48 hrs by sulforhodamine B assay	[PMID: 31239178]
SK-OV-3	IC₅₀	2.6 μM Compound: Etoposide	Cytotoxicity in human SKOV3 cells by SRB assay Cytotoxicity in human SKOV3 cells by SRB assay	[PMID: 26812172]
SK-OV-3	IC₅₀	2.9 μM Compound: Etoposide	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 28841320]
SK-OV-3	IC₅₀	3.46 μM Compound: Etoposide	Concentration required for inhibiting proliferation of human ovarian tumor cell line SK-OV-3 after 72 hr of incubation was determined Concentration required for inhibiting proliferation of human ovarian tumor cell line SK-OV-3 after 72 hr of incubation was determined	[PMID: 15482917]
SK-OV-3	IC₅₀	3.84 μg/mL Compound: Etoposide	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28351589]
SK-OV-3	IC₅₀	4.28 μM Compound: etoposide	Cytotoxicity against human SK-OV-3 cells by SRB assay Cytotoxicity against human SK-OV-3 cells by SRB assay	[PMID: 17194596]
SK-OV-3	IC₅₀	4.28 μM Compound: etoposide	Cytotoxicity against human SKOV3 cells after 3 days by SRB assay Cytotoxicity against human SKOV3 cells after 3 days by SRB assay	[PMID: 18321715]
SK-OV-3	IC₅₀	4.9 μM Compound: VP-16	Antiproliferative activity against human SKOV-3 ovarian cell line Antiproliferative activity against human SKOV-3 ovarian cell line	[PMID: 10498216]
SK-OV-3	IC₅₀	9.2 μM Compound: Etoposide	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31669850]
SK-OV-3	IC₅₀	>= 2.91 μM Compound: Etoposide	Anticancer activity against human SKOV3 cells after 48 hrs by SRB assay Anticancer activity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 30660827]
SK-OV-3	IC₅₀	>= 6.94 μM Compound: Etoposide	Antiproliferative activity against human SKOV3 cells by SRB assay Antiproliferative activity against human SKOV3 cells by SRB assay	[PMID: 31546197]
SMMC-7721	IC₅₀	0.15 μM Compound: Etoposide	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28169166]
SMMC-7721	IC₅₀	0.31 μM Compound: Ref 34, Cpd 2	Antiproliferative activity against human SMMC-7721 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human SMMC-7721 cells incubated for 48 hrs by MTT assay	[PMID: 32992133]
SMMC-7721	IC₅₀	21.03 μM Compound: Etoposide	Cytotoxic activity against human SMMC7721 cells after 72 hrs by MTT assay Cytotoxic activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 28733083]
SMMC-7721	IC₅₀	23.2 μM Compound: Etoposide	Cytotoxicity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 68 hrs by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 68 hrs by MTT assay	[PMID: 37267043]
SMMC-7721	IC₅₀	40.44 μM Compound: Etoposide	Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 28431878]
SMMC-7721	IC₅₀	8.12 μM Compound: 2	Anticancer activity against human SMMC7721 cells after 48 hrs by MTT assay Anticancer activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 25744190]
SNU-638	IC₅₀	0.2 μM Compound: Etoposide	Cytotoxicity against human SNU-638 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human SNU-638 cells assessed as reduction in cell viability by SRB assay	[PMID: 33636429]
SNU-638	IC₅₀	0.23 μM Compound: etoposide	Cytotoxicity against human SNU638 cells by SRB assay Cytotoxicity against human SNU638 cells by SRB assay	[PMID: 17194596]
SNU-638	IC₅₀	0.23 μM Compound: etoposide	Cytotoxicity against human SNU638 cells after 3 days by SRB assay Cytotoxicity against human SNU638 cells after 3 days by SRB assay	[PMID: 18321715]
SNU-638	IC₅₀	0.3 μM Compound: etoposide	Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
SNU-638	IC₅₀	0.34 μM Compound: Etoposide	Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay	[PMID: 30755350]
SNU-638	IC₅₀	0.4 μM Compound: Etoposide	Antiproliferative activity against human SNU-638 cells assessed as reduction in cell viability incubated for 72 hr by SRB assay Antiproliferative activity against human SNU-638 cells assessed as reduction in cell viability incubated for 72 hr by SRB assay	[PMID: 34931849]
SNU-638	IC₅₀	0.4 μM Compound: Etoposide	Antiproliferative activity against human SNU-638 cells measured after 72 hrs by SRB assay Antiproliferative activity against human SNU-638 cells measured after 72 hrs by SRB assay	[PMID: 35362983]
SNU-638	IC₅₀	0.4 μM Compound: Etoposide	Cytotoxicity against human SNU-638 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human SNU-638 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 37672645]
SNU-638	IC₅₀	0.43 μM Compound: Etoposide	Cytotoxicity against human SNU638 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human SNU638 cells after 72 hrs by sulforhodamine B assay	[PMID: 29893558]
SNU-638	IC₅₀	0.5 μM Compound: etoposide	Cytotoxicity against human SNU638 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human SNU638 cells after 72 hrs by sulforhodamine B assay	[PMID: 25495422]
SNU-638	IC₅₀	0.5 μM Compound: etoposide	Antiproliferative activity against human SNU638 cells after 3 days by sulforhodamine B assay Antiproliferative activity against human SNU638 cells after 3 days by sulforhodamine B assay	[PMID: 25700232]
SNU-638	IC₅₀	0.52 μM Compound: Etoposide	Antiproliferative activity against human SNU638 cells assessed as reduction in cell viability by sulforhodamine B assay Antiproliferative activity against human SNU638 cells assessed as reduction in cell viability by sulforhodamine B assay	[PMID: 32073848]
SNU-638	IC₅₀	0.56 μM Compound: Etoposide	Cytotoxicity in human SNU-638 cells by sulforhodamine B colorimetric assay Cytotoxicity in human SNU-638 cells by sulforhodamine B colorimetric assay	[PMID: 27933890]
SNU-638	IC₅₀	0.82 μM Compound: Etoposide	Antiproliferative activity against human SNU638 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human SNU638 cells after 72 hrs by sulforhodamine B assay	[PMID: 31894983]
SNU-638	IC₅₀	1.05 μM Compound: Etoposide	Growth inhibition of human SNU638 cells incubated for 72 hrs by sulforhodamine B assay Growth inhibition of human SNU638 cells incubated for 72 hrs by sulforhodamine B assay	[PMID: 28625715]
SNU-638	IC₅₀	1.05 μM Compound: Etoposide	Cytotoxicity against human SNU638 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human SNU638 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30041947]
SNU-638	IC₅₀	2.57 μM Compound: Etoposide	Cytotoxicity against human SNU638 cells by MTT assay Cytotoxicity against human SNU638 cells by MTT assay	[PMID: 23608763]
SU-DHL-2	IC₅₀	2.1 μM Compound: Etoposide	Cytotoxicity against human SUDHL2 cells assessed as cell growth inhibition by MTT assay Cytotoxicity against human SUDHL2 cells assessed as cell growth inhibition by MTT assay	[PMID: 37676247]
SW-620	GI₅₀	90 μM Compound: 2	In vitro cytotoxic activity against colon (SW 620) cancer cell line. In vitro cytotoxic activity against colon (SW 620) cancer cell line.	[PMID: 10465531]
SW-620	IC₅₀	13.24 μM Compound: Etoposide	Cytotoxicity against human SW620 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human SW620 cells assessed as growth inhibition after 48 hrs by SRB assay	10.1039/C4MD00325J
SW-620	IC₅₀	20 μM Compound: Eto	Antitumor activity against human SW620 cells after 72 hrs by MTT assay Antitumor activity against human SW620 cells after 72 hrs by MTT assay	[PMID: 17935309]
SW-620	IC₅₀	20 μM Compound: etoposide	Growth inhibition of human SW620 cells by MTT assay Growth inhibition of human SW620 cells by MTT assay	[PMID: 17482821]
SW1573	GI₅₀	14 μM Compound: Etoposide	Antiproliferative activity against human SW1573 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human SW1573 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
SW1573	GI₅₀	15 μM Compound: Etoposide	Growth inhibition of human SW1573 cells Growth inhibition of human SW1573 cells	[PMID: 21986585]
SW1573	GI₅₀	15 μM Compound: Etoposide	Growth inhibition of human SW1573 cells after 48 hrs by SRB assay Growth inhibition of human SW1573 cells after 48 hrs by SRB assay	[PMID: 24211632]
SW1573	GI₅₀	15 μM Compound: Etoposide	Antiproliferative activity against human SW1573 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SW1573 cells after 48 hrs by sulforhodamine B assay	[PMID: 27023255]
SW1573	GI₅₀	15 μM Compound: Etoposide	Antiproliferative activity against human SW1573 cells after 48 hrs by SRB assay Antiproliferative activity against human SW1573 cells after 48 hrs by SRB assay	[PMID: 30840453]
SW1573	GI₅₀	15 μM Compound: VP-16	Cytotoxicity against human SW1573 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human SW1573 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27765506]
SW1573	GI₅₀	15 μM Compound: VP-16	Antiproliferative activity against human SW1573 cells after 48 hrs by SRB assay Antiproliferative activity against human SW1573 cells after 48 hrs by SRB assay	[PMID: 29129514]
SW1573	GI₅₀	3 μM Compound: VP-16	Antiproliferative activity against human SW1573 cells after 48 hrs incubation by SRB assay Antiproliferative activity against human SW1573 cells after 48 hrs incubation by SRB assay	[PMID: 25899335]
SW480	IC₅₀	0.07 μM Compound: Etoposide	Cytotoxicity against human SW480 cells measured after 9 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay Cytotoxicity against human SW480 cells measured after 9 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay	[PMID: 35231830]
SW480	IC₅₀	0.08 μM Compound: Etoposide	Additive cytotoxicity against human SW480 cells measured after 9 days in presence of 5 uM KU55933 by SRB assay Additive cytotoxicity against human SW480 cells measured after 9 days in presence of 5 uM KU55933 by SRB assay	[PMID: 35231830]
SW480	IC₅₀	0.31 μM Compound: Etoposide	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
SW480	IC₅₀	0.6 μM Compound: VP16	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 33191085]
SW480	IC₅₀	0.8 μM Compound: Etoposide	Antiproliferative activity against human SW480 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human SW480 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
SW480	IC₅₀	1.11 μM Compound: Etoposide	Antiproliferative activity against human SW480 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human SW480 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33398999]
SW480	IC₅₀	17.11 μM Compound: 2	Anticancer activity against human SW480 cells after 48 hrs by MTT assay Anticancer activity against human SW480 cells after 48 hrs by MTT assay	[PMID: 25744190]
SW480	IC₅₀	3.5 μM Compound: Etoposide	Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 5 uM KU55933 by SRB assay Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 5 uM KU55933 by SRB assay	[PMID: 35231830]
SW480	IC₅₀	3.6 μM Compound: Etoposide	Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay	[PMID: 35231830]
SW480	IC₅₀	3.6 μM Compound: Etoposide	Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 50 nM AZD0156 by SRB assay Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 50 nM AZD0156 by SRB assay	[PMID: 35231830]
SW480	IC₅₀	3.8 μM Compound: Etoposide	Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 5 uM KU60019 by SRB assay Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 5 uM KU60019 by SRB assay	[PMID: 35231830]
SW480	IC₅₀	50 μM Compound: 1	Tested for cytotoxicity against Colon adenocarcinoma resistant type SW480 cell line expressing MDR-1 (+) gene; ~50% cells affected by drug Tested for cytotoxicity against Colon adenocarcinoma resistant type SW480 cell line expressing MDR-1 (+) gene; ~50% cells affected by drug	[PMID: 11844671]
SW480	IC₅₀	6.4 μM Compound: Etoposide	Cytotoxicity against Homo sapiens (human) SW480 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) SW480 cells after 72 hr by MTT assay	10.1007/s00044-011-9937-1
SW480	IC₅₀	6.4 μM Compound: Etoposide	Anticancer activity against Homo sapiens (human) SW480 cells assessed as decrease in cell growth after 3 days by MTT assay Anticancer activity against Homo sapiens (human) SW480 cells assessed as decrease in cell growth after 3 days by MTT assay	10.1007/s00044-012-0245-1
SW480	IC₅₀	7.7 μg/mL Compound: Etoposide	Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay	[PMID: 29335206]
SW480	IC₅₀	7.7 μg/mL Compound: Etoposide	Cytotoxicity against human SW480 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 29908441]
SW480	IC₅₀	764 nM Compound: Ref 34, Cpd 2	Antiproliferative activity against human SW480 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human SW480 cells incubated for 48 hrs by MTT assay	[PMID: 32992133]
SW480	IC₅₀	< 0.01 μM Compound: Etoposide	Synergistic cytotoxicity against human SW480 cells measured after 9 days in presence of 5 uM KU60019 by SRB assay Synergistic cytotoxicity against human SW480 cells measured after 9 days in presence of 5 uM KU60019 by SRB assay	[PMID: 35231830]
SW480	IC₅₀	< 0.01 μM Compound: Etoposide	Synergistic cytotoxicity against human SW480 cells measured after 9 days in presence of 50 nM AZD0156 by SRB assay Synergistic cytotoxicity against human SW480 cells measured after 9 days in presence of 50 nM AZD0156 by SRB assay	[PMID: 35231830]
SW948	IC₅₀	1.3 μM Compound: etoposide	Antiproliferative activity against human SW948 cells after 3 days by XTT assay Antiproliferative activity against human SW948 cells after 3 days by XTT assay	[PMID: 19691293]
SiHa	GI₅₀	3.1 μM Compound: 2, VP-16	Growth inhibition of human SiHa cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SiHa cells after 48 hrs by sulforhodamine B assay	[PMID: 21489802]
SiHa	GI₅₀	3.11 μM Compound: 2, Eto	Growth inhibition of human SiHa cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SiHa cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
SiHa	IC₅₀	2.76 μM Compound: 2, VP-16	Cytotoxicity against human SiHa cells after 48 hrs by MTT assay Cytotoxicity against human SiHa cells after 48 hrs by MTT assay	[PMID: 22244588]
SiHa	IC₅₀	30.7 μM Compound: VP-16	Cytotoxicity against human SiHa cells after 48 hrs by MTT assay Cytotoxicity against human SiHa cells after 48 hrs by MTT assay	[PMID: 21733601]
SiHa	IC₅₀	40.4 μM Compound: 5, VP-16	Cytotoxicity against human SiHa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human SiHa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 22041063]
T47D	GI₅₀	15 μM Compound: VP-16	Antiproliferative activity against human T47D cells after 48 hrs incubation by SRB assay Antiproliferative activity against human T47D cells after 48 hrs incubation by SRB assay	[PMID: 25899335]
T47D	GI₅₀	22 μM Compound: Etoposide	Growth inhibition of human T47D cells Growth inhibition of human T47D cells	[PMID: 21986585]
T47D	GI₅₀	22 μM Compound: Etoposide	Growth inhibition of human T47D cells after 48 hrs by SRB assay Growth inhibition of human T47D cells after 48 hrs by SRB assay	[PMID: 24211632]
T47D	GI₅₀	22 μM Compound: Etoposide	Antiproliferative activity against human T47D cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human T47D cells after 48 hrs by sulforhodamine B assay	[PMID: 27023255]
T47D	GI₅₀	22 μM Compound: Etoposide	Antiproliferative activity against human T47D cells after 48 hrs by SRB assay Antiproliferative activity against human T47D cells after 48 hrs by SRB assay	[PMID: 30840453]
T47D	GI₅₀	22 μM Compound: Etoposide	Antiproliferative activity against human T47D cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human T47D cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
T47D	GI₅₀	22 μM Compound: VP-16	Antiproliferative activity against human T47D cells after 48 hrs by SRB assay Antiproliferative activity against human T47D cells after 48 hrs by SRB assay	[PMID: 29129514]
T47D	GI₅₀	7.9 μg/mL Compound: Etoposide	Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
T47D	IC₅₀	0.05 μg/mL Compound: Etoposide	Cytotoxicity against human T47D cells after 3 days by MTT assay Cytotoxicity against human T47D cells after 3 days by MTT assay	[PMID: 21216051]
T47D	IC₅₀	0.1 μM Compound: Etoposide	Cytotoxicity against human T47D cells Cytotoxicity against human T47D cells	[PMID: 19788270]
T47D	IC₅₀	0.16 μM Compound: Etoposide	Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53) Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53)	[PMID: 10780913]
T47D	IC₅₀	0.32 μM Compound: Etoposide	Antiproliferative activity against human T47D cells after 72 hrs by CCK-8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK-8 assay	[PMID: 29510948]
T47D	IC₅₀	0.4 μM Compound: Etoposide	Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK8 assay	[PMID: 29402741]
T47D	IC₅₀	0.4 μM Compound: Etoposide	Antiproliferative activity against human T47D cells after 72 hrs by EZ-CYTOX reagent based assay Antiproliferative activity against human T47D cells after 72 hrs by EZ-CYTOX reagent based assay	[PMID: 30262132]
T47D	IC₅₀	0.7 μM Compound: Etoposide	Cytotoxicity against human T47D cells incubated from day 2 to day 4 by CCK8 assay Cytotoxicity against human T47D cells incubated from day 2 to day 4 by CCK8 assay	[PMID: 26022080]
T47D	IC₅₀	0.88 μM Compound: Etoposide	Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by WST assay Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by WST assay	[PMID: 36493620]
T47D	IC₅₀	0.94 μM Compound: Etoposide	Cytotoxicity against human T47D cells after 2 days by CCK8 assay Cytotoxicity against human T47D cells after 2 days by CCK8 assay	[PMID: 26361737]
T47D	IC₅₀	0.97 μM Compound: Etoposide	Antiproliferative activity against human T47D cells incubated for 72 hrs by microplate reader analysis Antiproliferative activity against human T47D cells incubated for 72 hrs by microplate reader analysis	[PMID: 37418826]
T47D	IC₅₀	1.21 μM Compound: ETO	Cytotoxicity against human T47D cells after 72 hrs by MTT assay Cytotoxicity against human T47D cells after 72 hrs by MTT assay	[PMID: 22819942]
T47D	IC₅₀	1.64 μM Compound: Etoposide	Antiproliferative activity against human T47D cells measured after 72 hrs by EZ-Cytox assay Antiproliferative activity against human T47D cells measured after 72 hrs by EZ-Cytox assay	[PMID: 31398033]
T47D	IC₅₀	1.84 μM Compound: Etoposide	Cytotoxicity against human T47D cells after 3 days by CCK8 assay Cytotoxicity against human T47D cells after 3 days by CCK8 assay	[PMID: 26927425]
T47D	IC₅₀	1.84 μM Compound: Etoposide	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 27643560]
T47D	IC₅₀	1.96 μM Compound: Etoposide	Cytotoxicity against human T47D cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay Cytotoxicity against human T47D cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay	[PMID: 27707625]
T47D	IC₅₀	11.8 μM Compound: Etoposide	Cytotoxicity against human T47D cells after 48 hrs by MTT assay Cytotoxicity against human T47D cells after 48 hrs by MTT assay	[PMID: 26890115]
T47D	IC₅₀	11.8 μM Compound: Etoposide	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30660827]
T47D	IC₅₀	13.7 μM Compound: Etoposide	Cytotoxicity against human T47D cells measured on day 4 by CCK8 assay Cytotoxicity against human T47D cells measured on day 4 by CCK8 assay	[PMID: 25936262]
T47D	IC₅₀	13.7 μM Compound: Etoposide	Cytotoxicity against human T47D cells after 48 hrs by CCK8 assay Cytotoxicity against human T47D cells after 48 hrs by CCK8 assay	[PMID: 26945111]
T47D	IC₅₀	2.39 μM Compound: Etoposide	Cytotoxicity against human T47D cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human T47D cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
T47D	IC₅₀	2.57 μM Compound: Etoposide	Cytotoxicity against human T47D cells after 2 days Cytotoxicity against human T47D cells after 2 days	[PMID: 24904965]
T47D	IC₅₀	2.8 μM Compound: Etoposide	Cytotoxicity against human T47D cells assessed as reduction in cell growth after 72 hrs by CCK8 assay Cytotoxicity against human T47D cells assessed as reduction in cell growth after 72 hrs by CCK8 assay	[PMID: 27484510]
T47D	IC₅₀	3.25 μM Compound: Etoposide	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 28384547]
T47D	IC₅₀	3.42 μM Compound: Etoposide	Cytotoxicity against human T47D cells after 2 days by CCK-8 assay Cytotoxicity against human T47D cells after 2 days by CCK-8 assay	[PMID: 24013413]
T47D	IC₅₀	4.85 μM Compound: Etoposide	Antiproliferative activity against human T47D cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells measured after 72 hrs by CCK8 assay	[PMID: 27654394]
T47D	IC₅₀	4.98 μM Compound: Etoposide	Cytotoxicity against human T47D cells by MTT assay Cytotoxicity against human T47D cells by MTT assay	[PMID: 23608763]
T47D	IC₅₀	5.58 μM Compound: Etopo	Antiproliferative activity against human T47D cells after 72 hrs by EZ-Cytox colorimetric assay Antiproliferative activity against human T47D cells after 72 hrs by EZ-Cytox colorimetric assay	[PMID: 34678573]
T47D	IC₅₀	5.82 μM Compound: Etoposide	Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation	[PMID: 35123005]
T47D	IC₅₀	6.4 μM Compound: Etoposide	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 26988802]
T47D	IC₅₀	7 μM Compound: Etoposide	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 28068603]
T47D	IC₅₀	8.2 μg/mL Compound: Etoposide	Cytotoxicity against human T47D cells after 48 hrs by MTT assay Cytotoxicity against human T47D cells after 48 hrs by MTT assay	[PMID: 24219991]
T47D	IC₅₀	8.74 μM Compound: Etoposide	Cytotoxicity against human T47D cells after 4 days by CCK-8 assay Cytotoxicity against human T47D cells after 4 days by CCK-8 assay	[PMID: 25062006]
T47D	IC₅₀	8.81 μM Compound: Etoposide	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 28633898]
T47D	IC₅₀	8.9 μM Compound: Etoposide	Cytotoxicity against human T47D cells by MTT assay Cytotoxicity against human T47D cells by MTT assay	[PMID: 25847767]
T47D	IC₅₀	9.28 μM Compound: Etoposide	Cytotoxicity against human T47D cells measured after 2 days by MTT assay Cytotoxicity against human T47D cells measured after 2 days by MTT assay	[PMID: 26334499]
T47D	IC₅₀	9.8 μM Compound: Etoposide	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27863370]
T84	IC₅₀	3 μM Compound: Etoposide	Antiproliferative activity against human T84 cells assessed as cellular DNA content after 96 hrs by CyQUANT NF fluorescence assay Antiproliferative activity against human T84 cells assessed as cellular DNA content after 96 hrs by CyQUANT NF fluorescence assay	[PMID: 26731300]
T98G	IC₅₀	460 nM Compound: Etoposide	Cytotoxicity against human T98G cells expressing mutant p53 after 48 hrs by MTT assay Cytotoxicity against human T98G cells expressing mutant p53 after 48 hrs by MTT assay	[PMID: 22564383]
TERT-RPE1	IC₅₀	0.09 μM Compound: Etoposide	Compound was tested for growth inhibition against human h-TERTRPE1 cell lines Compound was tested for growth inhibition against human h-TERTRPE1 cell lines	[PMID: 15189040]
TERT-RPE1	IC₅₀	0.23 μM Compound: Etoposide	Cytostatic activity against human hTERT-RPE1 cells Cytostatic activity against human hTERT-RPE1 cells	[PMID: 30738653]
THP-1	IC₅₀	1 μM Compound: Etoposide	Cytotoxicity against human THP1 cells after 72 hrs by MTT assay Cytotoxicity against human THP1 cells after 72 hrs by MTT assay	[PMID: 30447888]
THP-1	IC₅₀	1.27 μg/mL Compound: Etoposide	Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay	[PMID: 19410455]
THP-1	IC₅₀	1.82 μM Compound: Etoposide	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay	[PMID: 25644672]
THP-1	IC₅₀	1.82 μM Compound: Etoposide	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28062194]
THP-1	IC₅₀	1.83 μM Compound: Etoposide	Cytotoxicity against human THP1 cells by MTT assay Cytotoxicity against human THP1 cells by MTT assay	[PMID: 19782567]
THP-1	IC₅₀	2.16 μM Compound: Etoposide	Cytotoxicity against human THP1 cells by MTT assay Cytotoxicity against human THP1 cells by MTT assay	[PMID: 19036584]
THP-1	IC₅₀	2.16 μM Compound: Etoposide	Cytotoxicity against human THP1 cells after 48 hrs by MTT assay Cytotoxicity against human THP1 cells after 48 hrs by MTT assay	[PMID: 22115593]
THP-1	IC₅₀	2.16 μM Compound: Etoposide	Cytotoxicity against human THP1 cells after 2 days by MTT assay Cytotoxicity against human THP1 cells after 2 days by MTT assay	[PMID: 22325897]
THP-1	IC₅₀	2.16 μM Compound: Etoposide	Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay	[PMID: 22578452]
THP-1	IC₅₀	2.16 μg/mL Compound: Etoposide	Cytotoxicity against human THP1 cells after 24 hrs by MTT assay Cytotoxicity against human THP1 cells after 24 hrs by MTT assay	[PMID: 21632155]
THP-1	IC₅₀	2.16 μg/mL Compound: Etoposide	Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25016373]
THP-1	IC₅₀	3.66 μM Compound: Etoposide	Cytotoxicity against human THP1 cells after 24 hrs by MTT assay Cytotoxicity against human THP1 cells after 24 hrs by MTT assay	10.1007/s00044-013-0757-3
THP-1	IC₅₀	4.42 μg/mL Compound: Etoposide	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28351589]
THP-1	IC₅₀	5.02 μg/mL Compound: Etoposide	Cytotoxicity against human THP1 cells assessed as decrease in cell number after 24 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as decrease in cell number after 24 hrs by MTT assay	[PMID: 25978960]
THP-1	IC₅₀	59 μM Compound: Etop	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human THP-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 34606997]
THP-1	IC₅₀	6.34 μg/mL Compound: Etoposide	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 24424132]
THP-1	IC₅₀	< 6.25 μM Compound: Etop	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human THP-1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34606997]
TK-10	GI₅₀	5.89 μM Compound: ET	Cytotoxicity against human TK10 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human TK10 cells after 48 hrs by sulforhodamine B assay	[PMID: 22889556]
TK-10	GI₅₀	7.19 μM Compound: Etoposide	Antiproliferative activity against human TK10 cells after 48 hrs by SRB assay Antiproliferative activity against human TK10 cells after 48 hrs by SRB assay	[PMID: 22682920]
TK-10	GI₅₀	7.19 μM Compound: Etoposide	Cytotoxicity against human TK10 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human TK10 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 28041801]
TK-10	IC₅₀	0.83 μM Compound: Etoposide	Antiproliferative activity against human TK-10 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human TK-10 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 27010926]
TK-10	IC₅₀	0.83 μM Compound: Etoposide	Anticancer activity against human TK-10 cells Anticancer activity against human TK-10 cells	[PMID: 31945642]
TK-10	IC₅₀	20.4 μg/mL Compound: Etoposide	Anticancer activity against human TK10 cells after 48 hrs by sulforhodamine B assay Anticancer activity against human TK10 cells after 48 hrs by sulforhodamine B assay	[PMID: 21816519]
TK-10	IC₅₀	9952.5 nM Compound: etoposide	Cytotoxicity against human TK10 cells after 48 hrs by SRB assay Cytotoxicity against human TK10 cells after 48 hrs by SRB assay	[PMID: 16309315]
U-251	IC₅₀	0.5 μM Compound: Etoposide	Cytotoxicity against human U251 RCB 0641 cells after 72 hrs by MTT assay Cytotoxicity against human U251 RCB 0641 cells after 72 hrs by MTT assay	[PMID: 18558490]
U-373MG ATCC	GI₅₀	24.9 μM Compound: Etoposide	Growth inhibition of human U373 cells after 72 hrs by MTT assay Growth inhibition of human U373 cells after 72 hrs by MTT assay	[PMID: 28406636]
U-373MG ATCC	IC₅₀	25 μM Compound: Etoposide	Growth inhibition of human U373 cells after 72 hrs by MTT assay Growth inhibition of human U373 cells after 72 hrs by MTT assay	[PMID: 24180210]
U-373MG ATCC	IC₅₀	7 μM Compound: Etoposide	Growth inhibition of human U373 cells after 72 hrs by MTT assay Growth inhibition of human U373 cells after 72 hrs by MTT assay	[PMID: 24950030]
U-373MG ATCC	IC₅₀	8.5 μM Compound: etoposide	Cytotoxicity against human U373 cells after 72 hrs by MTT assay Cytotoxicity against human U373 cells after 72 hrs by MTT assay	[PMID: 25402632]
U-87MG ATCC	ED₅₀	73.6 μM Compound: 1	Dose required for reduction in human glioblastoma U-87-MG cancer cells after 3 days incubation Dose required for reduction in human glioblastoma U-87-MG cancer cells after 3 days incubation	[PMID: 15456257]
U-87MG ATCC	IC₅₀	12.4 μM Compound: Etoposide	Cytotoxicity against human U87 cells after 72 hrs by MTT assay Cytotoxicity against human U87 cells after 72 hrs by MTT assay	[PMID: 22342101]
U-87MG ATCC	IC₅₀	145 nM Compound: Etoposide	Cytotoxicity against human U87MG cells after 48 hrs by [3H]thymidine incorporation assay Cytotoxicity against human U87MG cells after 48 hrs by [3H]thymidine incorporation assay	[PMID: 20210346]
U-87MG ATCC	IC₅₀	27 μM Compound: Etoposide	Cytotoxicity against human U87 cells incubated for 24 hrs by AlamarBlue staining based analysis Cytotoxicity against human U87 cells incubated for 24 hrs by AlamarBlue staining based analysis	[PMID: 36857518]
U-87MG ATCC	IC₅₀	5.09 μM Compound: vp16	Antiproliferative activity against human U87 cells measured after 72 hrs by MTT assay Antiproliferative activity against human U87 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
U-87MG ATCC	IC₅₀	620 nM Compound: Etoposide	Cytotoxicity against human U87 cells expressing wild-type p53 after 48 hrs by MTT assay Cytotoxicity against human U87 cells expressing wild-type p53 after 48 hrs by MTT assay	[PMID: 22564383]
U-937	IC₅₀	0.92 μM Compound: etoposide	Cytotoxicity against human U937 cells after 72 hrs by MTT assay Cytotoxicity against human U937 cells after 72 hrs by MTT assay	[PMID: 19053514]
U-937	IC₅₀	1.1 μM Compound: Etoposide	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay	[PMID: 25644672]
U-937	IC₅₀	1.1 μM Compound: Etoposide	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28062194]
U-937	IC₅₀	1.4 μM Compound: etoposide	Cytotoxicity against human U937 cells after 72 hrs by MTT assay Cytotoxicity against human U937 cells after 72 hrs by MTT assay	[PMID: 23865778]
U-937	IC₅₀	1.5 μM Compound: Etoposide	Cytotoxicity against human U937 cells after 24 hrs by MTT assay Cytotoxicity against human U937 cells after 24 hrs by MTT assay	[PMID: 25800433]
U-937	IC₅₀	10.1 μM Compound: Etoposide	Anticancer activity against human U937 cells by MTT assay Anticancer activity against human U937 cells by MTT assay	10.1039/C4MD00279B
U-937	IC₅₀	10.43 μM Compound: Etoposide	Cytotoxicity against human U937 cells after 24 hrs by MTT assay Cytotoxicity against human U937 cells after 24 hrs by MTT assay	10.1007/s00044-013-0757-3
U-937	IC₅₀	10.56 μg/mL Compound: Etoposide	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 19410455]
U-937	IC₅₀	10.56 μg/mL Compound: etoposide	Cytotoxicity against human U937 cells after 2 days by MTT assay Cytotoxicity against human U937 cells after 2 days by MTT assay	[PMID: 17689837]
U-937	IC₅₀	10.6 μg/mL Compound: Etoposide	Cytotoxicity against human U937 cells assessed as decrease in cell number after 24 hrs by MTT assay Cytotoxicity against human U937 cells assessed as decrease in cell number after 24 hrs by MTT assay	[PMID: 22704923]
U-937	IC₅₀	17.94 μM Compound: Etoposide	Cytotoxicity against human U937 cells after 48 hrs by MTT assay Cytotoxicity against human U937 cells after 48 hrs by MTT assay	[PMID: 22115593]
U-937	IC₅₀	17.94 μM Compound: Etoposide	Cytotoxicity against human U937 cells after 2 days by MTT assay Cytotoxicity against human U937 cells after 2 days by MTT assay	[PMID: 22325897]
U-937	IC₅₀	17.94 μg/mL Compound: Etoposide	Cytotoxicity against human U937 cells after 24 hrs by MTT assay Cytotoxicity against human U937 cells after 24 hrs by MTT assay	[PMID: 21632155]
U-937	IC₅₀	17.96 μM Compound: Etoposide	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 22578452]
U-937	IC₅₀	2.27 μg/mL Compound: Etoposide	Cytotoxicity against human U937 cells assessed as decrease in cell number after 24 hrs by MTT assay Cytotoxicity against human U937 cells assessed as decrease in cell number after 24 hrs by MTT assay	[PMID: 25978960]
U-937	IC₅₀	2.89 μg/mL Compound: Etoposide	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28351589]
U-937	IC₅₀	22.94 μM Compound: Etoposide	Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36996717]
U-937	IC₅₀	6.14 μg/mL Compound: Etoposide	Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25016373]
U-937	IC₅₀	6.7 μg/mL Compound: Etoposide	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 24424132]
U-937	IC₅₀	< 1 μM Compound: Etoposide	Activation of procaspase-3-mediated human U937 cell death after 72 hrs by MTS/PMS assay Activation of procaspase-3-mediated human U937 cell death after 72 hrs by MTS/PMS assay	[PMID: 16936720]
UACC-62	GI₅₀	0.89 μM Compound: Etoposide	Antiproliferative activity against human UACC62 cells after 48 hrs by SRB assay Antiproliferative activity against human UACC62 cells after 48 hrs by SRB assay	[PMID: 22682920]
UACC-62	GI₅₀	0.89 μM Compound: Etoposide	Cytotoxicity against human UACC62 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human UACC62 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 28041801]
UACC-62	GI₅₀	3.41 μM Compound: ET	Cytotoxicity against human UACC62 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human UACC62 cells after 48 hrs by sulforhodamine B assay	[PMID: 22889556]
UACC-62	IC₅₀	0.83 μM Compound: Etoposide	Antiproliferative activity against human UACC-62 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human UACC-62 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 27010926]
UACC-62	IC₅₀	0.83 μM Compound: Etoposide	Anticancer activity against human UACC-62 cells Anticancer activity against human UACC-62 cells	[PMID: 31945642]
UACC-62	IC₅₀	1.4 μg/mL Compound: Etoposide	Anticancer activity against human UACC62 cells after 48 hrs by sulforhodamine B assay Anticancer activity against human UACC62 cells after 48 hrs by sulforhodamine B assay	[PMID: 21816519]
UACC-62	IC₅₀	1130 nM Compound: etoposide	Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay	[PMID: 16309315]
UACC-62	IC₅₀	> 50 μM Compound: Etoposide	Activation of procaspase-3-mediated human UACC62 cell death after 72 hrs by MTS/PMS assay Activation of procaspase-3-mediated human UACC62 cell death after 72 hrs by MTS/PMS assay	[PMID: 16936720]
VCR100	IC₅₀	15.5 μM Compound: 1	Tested for cytotoxicity against T-lymphoblastoide VC resistant type VCR 100 cell line expressing MDR-1 (+) gene Tested for cytotoxicity against T-lymphoblastoide VC resistant type VCR 100 cell line expressing MDR-1 (+) gene	[PMID: 11844671]
Vero	IC₅₀	1.5 μM Compound: Etoposide	Cytotoxicity against human Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 27560280]
Vero	IC₅₀	16 μM Compound: ET	Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385594]
Vero	IC₅₀	31.14 μM Compound: 2	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 22687745]
Vero	IC₅₀	50 μM Compound: Etoposide	Cytotoxicity against African green monkey Vero cells assessed as cells growth inhibition after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cells growth inhibition after 48 hrs by MTT assay	[PMID: 27994737]
Vero	IC₅₀	> 10 μM Compound: Etoposide	Antiproliferative activity against African green monkey Vero cells by MTT assay Antiproliferative activity against African green monkey Vero cells by MTT assay	[PMID: 29072457]
Vero	IC₅₀	> 25 μM Compound: Etoposide	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 38784476]
WI-38	IC₅₀	17.6 μM Compound: VP16	Cytotoxicity against human WI38 cells measured after 48 hrs by MTT assay Cytotoxicity against human WI38 cells measured after 48 hrs by MTT assay	[PMID: 27517805]
WI-38	IC₅₀	25.7 μM Compound: 2; VP-16	Cytotoxicity against human WI38 cells assessed as reduction in inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human WI38 cells assessed as reduction in inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 29248296]
WI-38	IC₅₀	35.8 μM Compound: VP16; 2	Cytotoxicity against human WI38 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human WI38 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26873416]
WI-38	IC₅₀	46.9 μM Compound: 2; VP-16	Cytotoxicity against human WI38 cells after 48 hrs by MTT assay Cytotoxicity against human WI38 cells after 48 hrs by MTT assay	[PMID: 28512026]
WIL2-NS	CC₅₀	0.2 μM Compound: Etoposide	Antiproliferative activity against human WIL2-NS cells after 96 hrs by MTT assay Antiproliferative activity against human WIL2-NS cells after 96 hrs by MTT assay	[PMID: 21741130]
WiDr	GI₅₀	23 μM Compound: Etoposide	Growth inhibition of human WiDr cells Growth inhibition of human WiDr cells	[PMID: 21986585]
WiDr	GI₅₀	23 μM Compound: Etoposide	Growth inhibition of human WiDr cells after 48 hrs by SRB assay Growth inhibition of human WiDr cells after 48 hrs by SRB assay	[PMID: 24211632]
WiDr	GI₅₀	23 μM Compound: Etoposide	Antiproliferative activity against human WiDr cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human WiDr cells after 48 hrs by sulforhodamine B assay	[PMID: 27023255]
WiDr	GI₅₀	23 μM Compound: Etoposide	Antiproliferative activity against human WiDr cells after 48 hrs by SRB assay Antiproliferative activity against human WiDr cells after 48 hrs by SRB assay	[PMID: 30840453]
WiDr	GI₅₀	23 μM Compound: VP-16	Cytotoxicity against human WiDr cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human WiDr cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27765506]
WiDr	GI₅₀	23 μM Compound: VP-16	Antiproliferative activity against human WiDr cells after 48 hrs by SRB assay Antiproliferative activity against human WiDr cells after 48 hrs by SRB assay	[PMID: 29129514]
WiDr	GI₅₀	26 μM Compound: VP-16	Antiproliferative activity against human WiDr cells after 48 hrs incubation by SRB assay Antiproliferative activity against human WiDr cells after 48 hrs incubation by SRB assay	[PMID: 25899335]
WiDr	IC₅₀	1.63 μg/mL Compound: Etoposide	Cytotoxic activity against human WiDr colon tumor cell line Cytotoxic activity against human WiDr colon tumor cell line	[PMID: 15149673]
XF498	ED₅₀	2.6 μg/mL Compound: etoposide	Cytotoxicity against human XF498 cells by SRB method Cytotoxicity against human XF498 cells by SRB method	[PMID: 16252909]
XF498	IC₅₀	1.72 μM Compound: Etoposide	Cytotoxicity against human XF498 cells by SRB assay Cytotoxicity against human XF498 cells by SRB assay	[PMID: 21182258]
XF498	IC₅₀	1.72 μM Compound: Etoposide	Anticancer activity against human XF498 cells by SRB assay Anticancer activity against human XF498 cells by SRB assay	[PMID: 21420296]
XF498	IC₅₀	1.72 μM Compound: Etoposide	Cytotoxicity against human XF498 cells by SRB assay Cytotoxicity against human XF498 cells by SRB assay	[PMID: 26988298]
XF498	IC₅₀	3.14 μM Compound: Etoposide	Concentration required for inhibiting proliferation of human brain tumor cell line XF 498 by 50% after 72 hr of incubation was determined Concentration required for inhibiting proliferation of human brain tumor cell line XF 498 by 50% after 72 hr of incubation was determined	[PMID: 15482917]
XF498	IC₅₀	3.45 μM Compound: VP-16	Antiproliferative activity against human XF498 cells after 96 hrs by MTT assay Antiproliferative activity against human XF498 cells after 96 hrs by MTT assay	[PMID: 19053767]
XF498	IC₅₀	3.48 μM Compound: etoposide	Cytotoxicity against human XF498 cells by SRB assay Cytotoxicity against human XF498 cells by SRB assay	[PMID: 17194596]
XF498	IC₅₀	3.48 μM Compound: etoposide	Cytotoxicity against human XF498 cells after 3 days by SRB assay Cytotoxicity against human XF498 cells after 3 days by SRB assay	[PMID: 18321715]
XRS6	IC₅₀	0.14 μM Compound: etopside	Cytotoxicity against CHO cell line xrs6 Cytotoxicity against CHO cell line xrs6	[PMID: 7473578]
YAPC	IC₅₀	1.32 μM Compound: Etoposide	Compound was tested for growth inhibition against human YAPC cell lines Compound was tested for growth inhibition against human YAPC cell lines	[PMID: 15189040]
Z-138	IC₅₀	0.85 μM Compound: Etoposide	Antiproliferative activity against human Z138 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Antiproliferative activity against human Z138 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
Z-138	IC₅₀	1.06 μM Compound: Etoposide	Cytostatic activity against human Z138 cells Cytostatic activity against human Z138 cells	[PMID: 30738653]
ZR-75-1	GI₅₀	0.2 μM Compound: 2, Eto	Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
ZR-75-1	GI₅₀	0.2 μM Compound: 2, Eto	Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
ZR-75-1	GI₅₀	0.2 μM Compound: 2, VP-16	Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay	[PMID: 21489802]
ZR-75-1	GI₅₀	0.2 μM Compound: Etoposide	Cytotoxicity against human ZR-75-1 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human ZR-75-1 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
ZR-75-1	IC₅₀	0.24 μM Compound: Etoposide	Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53) Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53)	[PMID: 10780913]
ZR-75-1	IC₅₀	3.1 μM Compound: etoposide	Cytotoxicity against human ZR751cells by SRB microtiter plate assay Cytotoxicity against human ZR751cells by SRB microtiter plate assay	[PMID: 17585747]
ZR-75-30	IC₅₀	1.5 μM Compound: Eto	Antiproliferative activity against human ZR-7530 cells after 72 hrs by MTT assay Antiproliferative activity against human ZR-7530 cells after 72 hrs by MTT assay	[PMID: 30109001]
ZR-75-30	IC₅₀	2.5 μM Compound: etoposide	Cytotoxicity against human ZR-7530 cells after 72 hrs by MTT assay Cytotoxicity against human ZR-7530 cells after 72 hrs by MTT assay	[PMID: 25402632]

In Vitro

Etoposide is capable of causing cytotoxicity on pancreatic β-cells by inducing apoptosis through the JNK/ERK-mediated GSK-3 downstream-triggered mitochondria-dependent signaling pathway in RIN-m5F cells^[1].
Etoposide and Anti-Human VEGF significantly abolish P1 sphere-forming ability, an effect associated with apoptosis of this subset of cells^[2].
Etoposide phosphate (0-1μM; 72 hours) inhibits HCT116 FBXW^+/+, FBXW^-/- and p53^-/- as a dose-dependent manner, exhibits IC₅₀s of 0.945 μM; 0.375 μM; and 1.437 μM, respectively^[5].
Etoposide (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7^-/- cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[5]

Cell Line:	HCT116 FBXW^+/+, FBXW^-/- and p53^-/- cells
Concentration:	0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM
Incubation Time:	72 hours
Result:	Inhibits HCT116 FBXW^+/+p>, FBXW^-/- and p53^-/- cell growth as a concentration manner.

Western Blot Analysis^[5]

Cell Line:	HCT116 FBXW7^+/+ or FBXW7^-/- cells
Concentration:	25 μM
Incubation Time:	6 hours
Result:	Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7.

In Vivo

Etoposide (50 μM) and Anti-Human VEGF-treated hypoxic cells injected intravenously into immunodeficient mice reveals a reduced capacity to induce lung colonies, which also appear with a longer latency period^[2]. Etoposide (10 mg/kg/day, i.v.) with NSC 109724 and NSC 241240, reduces the tumor volume in the hepatoblastoma cell injected NMRI nude mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

588.56

Formula

C₂₉H₃₂O₁₃

CAS No.

33419-42-0

Appearance

Solid

Color

White to off-white

SMILES

O=C1OC[C@]2([H])[C@H](O[C@H]3[C@@H]([C@H]([C@@H]4O[C@H](C)OC[C@H]4O3)O)O)C5=C(C=C6OCOC6=C5)[C@@H](C7=CC(OC)=C(O)C(OC)=C7)[C@]21[H]

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : ≥ 39 mg/mL (66.26 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6991 mL	8.4953 mL	16.9906 mL
5 mM	0.3398 mL	1.6991 mL	3.3981 mL
10 mM	0.1699 mL	0.8495 mL	1.6991 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 3

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution
Protocol 4

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution
Protocol 5

Add each solvent one by one: 1% DMSO 99% Saline
Solubility: ≥ 0.5 mg/mL (0.85 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.93%

Select Batch:

Data Sheet (291 KB) SDS (420 KB)

COA (266 KB) HNMR (322 KB) RP-HPLC (245 KB) LCMS (106 KB)

Handling Instructions (2659 KB)

References

[1]. Lee KI, et al. Etoposide induces pancreatic β-cells cytotoxicity via the JNK/ERK/GSK-3 signaling-mediated mitochondria-dependent apoptosis pathway. Toxicol In Vitro. 2016 Jul 26. pii: S0887-2333(16)30147-3. [Content Brief]

[2]. Calvani M, det al. Etoposide-Anti-Human VEGF a new strategy against human melanoma cells expressing stem-like traits. Oncotarget. 2016 Jun 9. doi: 10.18632/oncotarget.9939. [Content Brief]

[3]. Fuchs, J., et al. Comparative activity of NSC 119875, NSC 109724, NSC 123127, NSC 241240, and etoposide in heterotransplanted hepatoblastoma. Cancer, 1998. 83(11): p. 2400-7. [Content Brief]

[4]. Hande KR, et al. The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example. Oncologist. 1996;1(4):234-239. [Content Brief]

[5]. Cui D, et al. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.Cell Rep. 2020 Jan 14;30(2):497-509.e4. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.6991 mL	8.4953 mL	16.9906 mL	42.4766 mL
	5 mM	0.3398 mL	1.6991 mL	3.3981 mL	8.4953 mL
	10 mM	0.1699 mL	0.8495 mL	1.6991 mL	4.2477 mL
	15 mM	0.1133 mL	0.5664 mL	1.1327 mL	2.8318 mL
	20 mM	0.0850 mL	0.4248 mL	0.8495 mL	2.1238 mL
	25 mM	0.0680 mL	0.3398 mL	0.6796 mL	1.6991 mL
	30 mM	0.0566 mL	0.2832 mL	0.5664 mL	1.4159 mL
	40 mM	0.0425 mL	0.2124 mL	0.4248 mL	1.0619 mL
	50 mM	0.0340 mL	0.1699 mL	0.3398 mL	0.8495 mL
	60 mM	0.0283 mL	0.1416 mL	0.2832 mL	0.7079 mL

Etoposide Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Etoposide (Synonyms: VP-16; VP-16-213)

Customer Review

Other Forms of Etoposide:

174 Publications Citing Use of MCE Etoposide

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Etoposide Related Classifications

Keywords:

Your Recently Viewed Products:

Etoposide (Synonyms: VP-16; VP-16-213)

Customer Review

Other Forms of Etoposide:

Etoposide Related Antibodies

174 Publications Citing Use of MCE Etoposide

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Etoposide Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Etoposide Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report